WO2021152181A1 - Virus therapy - Google Patents

Virus therapy Download PDF

Info

Publication number
WO2021152181A1
WO2021152181A1 PCT/EP2021/052336 EP2021052336W WO2021152181A1 WO 2021152181 A1 WO2021152181 A1 WO 2021152181A1 EP 2021052336 W EP2021052336 W EP 2021052336W WO 2021152181 A1 WO2021152181 A1 WO 2021152181A1
Authority
WO
WIPO (PCT)
Prior art keywords
sequence
seq
protein
rna
guide strand
Prior art date
Application number
PCT/EP2021/052336
Other languages
French (fr)
Inventor
Theodore Anastasius PRAMER
Original Assignee
Biomedrex Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biomedrex Ab filed Critical Biomedrex Ab
Publication of WO2021152181A1 publication Critical patent/WO2021152181A1/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1131Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/10Type of nucleic acid
    • C12N2310/20Type of nucleic acid involving clustered regularly interspaced short palindromic repeats [CRISPRs]

Definitions

  • This invention relates to CRISPR-related type therapies of infections, for example a virus infection, in particular a SARS-CoV-2 infection.
  • Endonucleases are enzymes that cleave polynucleotides.
  • Clustered regular interspaced short palin- dromic repeat (CRISPR)-type proteins are endonucleases that use an RNA guide strand to cut DNA or RNA at specific sites.
  • CRISPR-type proteins can be used for editing of DNA or for RNA knock down.
  • Cpfl and Casl3 are two recently identified CRISPR type proteins. The use of Cpfl for ge nome editing is described in Zetsche et al (Zetsche et al., 2015, Cell 163, 759-771). The use of Casl3 for knockdown has been reported in Abudayyeh et al (Abudayyeh et al (2017) Nature, 550280-284.
  • Pathogens such as virus, bacteria and eukaryotic parasites are still a major cause of suffering and death.
  • SARS-CoV-2 which is the virus that causes Covid-19.
  • RNA is an RNA guide strand that comprises a sequence that is complimentary to one of the sequences: SEQ ID NO 3029, OR ONE OF SEQ ID NO 1- SEQ ID NO 3028 or ONE OF SEQ ID NO 3030 to SEQ ID NO 3103.
  • sequences are suitable for selectively targeting of Covid-19, i.e. SARS-CoV-2 infection and for treating covid-19 in patients.
  • the use of Casl3 causes the destruction of virus RNA (such as mRNA) in virus infected cells.
  • virus RNA such as mRNA
  • the selected sequences are highly conserved and stable regions that do not mutate in the virus and hence and have flanking sequences that enable binding of CAS13.
  • the sequence is SEQ ID NO 3029. This sequence targets the spike pro tein gene of SARS-CoV-2.
  • a protein-RNA complex according to the first aspect of the invention for use in therapy, in particular in the treatment of a corona virus infection, in particular for treatment of Covid-19, i.e. SARS-CoV-2 infection.
  • a plasmid encoding the protein is CAS13 and an RNA guide strand that comprises a sequence that is complimentary to one of the sequences SEQ ID NO 1 to SEQ ID NO 3103, preferably SEQ ID no 3029, where the plasmid is adapted for expres sion of the protein and the transcription of the RNA guide strand in a mammalian cell.
  • a pharmaceutical composition comprising a. a protein -RNA complex according to the first aspect of the invention or b. a plasmid according to the third aspect of the invention; or c. two separate plasmids of which one encodes the protein is CAS13 and the other encodes an RNA guide strand that comprises a sequence that is complimentary to one of the sequences SEQ ID NO 1 to SEQ ID NO 3103, preferably SEQ ID no 3029, where the plasmids are adapted for expression of the protein and transcription of the RNA guide strand in a mammalian cell, or d.
  • RNA guide strand for Casl3 comprising a sequence that is complimentary to one of SEQ ID NO 1 to SEQ ID NO 3103, preferably SEQ ID no 3029, and a plasmid that encodes the protein Casl3 where the plasmid is adapted for expression of the protein in a mammalian cell.
  • a method of treatment of a virus infection comprising administering a protein-RNA complex or a plasmid or a pharmaceutical to a patient in need thereof.
  • a method for RNA knock-down of virus RNA in a virus-infected cell comprising using a protein-RNA complex comprising a Cas 13 protein and an RNA guide strand that comprises a sequence that is complimentary to one of sequences SEQ ID NO 1 to SEQ ID NO 3103, preferably SEQ ID no 3029, and where the method comprises introducing the protein-RNA complex, or means for expression of these, in a cell.
  • Fig. 1 is a schematic diagram showing an RNA guide strand for Cpfl which comprises a handle se quence and a guide sequence.
  • a recombinant CRISPR type protein in complex with an RNA guide strand (protein-RNA complex) that targets the CRISPR type protein to the DNA or the RNA of a pathogen is used for treating an infection in a patient.
  • the protein-RNA complex specifically cuts polynucleotides of the pathogen that causes the infection.
  • the patient may be a human or an animal, preferably a mam malian animal. In a preferred embodiment the patient is a human.
  • the protein-RNA complex may be used to cause double strand breaks in the DNA of pathogen-infected cells, or to knock down RNA in a pathogen-infected cell.
  • the pro tein-RNA complex may be directed to target a genomic locus of interest of the pathogen.
  • the disease being treated is an infection caused by a pathogen such as a virus, a bacteria or a eukaryotic parasite, such as a fungus.
  • a pathogen such as a virus, a bacteria or a eukaryotic parasite, such as a fungus.
  • the infec tion is caused by a bacteria or a virus, most preferably a corona virus, preferably SARS-CoV-2 infec tion.
  • SARS-CoV-2 is the virus that causes covid-19.
  • CRISPR -type proteins use an RNA guide strand to cut DNA or RNA.
  • a guide strand is an RNA mole cule that binds to the CRISPR-type protein and guides the CRISPR type protein to a certain polynu cleotide target sequence.
  • the guide strand is able to hybridize with the target strand (Watson- Crick base pairing).
  • a complex between a CRISPR-type protein and an RNA guide strand is referred to as a protein-RNA complex herein.
  • handle motif and “handle sequence” refers to a RNA sequence that interacts with a CRISPR type protein for example by mediating binding between an RNA guide strand and a CRISPR type protein. Examples of handle sequences for Cpfl and CAS13 are given below.
  • CRISPR-type proteins Preferably the CRISPR-type protein has en donuclease activity that causes a double strand breaks.
  • the most studied CRISPR protein is CRISPR/Cas9 which cuts DNA, leaving blunt ends.
  • CRISPR/Cas9 has been used for editing of eukary otic genomes (Cong et al, Science 339, (2013) 819-823, Mali et al, Science (2013) 823-826).
  • CRISPR/Cas9 uses a 42-nucleotide RNA guide strand and in addition a second strand (so called tra- crRNA strand) which may be 89 nucleotides long.
  • one of the CRISPR-type proteins Cpfl or Casl3 is used.
  • Cpfl for genome editing is described in Zetsche et al (Zetsche et al., 2015, Cell 163, 759-771).
  • Casl3 for RNA knockdown has been reported in Abudayyeh et al (Abudayyeh et al (2017) Na ture, 550280-284).
  • Cpfl (Zetsche et al., 2015, Cell 163, 759-771) cuts DNA in a staggered manner, leaving sticky ends with a 4 or 5 nucleotide 5'- overhang. This makes it difficult for DNA- repair system to repair the cut, compared to if a blunt end is created.
  • the unligated DNA may in hibit the pathogen in different ways including but not limited to: 1) triggering apoptosis of a virus- infected cell, 2) causing the death of a pathogen, for example a bacterium.
  • the pathogen is prefer ably a pathogen that has its genomic material in the form of DNA during at least some part of its life cycle. Many virus genomes become integrated into the host genomic DNA.
  • the Cpfl protein may be a Cpfl protein from Francisella novicida, Adamiococcus sp BV3L6 or Lach- nospiracea bacterium ND2006 in particular Adamiococcus sp BV3L6 or Lachnospiracea bacterium ND2006.
  • a useful variant of Cpfl is Alt-R Casl2a.
  • CRISPR/Cas 13 cuts RNA and can be used for knockdown of pathogen RNA. This may limit patho gen survival, replication or activation, or may cause the death of the pathogen.
  • the Casl3 protein may be Casl3 from Leptotrichia wadei (Abudayyeh et al (2017) Nature, 550 280-284.
  • Useful vari ants of Casl3 include PspCasl3b, LwaCasl3a, LbuCasl3a and LshCasl3a, LwaCAS13 and PsmCAS13.
  • PspCasl3b from Prevotella sp. may be used.
  • CRISPR type proteins edit polynucleotides by inserting an extra base in the polynucle otides, for example mRNA, leading to a frameshift and premature stop of translation.
  • CRISPR/Cas 9, Cpfl and CAS13 When it is referred to CRISPR/Cas 9, Cpfl and CAS13 it also includes functional equivalents and homologues of these proteins. Thus, modified or truncated proteins are included, provided that they have the same or comparable nuclease activity as the endogenous CRISPR/Cas 9 Cpfl and CAS13 proteins.
  • a homologue may have an amino acid identify with the original protein sequence of at least 70% more preferably at least 80%, even more preferably at least 90%, even more pref erably at least 95% and most preferably at least 99%, using amino acid sequence alignment in BLAST (for example BLAST2 sequences) using the following settings: word size: 3, gapcosts: 11, 1, Matrix: BLOSUM62, Filter string: F, Window Size 40, Threshold 11.
  • BLAST for example BLAST2 sequences
  • the guide strand for Cpfl preferably has a length of from 40 to 44, more preferably 41 to 44 nucleotides and comprises a 5' constant motif (handle sequence) which may be 5' - AAUUUCUACUCUUGUAGAU-3' or 5'-UAAUUUCUACUCUUGUAGAU-3'.
  • the handle se quence interacts with Cpfl and may be important for complexing with Cpfl or Cpfl activity.
  • the guide sequence is 21- 24 nucleotides long and is located at the 3' -terminal off the handle se quence.
  • the RNA is provided as single stranded RNA but parts, in particular parts of the handle se quence, may form a secondary structure.
  • the guide strand hybridizes with a target strand of dou ble stranded DNA. The opposite strand is referred to as the "displaced strand".
  • the guide strand for Cpfl may have a unspecific 5' extension of from 3 to 59 or more nucleotides as described in Park et al., Nature Communications, (2016) 9:3313 DOI: 10.1038/s41467-018-05641-3 in order to increase the efficacy.
  • the 5' extension is preferably not homologous to the human genome. For example, it may be a scrambled sequence. It has been hy pothesized that such a 5' extension increases efficacy by providing a negative charge.
  • Some CRISPR type proteins uses a PAM (Protospacer Adjacent Motif) motif to rec ognise target sequences.
  • the minimal PAM motif for Cpfl is TTN.
  • the TTN motif for Cpfl is prefer ably TTT, even more preferably TTTV where V is any nucleotide except T.
  • the PAM motif is local ized on the displaced strand and is not recognized by the guide strand of the RNA -protein complex but by the interaction between the TTN nucleotides and amino acid residues of the Cpfl protein.
  • Cpfl cuts the displaced strand with a 4-5 nucleotide overhang approximately 18-19 nucleotides from the PAM TTTN motif and cuts the target strand approximately 24- 25 nucleotides from the TTTN motif.
  • Suitable target RNA sequences for targeting CAS13 to corona virus RNA include the sequences SEQ ID NO 1 to SEQ ID NO 3103. The sequences are described in the attached provi sional sequence list, which is an integral part of the description of this patent application.
  • the pro visional sequence listing also provides a reference to the number of the sequence in the priority application (SE 2050090-6). The identified sequences are conserved over a large number of SARS- CoV-2 stains.
  • the target sequence may be a part of SEQ ID NO 1 to SEQ ID NO 3103.
  • the part may be from 25 to 30, more preferably from 28-39 consecutive nucleotides from any one of SEQ ID NO 1 to SEQ ID NO 3103.
  • the targeted sequence may be flanked by a protospacer flanking site (PFS), se for example Abudayyeh et al (2017) Nature, 550280-284 where the PFS for Leptotrichia shahii Casl3a is dis cussed.
  • PFS protospacer flanking site
  • the PFS may be for exam- pie UGG- target sequence- GGA.
  • the target sequence with flanking PFS motifs will be UGGGUGUUUAUUACCACAAAAACAACAAAAGUUGGA (PFS underlined).
  • PFS interacts with the CAS13 protein and not the guide strand.
  • the guide strand will comprise a sequence that is the reverse complement of one of the sequences SEQ ID NO 1 to SEQ ID NO 3103.
  • the sequence 5'- CACAAU U U U AAAAG AAAAGGGGGG AU UGGG -3' will be used as an example:
  • the guide sequence will be the reverse complement of this sequence, which is 5'- CCCAAUCCCCCCUUUUCUUUUAAAAUUGUG - 3'
  • the guide strand should also comprise a so called “direct repeat sequence” (DRS) ("handle se quence") that is specific for the CAS13 protein used, and which interacts with the CAS13 protein, and may mediate binding of the guide strand to the CAS13 protein.
  • DRS direct repeat sequence
  • the DRS is located 5' of the guide sequence and for others the DRS is located 3' of the guide sequence.
  • PspCasl3b 5'- GUUGUGGAAGGUCCAGUUUUGAGGGGCUAUUACAAC -3 ' (located 3 ' of guide se quence)
  • LwaCasl3a 5'- GAUUUAGACUACCCCAAAAACGAAGGGGACUAAAAC -3 ' (located 5' of the guide se quence) (Freije et al, 2019, Molecular Cell 76, 826-837).
  • PsmCasl3b 5'- GUUGUAGAAGCUUAUCGUUUGGAUAGGUAUGACAAC -3 ' (Freije et al, 2019, Mo lecular Cell 76, 826-837).
  • PspCasl3b from Prevotella sp 5' - GUUGUGGAAGGUCCAGUUUUGAGGGGCUAUUACAAC - 3'.
  • the guide strand for CAS13 preferably has a length of from 40 - 100 nucleotides more preferably from 60 to 80 nucleotides and comprises a handle sequence and a targeting sequence which is complimentary to a targeted sequence.
  • the targeted sequence is SEQ ID NO 3029
  • the guide strand is 5'
  • SEQ ID NO 480 spike protein RNA
  • SEQ ID NO 2077 spike protein RNA
  • SEQ ID NO 2177 ORF AB RNA
  • SEQ ID NO 2719 EndoRNAase RNA
  • the protein-RNA complexes, or the plasmids or the virus are preferably administered to the pa tient in the form of a pharmaceutical composition.
  • a pharmaceutical composition comprises an effective amount of the protein-RNA complexes, plasmids or virus, ("active component"), and a pharmaceutically acceptable carrier, which typically is an aqueous solution optionally comprising a variety of different pharmacologically acceptable compounds.
  • active component typically is an aqueous solution optionally comprising a variety of different pharmacologically acceptable compounds.
  • the formulation is made to suit the mode of administration. There is a wide variety of possible formulations.
  • the formulation may be adapted to increase the uptake or stability of the active component or to improve the pharmacoki netics or pharmacodynamics of the active component, or to enhance other desirable properties of the formulation.
  • the pharmaceutical composition, the complexes and the virus and plasmids de scribed herein are preferably non-naturally occurring or engineered.
  • the protein-RNA complex, the plasmid, or a virus may be an isolated protein-RNA complex, plasmid or virus.
  • a protein-RNA complex is delivered. Delivery of the protein-RNA complex can be made in any suitable way. Two reviews that describe useful methods of delivery are: Glass, Lee, LI and Xu; Trends in Biotechnology, 2017, and Liu, Zhang, Liu and Cheng, Journal of Controlled Disease, 266 (2017) 17-26. Suitable methods include nanoparticles for example gold particles, or polymeric carriers, such as polymers obtained from chitosan or poly-caprolactone or poly-lactic/glycolic acid-copolymers. The use of gold particles is a preferred method of delivery (Mout et al (2017) ACS Nano 11, 2452-2458) and Lee et al Nature Biomedical Engineering volume 1, pages 889-901 (2017).
  • lipid nanoparticles for example as described in Wang et al., PNAS March 15, 2016 vol. 113 no. 112868-2873, and Li et al., Biomaterials 178 (2016) 652 - 662.
  • a plasmid or plasmids encoding the protein and/or the guide RNA is admin istered to the patient, as is known in the art.
  • the plasmids are preferably adapted for expression of the protein and transcription of the RNA in the cell type of interest which may be a mammalian cell, preferably a human cell.
  • the protein gene and the guide strand gene is prefera bly under control of suitable promotors that induce expression in these cells.
  • suitable promotors that induce expression in these cells.
  • the route of admin istration, formulation and dose can be as in US Patent No 5,846,946 and as in clinical studies in volving plasmids.
  • the guide strand is delivered (as RNA) together with a plasmid that encodes the CRISPR-type protein, or the other way around.
  • a suitable promotor for expression in humans is chosen when the pathogen is a virus.
  • the pro motor is preferably chosen to suit the internal transcription system of the pathogen.
  • delivery of the CRISPR type protein or the RNA guide strand is carried out with the use of a virus.
  • the CRISPR-type protein and the guide RNA can be delivered using adeno associated virus (AAV), lentivirus, adenovirus or other plasmid or viral vector types, in particular, using formulations and doses from, for example, US Patents Nos. 8,454,972 (formulations, doses for adenovirus), 8,404,658 (formulations, doses for AAV) and 5,846,946 (formulations, doses for DNA plasmids) and from clinical trials and publications regarding the clinical trials involving lentivi rus, AAV and adenovirus.
  • AAV adeno associated virus
  • the route of administration, formulation and dose can be as in US Patent No. 8,454,972 and as in clinical trials involving AAV.
  • the route of administration, formulation and dose can be as in US Patent No. 8,404,658 and as in clinical trials involving adenovirus.
  • each of the sequences encoding the CRISPR-type protein and the guide strand is adapted for expression of the protein in the cell, and adapted for transcription of RNA.
  • the coding sequences are preferably under control of a regulatory element, which typically is a DNA sequence that controls the transcription of the gene of interest.
  • the regulatory element may comprise one more promotors, enhancers or the like.
  • the regulatory element is cho sen to suit the cell in which expression is to be achieved.
  • the regulatory element may be operably linked to the sequences.
  • Each of the CRISPR-type protein and the sequence encoding the guide stand may be operably linked to a separate regulatory element.
  • the genes for the CRISPR-type protein may be codon-optimized for expression in the cells of the interest, for example human cells.
  • the CRISPR-type protein and/or the guide strand may be targeted to the nucleus with the ad dition of nucleus targeting sequences.
  • Multiple guide strands that each target one separate se quence may be deliver simultaneously, for example with the use of a plasmid that encodes for sep arate guide strands or for one long RNA that is broken up into a plurality of guide strands with the use of a nuclease activity.
  • Formulation for parenteral administration such as for example intraarticular, intravenous, intra- dermal, intraperitoneal, or subcutaneous administration include aqueous and non-aqueous injec tion solutions.
  • Formulations for injection may be in unit dosage forms, for example ampules or in multidosage forms.
  • the formulation can be for administration topically, systemically or locally.
  • the formulation can also be provided as an aerosol.
  • the formulations may contain nuclease inhibitors (such as RNase inhibitors) antioxidants, buffers, antibiotics, salts, solutes that renders the formulation isotonic, lipids, carriers, diluents emulsifiers, chelating agents, excipients, fillers, drying agents, antioxidants, binding agents, solubilizers, stabi lizers, antimicrobial agents, preservatives and the like.
  • nuclease inhibitors such as RNase inhibitors
  • antioxidants such as buffers, antibiotics, salts, solutes that renders the formulation isotonic, lipids, carriers, diluents emulsifiers, chelating agents, excipients, fillers, drying agents, antioxidants, binding agents, solubilizers, stabi lizers, antimicrobial agents, preservatives and the like.
  • the protein-RNA complex, the plasmids or the virus may be administered to the subject in any suitable manner.
  • the protein-RNA complexes, the plasmids or the virus can be administered by a number of routes including intravenous injection, intraperitoneal, intramuscular, transdermal, subcutaneous, topical, sublingual, or rectal means. Suitable modes of administration include injec tion or infusion. Intravenous administration is a preferred mode of administration.
  • an effective amount of the protein-RNA complex, the plasmids or the virus is adminis tered to the subject.
  • An effective amount is an amount that is able to treat one or more symptoms of a disease, halt or reverse the progression of a disease.
  • Administration may be carried out at a single time point or repeatedly over a time period or from an implanted slow-release matrix.
  • Other delivery systems include bolus injections, time-release, delayed release, sustained release or controlled release systems.
  • Dosage and administration regimens may be determined by methods known in the art, for exam ple with testing in appropriate in vitro or in vivo models, such as animal models to analyse efficacy, pharmacokinetics, pharmacodynamics, excretion, tissue uptake and the like by methods known in the art.
  • a suitable way of finding a suitable dose is starting with a low amount and gradually in creasing the amount.
  • the CRISPR type protein for use in protein-RNA complexes are preferably produced in a suitable expression system.
  • Production of protein with the use of expression systems is well known in the art. In general, Current protocols in Molecular Biology (John Wiley & sons) provides guidance for polynucleotide handling and manipulation, and protein expression and handling.
  • CRISPR type pro tein, in particular Cpfl and CAS13 can be produced in any suitable manner.
  • Suitable expression systems include eukaryotic cells such as CHO cells, insect cells or bacteria. Often, E. coli is the pre ferred expression system because of its ease of use, and because the CRISPR-type proteins are of bacterial origin.
  • the production of protein involves cloning of the coding sequence for the protein into a plasmid suitable for expression.
  • the plasmid preferably has a promotor that drives expression.
  • the T7 promotor may be useful.
  • the CMV promotor may be useful.
  • the plasmid is introduced into the cells with the use of well-known transfection protocols, and stable or transient expressing cells are generated. Suitable transfection techniques may be the use of electroporation or the use of liposomes, such as Lipofectamine ® or virus-based methods. Clones stably expression the protein may be selected, expanded and propagated.
  • Expression plasmids for Cpfl are described in Zetsche et al and expres sion plasmids for CAS13 are described in Abudayyeh et al (see above).
  • the proteins may be ex pressed with a suitable tag for purification of the protein, such as poly-His tag.
  • Purification of protein may be carried out as is known in the art and may include steps such as: cell lysis, centrifugation, gel filtration, affinity chromatography and dialysis.
  • the protein is preferably purified and endotoxin-free.
  • Useful plasmids for expression of Cpfl include pTE4396, pTE4396, pAsCpfl(TYCV)(BB) (pY211) and pYOlO (pcDNA3.1-hAsCpfl).
  • Useful plasmids for expression of Casl3 include: pC0046-EFla-PspCasl3b-NES-HIV and pC0056 - LwCasl3a-msfGFP-NES (eukaryotic expression) and p2CT-Flis-MBP-Lwa_Casl3a_WT (expression in bacteria).
  • RNA guide strand can be produced in any suitable way.
  • a preferred way is chemical synthesis. Methods for synthesis of RNA are well known to a person skilled in the art. RNA synthesis is prefer able done in a controlled environment to avoid degradation of RNA by for example RNAses.
  • the conditions for complexing guide RNA with protein are known. Typically, the protein is incu bated with the guide RNA in a suitable buffer. Incubation time may be 10 minutes to 30 minutes.
  • the above-mentioned methods for administration of protein-RNA complexes, plasmids and virus can be used to introduce double strand breaks with the use of Cpfl pathogenic virus-infected cells, or to knock down pathogenic virus RNA in infected cells, in vivo, ex vivo or in vitro. In one embodi ment this is done in vitro.
  • the virus-infected cells may be a subpopulation of a larger population of cells, where not all cells are infected with the pathogenic virus.
  • PspCasl3b from Prevotella sp was expressed and purified and crRNA oligos synthesized. Protein was expressed and purified by method as follows.
  • Day 1 Inoculation of overnight cultures from fresh transformants in the afternoon. The cultures were grown at 30°C, 175 RPM overnight in the presence of 0.4% glucose.
  • IMAC lysis buffer 20 mM Tris-HCI, 500 mM NaCI, 1 mM DTT, pH 8.0
  • IMAC wash 1 buffer 20 mM HEPES, 500 mM NaCI, 10% glycerol, 10 mM imidazole, 0.5 mM TCEP, pH 7.5
  • IMAC wash 2 buffer 20 mM HEPES, 1000 mM NaCI, 10% glycerol, 50 mM imidazole, 0.5 mM TCEP, pH 7.5
  • IMAC elution buffer 20 mM HEPES, 500 mM NaCI, 10% glycerol, 500 mM imidaz ole, 0.5 mM TCEP, pH 7.5
  • Gel filtration buffer 20 mM HEPES, 300 mM NaCI, 10% glycerol, 0.5 mM TCEP, pH 7.5
  • Target concentration is 2.6 nM.
  • Protein -RNA complexes were formed by combining guide strand RNA and CAS13 protein, pipette mixing and letting them incubate for 10 minutes.

Abstract

In brief, a recombinant CRISPR type protein in complex with an RNA guide strand (protein-RNA complex) that targets the CRISPR type protein to the DNA or the RNA of a pathogen is used for treating an infection in a patient. The protein-RNA complex specifically cuts polynucleotides of the pathogen that causes the infection. In a preferred embodiment the patient is a human.

Description

Virus Therapy
FIELD OF TECHNOLOGY This invention relates to CRISPR-related type therapies of infections, for example a virus infection, in particular a SARS-CoV-2 infection.
BACKGROUND
Endonucleases are enzymes that cleave polynucleotides. Clustered regular interspaced short palin- dromic repeat (CRISPR)-type proteins are endonucleases that use an RNA guide strand to cut DNA or RNA at specific sites. CRISPR-type proteins can be used for editing of DNA or for RNA knock down. Cpfl and Casl3 are two recently identified CRISPR type proteins. The use of Cpfl for ge nome editing is described in Zetsche et al (Zetsche et al., 2015, Cell 163, 759-771). The use of Casl3 for knockdown has been reported in Abudayyeh et al (Abudayyeh et al (2017) Nature, 550280-284.
Pathogens, such as virus, bacteria and eukaryotic parasites are still a major cause of suffering and death. There is a need for improved therapies for infections in particular SARS-CoV-2 which is the virus that causes Covid-19. SUMMARY OF INVENTION
In a first aspect of the intervention there is provided a protein-RNA complex where here the pro tein is CAS13 and where and the RNA is an RNA guide strand that comprises a sequence that is complimentary to one of the sequences: SEQ ID NO 3029, OR ONE OF SEQ ID NO 1- SEQ ID NO 3028 or ONE OF SEQ ID NO 3030 to SEQ ID NO 3103.
These sequences are suitable for selectively targeting of Covid-19, i.e. SARS-CoV-2 infection and for treating covid-19 in patients. The use of Casl3 causes the destruction of virus RNA (such as mRNA) in virus infected cells. The selected sequences are highly conserved and stable regions that do not mutate in the virus and hence and have flanking sequences that enable binding of CAS13. In a preferred embodiment the sequence is SEQ ID NO 3029. This sequence targets the spike pro tein gene of SARS-CoV-2.
In a second aspect of the invention there is provided a protein-RNA complex according to the first aspect of the invention for use in therapy, in particular in the treatment of a corona virus infection, in particular for treatment of Covid-19, i.e. SARS-CoV-2 infection.
In a third aspect of the invention there is provided a plasmid encoding the protein is CAS13 and an RNA guide strand that comprises a sequence that is complimentary to one of the sequences SEQ ID NO 1 to SEQ ID NO 3103, preferably SEQ ID no 3029, where the plasmid is adapted for expres sion of the protein and the transcription of the RNA guide strand in a mammalian cell.
In a fourth aspect of the invention there is provided a pharmaceutical composition comprising a. a protein -RNA complex according to the first aspect of the invention or b. a plasmid according to the third aspect of the invention; or c. two separate plasmids of which one encodes the protein is CAS13 and the other encodes an RNA guide strand that comprises a sequence that is complimentary to one of the sequences SEQ ID NO 1 to SEQ ID NO 3103, preferably SEQ ID no 3029, where the plasmids are adapted for expression of the protein and transcription of the RNA guide strand in a mammalian cell, or d. an RNA guide strand for Casl3 comprising a sequence that is complimentary to one of SEQ ID NO 1 to SEQ ID NO 3103, preferably SEQ ID no 3029, and a plasmid that encodes the protein Casl3 where the plasmid is adapted for expression of the protein in a mammalian cell.
In a fifth aspect of the invention, there is provided a method of treatment of a virus infection, in particular covid-19 i.e. SARS-CoV-2 infection, comprising administering a protein-RNA complex or a plasmid or a pharmaceutical to a patient in need thereof.
In a sixths aspect of the invention there is provided a method for RNA knock-down of virus RNA in a virus-infected cell comprising using a protein-RNA complex comprising a Cas 13 protein and an RNA guide strand that comprises a sequence that is complimentary to one of sequences SEQ ID NO 1 to SEQ ID NO 3103, preferably SEQ ID no 3029, and where the method comprises introducing the protein-RNA complex, or means for expression of these, in a cell. BRIEF DESCRIPTION OF DRAWINGS
Fig. 1 is a schematic diagram showing an RNA guide strand for Cpfl which comprises a handle se quence and a guide sequence.
DETAILED DESCRIPTION
In brief, a recombinant CRISPR type protein in complex with an RNA guide strand (protein-RNA complex) that targets the CRISPR type protein to the DNA or the RNA of a pathogen is used for treating an infection in a patient. The protein-RNA complex specifically cuts polynucleotides of the pathogen that causes the infection. The patient may be a human or an animal, preferably a mam malian animal. In a preferred embodiment the patient is a human.
In a more general sense, the protein-RNA complex may be used to cause double strand breaks in the DNA of pathogen-infected cells, or to knock down RNA in a pathogen-infected cell. The pro tein-RNA complex may be directed to target a genomic locus of interest of the pathogen.
In a preferred embodiment the disease being treated is an infection caused by a pathogen such as a virus, a bacteria or a eukaryotic parasite, such as a fungus. In a preferred embodiment the infec tion is caused by a bacteria or a virus, most preferably a corona virus, preferably SARS-CoV-2 infec tion. SARS-CoV-2 is the virus that causes covid-19.
CRISPR -type proteins use an RNA guide strand to cut DNA or RNA. A guide strand is an RNA mole cule that binds to the CRISPR-type protein and guides the CRISPR type protein to a certain polynu cleotide target sequence. The guide strand is able to hybridize with the target strand (Watson- Crick base pairing). A complex between a CRISPR-type protein and an RNA guide strand is referred to as a protein-RNA complex herein.
As used herein "handle motif" and "handle sequence" refers to a RNA sequence that interacts with a CRISPR type protein for example by mediating binding between an RNA guide strand and a CRISPR type protein. Examples of handle sequences for Cpfl and CAS13 are given below. There are many different useful CRISPR-type proteins. Preferably the CRISPR-type protein has en donuclease activity that causes a double strand breaks. The most studied CRISPR protein is CRISPR/Cas9 which cuts DNA, leaving blunt ends. CRISPR/Cas9 has been used for editing of eukary otic genomes (Cong et al, Science 339, (2013) 819-823, Mali et al, Science (2013) 823-826).
CRISPR/Cas9 uses a 42-nucleotide RNA guide strand and in addition a second strand (so called tra- crRNA strand) which may be 89 nucleotides long.
In a preferred embodiment, one of the CRISPR-type proteins Cpfl or Casl3 is used. The use of Cpfl for genome editing is described in Zetsche et al (Zetsche et al., 2015, Cell 163, 759-771). The use of Casl3 for RNA knockdown has been reported in Abudayyeh et al (Abudayyeh et al (2017) Na ture, 550280-284).
In contrast to CRISPR/Cas 9, Cpfl (Zetsche et al., 2015, Cell 163, 759-771) cuts DNA in a staggered manner, leaving sticky ends with a 4 or 5 nucleotide 5'- overhang. This makes it difficult for DNA- repair system to repair the cut, compared to if a blunt end is created. The unligated DNA may in hibit the pathogen in different ways including but not limited to: 1) triggering apoptosis of a virus- infected cell, 2) causing the death of a pathogen, for example a bacterium. The pathogen is prefer ably a pathogen that has its genomic material in the form of DNA during at least some part of its life cycle. Many virus genomes become integrated into the host genomic DNA.
The Cpfl protein may be a Cpfl protein from Francisella novicida, Adamiococcus sp BV3L6 or Lach- nospiracea bacterium ND2006 in particular Adamiococcus sp BV3L6 or Lachnospiracea bacterium ND2006. A useful variant of Cpfl is Alt-R Casl2a.
CRISPR/Cas 13 cuts RNA and can be used for knockdown of pathogen RNA. This may limit patho gen survival, replication or activation, or may cause the death of the pathogen. The Casl3 protein may be Casl3 from Leptotrichia wadei (Abudayyeh et al (2017) Nature, 550 280-284. Useful vari ants of Casl3 include PspCasl3b, LwaCasl3a, LbuCasl3a and LshCasl3a, LwaCAS13 and PsmCAS13. For example PspCasl3b from Prevotella sp. may be used.
Other useful CRISPR type proteins edit polynucleotides by inserting an extra base in the polynucle otides, for example mRNA, leading to a frameshift and premature stop of translation.
When it is referred to CRISPR/Cas 9, Cpfl and CAS13 it also includes functional equivalents and homologues of these proteins. Thus, modified or truncated proteins are included, provided that they have the same or comparable nuclease activity as the endogenous CRISPR/Cas 9 Cpfl and CAS13 proteins. A homologue may have an amino acid identify with the original protein sequence of at least 70% more preferably at least 80%, even more preferably at least 90%, even more pref erably at least 95% and most preferably at least 99%, using amino acid sequence alignment in BLAST (for example BLAST2 sequences) using the following settings: word size: 3, gapcosts: 11, 1, Matrix: BLOSUM62, Filter string: F, Window Size 40, Threshold 11.
With reference to Fig. 1, the guide strand for Cpfl preferably has a length of from 40 to 44, more preferably 41 to 44 nucleotides and comprises a 5' constant motif (handle sequence) which may be 5' - AAUUUCUACUCUUGUAGAU-3' or 5'-UAAUUUCUACUCUUGUAGAU-3'. The handle se quence interacts with Cpfl and may be important for complexing with Cpfl or Cpfl activity. The guide sequence is 21- 24 nucleotides long and is located at the 3' -terminal off the handle se quence. The RNA is provided as single stranded RNA but parts, in particular parts of the handle se quence, may form a secondary structure. The guide strand hybridizes with a target strand of dou ble stranded DNA. The opposite strand is referred to as the "displaced strand".
In addition, the guide strand for Cpfl may have a unspecific 5' extension of from 3 to 59 or more nucleotides as described in Park et al., Nature Communications, (2018) 9:3313 DOI: 10.1038/s41467-018-05641-3 in order to increase the efficacy. The 5' extension is preferably not homologous to the human genome. For example, it may be a scrambled sequence. It has been hy pothesized that such a 5' extension increases efficacy by providing a negative charge.
Some CRISPR type proteins, including Cpfl, uses a PAM (Protospacer Adjacent Motif) motif to rec ognise target sequences. The minimal PAM motif for Cpfl is TTN. The TTN motif for Cpfl is prefer ably TTT, even more preferably TTTV where V is any nucleotide except T. The PAM motif is local ized on the displaced strand and is not recognized by the guide strand of the RNA -protein complex but by the interaction between the TTN nucleotides and amino acid residues of the Cpfl protein. Cpfl cuts the displaced strand with a 4-5 nucleotide overhang approximately 18-19 nucleotides from the PAM TTTN motif and cuts the target strand approximately 24- 25 nucleotides from the TTTN motif.
Examples of suitable target RNA sequences for targeting CAS13 to corona virus RNA, include the sequences SEQ ID NO 1 to SEQ ID NO 3103. The sequences are described in the attached provi sional sequence list, which is an integral part of the description of this patent application. The pro visional sequence listing also provides a reference to the number of the sequence in the priority application (SE 2050090-6). The identified sequences are conserved over a large number of SARS- CoV-2 stains.
The target sequence may be a part of SEQ ID NO 1 to SEQ ID NO 3103. The part may be from 25 to 30, more preferably from 28-39 consecutive nucleotides from any one of SEQ ID NO 1 to SEQ ID NO 3103.
The targeted sequence may be flanked by a protospacer flanking site (PFS), se for example Abudayyeh et al (2017) Nature, 550280-284 where the PFS for Leptotrichia shahii Casl3a is dis cussed. The PFS may be a preference for FI (=not G). It is referred to (Smargon, Cox, Pyzocha et al., Molecular cell 2017;Cox, Gootenberg, Abudayyeh et al., Science 2017). The PFS may be for exam- pie UGG- target sequence- GGA. Flence for the SEQ ID 3029 the target sequence with flanking PFS motifs will be UGGGUGUUUAUUACCACAAAAACAACAAAAGUUGGA (PFS underlined). Typically the PFS interacts with the CAS13 protein and not the guide strand.
The guide strand will comprise a sequence that is the reverse complement of one of the sequences SEQ ID NO 1 to SEQ ID NO 3103. The sequence 5'- CACAAU U U U AAAAG AAAAGGGGGG AU UGGG -3'will be used as an example:
The guide sequence will be the reverse complement of this sequence, which is 5'- CCCAAUCCCCCCUUUUCUUUUAAAAUUGUG - 3'
The guide strand should also comprise a so called "direct repeat sequence" (DRS) ("handle se quence") that is specific for the CAS13 protein used, and which interacts with the CAS13 protein, and may mediate binding of the guide strand to the CAS13 protein. For some CAS13 proteins, the DRS is located 5' of the guide sequence and for others the DRS is located 3' of the guide sequence.
Below are some examples of DRS for CAS 13 proteins:
PspCasl3b: 5'- GUUGUGGAAGGUCCAGUUUUGAGGGGCUAUUACAAC -3' (located 3' of guide se quence) LwaCasl3a: 5'- GAUUUAGACUACCCCAAAAACGAAGGGGACUAAAAC -3' (located 5' of the guide se quence) (Freije et al, 2019, Molecular Cell 76, 826-837).
PsmCasl3b: 5'- GUUGUAGAAGCUUAUCGUUUGGAUAGGUAUGACAAC -3' (Freije et al, 2019, Mo lecular Cell 76, 826-837). PspCasl3b from Prevotella sp: 5' - GUUGUGGAAGGUCCAGUUUUGAGGGGCUAUUACAAC - 3'.
The guide strand for CAS13 preferably has a length of from 40 - 100 nucleotides more preferably from 60 to 80 nucleotides and comprises a handle sequence and a targeting sequence which is complimentary to a targeted sequence.
In a preferred embodiment the targeted sequence is SEQ ID NO 3029
(G U G U U U AU U ACCACAAAAAC AACAAAAG U U ) . This targets the spike protein gene in SARS-CoV-2.
In a preferred embodiment the guide strand is 5'
AACUUUUGUUGUUUUUGUGGUAAUAAACACGUUGUGGAAGGUCCAGUUUUGAGGGGCUAUUACAA C-3' for targeting SEQ ID NO 3029 with the use of PspCasl3b from Prevotella sp. This sequence comprises the 5' reverse complement of SEQ ID 3029 followed by the handle sequence GUUGUGGAAGGUCCAGUUUUGAGGGGCUAUUACAAC located in the 3' end of the guide strand.
Other preferred sequences for targeting in SARS-CoV-2 includes SEQ ID NO 480 (spike protein RNA), SEQ ID NO 2077 (spike protein RNA), SEQ ID NO 2177 (ORF AB RNA) and SEQ ID NO 2719 (EndoRNAase RNA).
The protein-RNA complexes, or the plasmids or the virus are preferably administered to the pa tient in the form of a pharmaceutical composition. Such a pharmaceutical composition comprises an effective amount of the protein-RNA complexes, plasmids or virus, ("active component"), and a pharmaceutically acceptable carrier, which typically is an aqueous solution optionally comprising a variety of different pharmacologically acceptable compounds. The formulation is made to suit the mode of administration. There is a wide variety of possible formulations. The formulation may be adapted to increase the uptake or stability of the active component or to improve the pharmacoki netics or pharmacodynamics of the active component, or to enhance other desirable properties of the formulation. The pharmaceutical composition, the complexes and the virus and plasmids de scribed herein are preferably non-naturally occurring or engineered. The protein-RNA complex, the plasmid, or a virus may be an isolated protein-RNA complex, plasmid or virus.
In certain embodiments a protein-RNA complex is delivered. Delivery of the protein-RNA complex can be made in any suitable way. Two reviews that describe useful methods of delivery are: Glass, Lee, LI and Xu; Trends in Biotechnology, 2017, and Liu, Zhang, Liu and Cheng, Journal of Controlled Disease, 266 (2017) 17-26. Suitable methods include nanoparticles for example gold particles, or polymeric carriers, such as polymers obtained from chitosan or poly-caprolactone or poly-lactic/glycolic acid-copolymers. The use of gold particles is a preferred method of delivery (Mout et al (2017) ACS Nano 11, 2452-2458) and Lee et al Nature Biomedical Engineering volume 1, pages 889-901 (2017). Another preferred method of delivery is lipid nanoparticles, for example as described in Wang et al., PNAS March 15, 2016 vol. 113 no. 112868-2873, and Li et al., Biomaterials 178 (2018) 652 - 662.
In other embodiments a plasmid or plasmids encoding the protein and/or the guide RNA is admin istered to the patient, as is known in the art. The plasmids are preferably adapted for expression of the protein and transcription of the RNA in the cell type of interest which may be a mammalian cell, preferably a human cell. For example, the protein gene and the guide strand gene is prefera bly under control of suitable promotors that induce expression in these cells. A skilled person knows how to achieve expression in mammalian cells. For plasmid delivery, the route of admin istration, formulation and dose can be as in US Patent No 5,846,946 and as in clinical studies in volving plasmids. In some embodiments, the guide strand is delivered (as RNA) together with a plasmid that encodes the CRISPR-type protein, or the other way around. A suitable promotor for expression in humans is chosen when the pathogen is a virus. When the plasmid or plasmids are delivered to pathogens that are bacterial or eukaryotes for expression in the pathogen, the pro motor is preferably chosen to suit the internal transcription system of the pathogen.
In other embodiments delivery of the CRISPR type protein or the RNA guide strand is carried out with the use of a virus. The CRISPR-type protein and the guide RNA can be delivered using adeno associated virus (AAV), lentivirus, adenovirus or other plasmid or viral vector types, in particular, using formulations and doses from, for example, US Patents Nos. 8,454,972 (formulations, doses for adenovirus), 8,404,658 (formulations, doses for AAV) and 5,846,946 (formulations, doses for DNA plasmids) and from clinical trials and publications regarding the clinical trials involving lentivi rus, AAV and adenovirus. For examples, for AAV, the route of administration, formulation and dose can be as in US Patent No. 8,454,972 and as in clinical trials involving AAV. For adenovirus, the route of administration, formulation and dose can be as in US Patent No. 8,404,658 and as in clinical trials involving adenovirus.
When a virus or a plasmid is used, each of the sequences encoding the CRISPR-type protein and the guide strand is adapted for expression of the protein in the cell, and adapted for transcription of RNA. Thus, the coding sequences are preferably under control of a regulatory element, which typically is a DNA sequence that controls the transcription of the gene of interest. The regulatory element may comprise one more promotors, enhancers or the like. The regulatory element is cho sen to suit the cell in which expression is to be achieved. The regulatory element may be operably linked to the sequences. Each of the CRISPR-type protein and the sequence encoding the guide stand may be operably linked to a separate regulatory element. The genes for the CRISPR-type protein may be codon-optimized for expression in the cells of the interest, for example human cells. The CRISPR-type protein and/or the guide strand may be targeted to the nucleus with the ad dition of nucleus targeting sequences. Multiple guide strands that each target one separate se quence may be deliver simultaneously, for example with the use of a plasmid that encodes for sep arate guide strands or for one long RNA that is broken up into a plurality of guide strands with the use of a nuclease activity.
Formulation for parenteral administration such as for example intraarticular, intravenous, intra- dermal, intraperitoneal, or subcutaneous administration include aqueous and non-aqueous injec tion solutions. Formulations for injection may be in unit dosage forms, for example ampules or in multidosage forms. The formulation can be for administration topically, systemically or locally. The formulation can also be provided as an aerosol.
The formulations may contain nuclease inhibitors (such as RNase inhibitors) antioxidants, buffers, antibiotics, salts, solutes that renders the formulation isotonic, lipids, carriers, diluents emulsifiers, chelating agents, excipients, fillers, drying agents, antioxidants, binding agents, solubilizers, stabi lizers, antimicrobial agents, preservatives and the like.
The protein-RNA complex, the plasmids or the virus may be administered to the subject in any suitable manner. The protein-RNA complexes, the plasmids or the virus can be administered by a number of routes including intravenous injection, intraperitoneal, intramuscular, transdermal, subcutaneous, topical, sublingual, or rectal means. Suitable modes of administration include injec tion or infusion. Intravenous administration is a preferred mode of administration.
Preferably an effective amount of the protein-RNA complex, the plasmids or the virus is adminis tered to the subject. An effective amount is an amount that is able to treat one or more symptoms of a disease, halt or reverse the progression of a disease.
Administration may be carried out at a single time point or repeatedly over a time period or from an implanted slow-release matrix. Other delivery systems include bolus injections, time-release, delayed release, sustained release or controlled release systems. Dosage and administration regimens may be determined by methods known in the art, for exam ple with testing in appropriate in vitro or in vivo models, such as animal models to analyse efficacy, pharmacokinetics, pharmacodynamics, excretion, tissue uptake and the like by methods known in the art. A suitable way of finding a suitable dose is starting with a low amount and gradually in creasing the amount.
The CRISPR type protein for use in protein-RNA complexes are preferably produced in a suitable expression system. Production of protein with the use of expression systems is well known in the art. In general, Current protocols in Molecular Biology (John Wiley & sons) provides guidance for polynucleotide handling and manipulation, and protein expression and handling. CRISPR type pro tein, in particular Cpfl and CAS13 can be produced in any suitable manner. Suitable expression systems include eukaryotic cells such as CHO cells, insect cells or bacteria. Often, E. coli is the pre ferred expression system because of its ease of use, and because the CRISPR-type proteins are of bacterial origin. Typically, the production of protein involves cloning of the coding sequence for the protein into a plasmid suitable for expression. The plasmid preferably has a promotor that drives expression. For expression in E. coli the T7 promotor may be useful. For expression in mam malian cells, the CMV promotor may be useful. The plasmid is introduced into the cells with the use of well-known transfection protocols, and stable or transient expressing cells are generated. Suitable transfection techniques may be the use of electroporation or the use of liposomes, such as Lipofectamine® or virus-based methods. Clones stably expression the protein may be selected, expanded and propagated. Expression plasmids for Cpfl are described in Zetsche et al and expres sion plasmids for CAS13 are described in Abudayyeh et al (see above). The proteins may be ex pressed with a suitable tag for purification of the protein, such as poly-His tag.
Purification of protein may be carried out as is known in the art and may include steps such as: cell lysis, centrifugation, gel filtration, affinity chromatography and dialysis. The protein is preferably purified and endotoxin-free. Useful plasmids for expression of Cpfl include pTE4396, pTE4396, pAsCpfl(TYCV)(BB) (pY211) and pYOlO (pcDNA3.1-hAsCpfl). Useful plasmids for expression of Casl3 include: pC0046-EFla-PspCasl3b-NES-HIV and pC0056 - LwCasl3a-msfGFP-NES (eukaryotic expression) and p2CT-Flis-MBP-Lwa_Casl3a_WT (expression in bacteria).
The RNA guide strand can be produced in any suitable way. A preferred way is chemical synthesis. Methods for synthesis of RNA are well known to a person skilled in the art. RNA synthesis is prefer able done in a controlled environment to avoid degradation of RNA by for example RNAses. The conditions for complexing guide RNA with protein are known. Typically, the protein is incu bated with the guide RNA in a suitable buffer. Incubation time may be 10 minutes to 30 minutes.
The above-mentioned methods for administration of protein-RNA complexes, plasmids and virus can be used to introduce double strand breaks with the use of Cpfl pathogenic virus-infected cells, or to knock down pathogenic virus RNA in infected cells, in vivo, ex vivo or in vitro. In one embodi ment this is done in vitro. The virus-infected cells may be a subpopulation of a larger population of cells, where not all cells are infected with the pathogenic virus.
There are known in vitro methods for assessing the efficacy of treatment and delivery. Examples include the methods used in Ueda et at, Microbiology and Immunology Volume60, Issue7, July 2016, 483-496
EXAMPLE 1
Genomes for a large number of corona virus subtypes where downloaded from www.hiv.lanl.gov.
Data was imported into a table in a relational database. An algorithm was used to search in the da tabase of sequences that are likely to be transcribed to RNA, as being suitable targets for CAS13. The most conserved sequences were selected for further processing. It was checked that none of the selected sequences were present in the consensus human genome. The sequences were then selected based on that they should be present in sequences that are important for virus survival, replication or activation. The results are shown in the appended provisional sequence listing de scribing the sequences SEQ ID NO 1 to SEQ ID NO 3103.
EXAMPLE 2
PspCasl3b from Prevotella sp was expressed and purified and crRNA oligos synthesized. Protein was expressed and purified by method as follows.
Day 1: Inoculation of overnight cultures from fresh transformants in the afternoon. The cultures were grown at 30°C, 175 RPM overnight in the presence of 0.4% glucose.
Day 2: Cultures were grown in the LEX system with start in the morning Cultivation temperature before induction: 37°C. Protein expression temperature: 18°C At different times, the OD was measured for the cultures and the temperature was set to 18°C at OD 2. The protein expression was induced at approximately OD 3 (IPTG, final concentration 0.5 mM). Protein expression continued overnight before the cells were harvested by centrifugation (10 min at 4500 x g). IMAC lysis buffer (1.5 ml buffer per gram cell pellet) and the complete stock solution (1 ml per 1.5 I culture) were added and the cell pellets were re-suspended on a shaker table (cold room). The re suspended cell pellets were frozen at -80°C.
Complete stock solution: 1 tablet Complete EDTA-free (protease inhibitor cocktail, Roche) and 50 pi benzonase nuclease cell resuspension (PSF) per 1 ml. Purification Buffers:
IMAC lysis buffer: 20 mM Tris-HCI, 500 mM NaCI, 1 mM DTT, pH 8.0
IMAC wash 1 buffer: 20 mM HEPES, 500 mM NaCI, 10% glycerol, 10 mM imidazole, 0.5 mM TCEP, pH 7.5 IMAC wash 2 buffer: 20 mM HEPES, 1000 mM NaCI, 10% glycerol, 50 mM imidazole, 0.5 mM TCEP, pH 7.5 IMAC elution buffer: 20 mM HEPES, 500 mM NaCI, 10% glycerol, 500 mM imidaz ole, 0.5 mM TCEP, pH 7.5 Gel filtration buffer: 20 mM HEPES, 300 mM NaCI, 10% glycerol, 0.5 mM TCEP, pH 7.5
Final Storage buffer: 20 mM HEPES, 300 mM NaCI, 10% glycerol, 2 mM TCEP, pH 7.5 Sample preparation The resuspended cells were disrupted by pulsed sonication (4s/4s 4 min, 80% amplitude). The sonicated lysate was centrifuged (20 min at 49000 c g) and the supernatant was filtered through 0.45 pm filters and loaded onto the AKTA Xpress and purified.
IMAC Column: 5 ml HisTrap HP (GE Healthcare) Gel Filtration Column: HiLoad 16/60 Superdex 200 Pooling and concentration Fractions were examined on SDS-PAGE gel before pooling. The pooled fractions were concentrated on an Amicon Ultra-15 centrifugation filter (molecular weight cutoff = 100 kDa). The protein sam ples were aliquoted (50* or 100 mI per tube), flash-frozen in liquid Nitrogen and stored at -80°C.
Experimental method. Target concentration is 2.6 nM. Total 50 ng per condition, 10 pL of 5 ng/pL in final eluate.
CRISPR protein concentration used evaluated between 31 to 250 nM.
Protein -RNA complexes were formed by combining guide strand RNA and CAS13 protein, pipette mixing and letting them incubate for 10 minutes.
Sequence in priority
SEQ ID NO document Sequence
1 8 GCUACAACUUCCUCAAGGAACAACAUUGCC
2 28 GCGUACUGCUGCAAUAUUGUUAACGUGAGU
3 31 GUGCGUACUGCUGCAAUAUUGUUAACGUGA
4 51 UGUGACCGAAAGGUAAGAUGGAGAGCCUUG
5 52 GUGUGACCGAAAGGUAAGAUGGAGAGCCUU
6 64 CCGGGUGUGACCGAAAGGUAAGAUGGAGAG
7 95 GUGACCGAAAGGUAAGAUGGAGAGCCUUGU
8 104 ACAUAAUCAGGAUGUAAACUUACAUAGCUC 9 122 AACAACAUUGCCAAAAGGCUUCUACGCAGA
10 129 UACGUUAAUAGUUAAUAGCGUACUUCUUUU
11 131 UUCGUCCGGGUGUGACCGAAAGGUAAGAUG
12 132 UGCUUUUCAAACUGUCAAACCCGGUAAUUU
13 137 UUUCGUCCGGGUGUGACCGAAAGGUAAGAU
14 142 AUGCCAUUAGUGCAAAGAAUAGAGCUCGCA
15 160 ACGAACUUAUGUACUCAUUCGUUUCGGAAG
16 165 UUUACCCAAUAAUACUGCGUCUUGGUUCAC
17 177 UAACUUUAAUCUCACAUAGCAAUCUUUAAU
18 183 AGUUAACUUUAAUCUCACAUAGCAAUCUUU
19 195 GUUUGCGGUGUAAGUGCAGCCCGUCUUACA
20 196 UUGCGGUGU A AG UGCAGCCCGUCUUACACC 21 197 UUUUAAACGGGUUUGCGGUGUAAGUGCAGC 22 199 U UUGCGGUGU AAGUGCAGCCCGUCUUACAC
23 216 AGAGCUGCCUAUAUGGAAGAGCCCUAAUGU
24 219 A A AG G CCA AC A AC A AC A AG G CCA A AC U G U C
25 226 GUAAGUGCAGCCCGUCUUACACCGUGCGGC
26 236 GAGAGCUGCCUAUAUGGAAGAGCCCUAAUG
27 237 GUGUAACAUUAGGGAGGACUUGAAAGAGCC
28 239 AACAUUAGGGAGGACUUGAAAGAGCCACCA
29 240 GUAACAUUAGGGAGGACUUGAAAGAGCCAC
30 246 U G U A AG UGCAGCCCGUCUUACACCGUGCGG
31 254 U A A AG G CCA AC A AC A AC A AG G CCA A AC U G U
32 265 AAGUGCAGCCCGUCUUACACCGUGCGGCAC
33 266 AAG AGCCCU AAUG UG U AAAAU U AAU U U U AG
34 276 CCA AC A AC A AC A AG G CCA A AC U G U C AC U A A
35 284 C U G G U A A AG G CC A AC AAC A AC A AG G CCA A A
36 296 GCAGCCCGUCUUACACCGUGCGGCACAGGC
37 321 CCAAACUGUCACUAAGAAAUCUGCUGCUGA
38 324 ACGUUAAUAGUUAAUAGCGUACUUCUUUUU
39 352 AACCACCU UG U AGG U U UG U U ACAG ACACAC
40 358 AGAGUACACCUUUGAAAAAGGUGACUAUGG
41 362 CCCCAAGGUUUACCCAAUAAUACUGCGUCU
42 367 UGGACUGAGACUGACCUUACUAAAGGACCU
43 374 ACUUUGAUUGUUACGAUGGUGGCUGUAUUA
44 385 AGCUGGUGUCUCUAUCUGUAGUACUAUGAC
45 389 ACACCUUUGAAAAAGGUGACUAUGGUGAUG Sequence in priority
SEQ ID NO document Sequence
46 411 AGAUCUGUUCUCUAAACGAACUUUAAAAUC
47 413 CUCUGAAGAAGUAGUGGAAAAUCCUACCAU
48 422 UAAUAGUUAAUAGCGUACUUCUUUUUCUUG
49 432 CAUCCCUACUAUAACUCAAAUGAAUCUUAA
50 453 ACUUCUUUUUCUUGCUUUCGUGGUAUUCUU
51 458 AAUGUCAUCCCUACUAUAACUCAAAUGAAU
52 460 UAAUAGCGUACUUCUUUUUCUUGCUUUCGU
53 489 GCAAAGAAUAGAGCUCGCACCGUAGCUGGU
54 495 CCAGAUGACCAAAUUGGCUACUACCGAAGA
55 514 CUACUCUUGUGCAGAAUGAAUUCUCGUAAC
56 518 GCUUUUUAGCCUUUCUGCUAUUCCUUGUUU
57 530 A AC U G A U U AC A A AC A U U G G CCG C A A A U U G C
58 540 ACCACCUGGUACUGGUAAGAGUCAUUUUGC
59 543 GACCACCUGGUACUGGUAAGAGUCAUUUUG
60 554 UUUCUAGCAAUGUUGCAAAUUAUCAAAAGG 61 558 UCUGAUAAAGGAGUUGCACCAGGUACAGCU 62 577 GUAGAGUGUUUUGAUAAAUUCAAAGUGAAU
63 579 AGAGUGUUUUGAUAAAUUCAAAGUGAAUUC
64 580 CAAAU U ACAU U ACACAU AAACG AACU U AUG
65 593 CUUACACCGUGCGGCACAGGCACUAGUACU
66 596 GAACCUGAGUUUUAUGAGGCUAUGUACACA
67 600 AACCUGAGUUUUAUGAGGCUAUGUACACAC
68 611 UGUCCUGCUGAAAUUGUUGACACUGUGAGU
69 616 CCUGCUGAAAUUGUUGACACUGUGAGUGCU
70 622 CGUUGUCCUGCUGAAAUUGUUGACACUGUG
71 646 AAAAUUAAUUUUAGUAGUGCUAUCCCCAUG
72 655 GUAAAAUUAAUUUUAGUAGUGCUAUCCCCA
73 660 AGUGCUAUCCCCAUGUGAUUUUAAUAGCUU
74 668 GCUAUCCCCAUGUGAUUUUAAUAGCUUCUU
75 680 GAUUUUAAUAGCUUCUUAGGAGAAUGACAA
76 700 UAUGGCUGUAGUUGUGAUCAACUCCGCGAA
77 701 UUAUGGCUGUAGUUGUGAUCAACUCCGCGA
78 707 GGAAAGGUUAUGGCUGUAGUUGUGAUCAAC
79 708 AAAGGUUAUGGCUGUAGUUGUGAUCAACUC
80 713 AUGUGGAAAGGUUAUGGCUGUAGUUGUGAU 81 716 AG A A U G AC A A A A A A A AAA A A A A A A A A A A A A 82 719 CUGUAGUUGUGAUCAACUCCGCGAACCCAU
83 723 GUUGUACAUAAUCAGGAUGUAAACUUACAU
84 726 UGUACAUAAUCAGGAUGUAAACUUACAUAG
85 729 G AGG ACU UG AAAG AGCCACCACAU U U UCAC
86 737 AG G AC U U G AAAG AGCCACCACAU UUUCACC
87 738 ACU UG AAAG AGCCACCACAU U U UCACCG AG
88 794 CACAUACAAUUGUUGUGAUGAUGAUUAUUU
89 811 GAGCAGAGGCGGCAGUCAAGCCUCUUCUCG
90 822 CUCUAUCUGUAGUACUAUGACCAAUAGACA Sequence in priority
SEQ ID NO document Sequence
91 825 GUCUCUAUCUGUAGUACUAUGACCAAUAGA
92 832 UGUCUCUAUCUGUAGUACUAUGACCAAUAG
93 840 UGACAUGGUACCACAUAUAUCACGUCAACG
94 841 GACAUGGUACCACAUAUAUCACGUCAACGU
95 854 AG UCAAAU U ACAU UACACAUAAACGAACU U
96 859 U UCGG AAG AG ACAGG U ACG U U AAU AG U U AA
97 882 ACUCAUUCGUUUCGGAAGAGACAGGUACGU
98 884 AAG AG ACAGG U ACG U U AAU AG U U AAU AGCG
99 896 CACACCGUUUCUAUAGAUUAGCUAAUGAGU 100 906 UCUGUUGAAUUAAAACACUUCUUCUUUGCU 101 907 UGAAUUAAAACACUUCUUCUUUGCUCAGGA 102 919 GCUCAAAGGAGUCAAAUUACAUUACACAUA
103 929 AAGUUCUGUUGAAUUAAAACACUUCUUCUU
104 935 AAGGAAGUUCUGUUGAAUUAAAACACUUCU
105 952 UUCUUUAAGGAAGGAAGUUCUGUUGAAUUA
106 971 UCUCUAAACGAACUUUAAAAUCUGUGUGGC
107 982 UACACUAGCCAUCCUUACUGCGCUUCGAUU
108 990 UAUUCUUGCUAGUUACACUAGCCAUCCUUA
109 999 AUUCUUGCUAGUUACACUAGCCAUCCUUAC
110 1009 GGUAUUCUUGCUAGUUACACUAGCCAUCCU 111 1031 UACUAUCUAUACAGAACUGGAACCACCUUG 112 1036 AUGGCUUAUUGUUGGCGUUGCACUUCUUGC
113 1048 CUUAUUGUUGGCGUUGCACUUCUUGCUGUU
114 1062 AACUAAUCAGACAAGGAACUGAUUACAAAC
115 1080 UACCCUAACAUGUUUAUCACCCGCGAAGAA
116 1085 U U ACCCU AACAUG U U U AUCACCCGCG AAG A
117 1092 CGGCCCCAAGGUUUACCCAAUAAUACUGCG
118 1128 CUUCUACGCAGAAGGGAGCAGAGGCGGCAG
119 1176 UGUUGAUAAGUACUUUGAUUGUUACGAUGG
120 1180 UACGAUGGUGGCUGUAUUAAUGCUAACCAA 121 1190 UGAAGUUGUUGAUAAGUACUUUGAUUGUUA 122 1191 UGAUAAGUACUUUGAUUGUUACGAUGGUGG
123 1207 GCCACAAGAGCACUAUGUUAGAAUUACUGG
124 1211 ACAGUAAGUGACAACAGAUGUUUCAUCUCG
125 1225 AGUUGAAGUUGUUGAUAAGUACUUUGAUUG
126 1232 AAGUGACAACAGAUGUUUCAUCUCGUUGAC
127 1240 GACAACAGAUGUUUCAUCUCGUUGACUUUC
128 1247 AGCUACUGUAGUAAUUGGAACAAGCAAAUU
129 1257 GCACACUAGAACCAGAAUAUUUCAAUUCAG
130 1264 ACUGAGACUGACCUUACUAAAGGACCUCAU
131 1270 CACACUAGAACCAGAAUAUUUCAAUUCAGU
132 1305 UAAACAACUUAGCUCCAAUUUUGGUGCAAU
133 1325 CUAGACUUUAUUAUGAUUCAAUGAGUUAUG
134 1331 ACAUACAGCUAAUAAAUGGGAUCUCAUUAU
135 1337 CUUUAUUUCACCUUAUAAUUCACAGAAUGC Sequence in priority
SEQ ID NO document Sequence
136 1356 CCUCUUUUGUUUACUCAACCGCUACUUUAG
137 1357 AAGGCUAGACUUUAUUAUGAUUCAAUGAGU
138 1358 GGUAAGGCUAGACUUUAUUAUGAUUCAAUG
139 1365 GUAAGGCUAGACUUUAUUAUGAUUCAAUGA
140 1371 AUGUUUGCAAUGCUCCAGGUUGUGAUGUCA
141 1388 UAAUGGUUACCCUAACAUGUUUAUCACCCG
142 1389 GUUUUGAUAAAUUCAAAGUGAAUUCAACAU
143 1392 UAUACAUUUUGGUGCUGGUUCUGAUAAAGG
144 1397 UACUUUGGCCUCUUUUGUUUACUCAACCGC
145 1399 UUUGAUAAAUUCAAAGUGAAUUCAACAUUA
146 1401 UAAGGCUAGACUUUAUUAUGAUUCAAUGAG
147 1404 UUUGCAGAGUGGUUUUAGAAAAAUGGCAUU
148 1413 U CC A A A A ACCC A UUACUUUAUGAU G CCA AC
149 1417 UGGAGCUAAACUUAAAGCCUUGAAUUUAGG
150 1422 GUUUCUUUAAGGAAGGAAGUUCUGUUGAAU
151 1441 UAAGAUGGAGAGCCUUGUCCCUGGUUUCAA
152 1442 UAUGAGGAUCAAGAUGCACUUUUCGCAUAU
153 1444 UUUCGUCCGUGUUGCAGCCGAUCAUCAGCA
154 1450 UUUCUUUAAGGAAGGAAGUUCUGUUGAAUU
155 1454 UUACGAUAUAUAGUCUACUCUUGUGCAGAA
156 1468 AGCUAAACUUAAAGCCUUGAAUUUAGGUGA
157 1473 AGAGCCUUGUCCCUGGUUUCAACGAGAAAA
158 1485 AUUGAUAAAGUACUUAAUGAGAAGUGCUCU
159 1503 CAUCAUAUGGGUUGCAACUGAGGGAGCCUU
160 1522 AAGAUGGAGAGCCUUGUCCCUGGUUUCAAC 161 1524 GGAGCUAAACUUAAAGCCUUGAAUUUAGGU 162 1532 ACAAGAGGGCAAAAGUUACUAGUGCUAUGC
163 1594 G AG AAACACU UCCCACAG AAG UG U U A AC AG
164 1601 ACUUGGAUUGGCUGCAAUCAUGCAAUUGUU
165 1611 CAAUUCACCAUUUCAUCCUCUAGCUGAUAA
166 1622 CUUCAUUUAAUUAUUUGAAGUCACCUAAUU
167 1637 GAUACAUUCUGUGCUGGUAGUACAUUUAUU
168 1652 GUAGUGCUUUAUUAGAAGAUGAAUUUACAC
169 1665 CUAUGCUAAUGGAGGUAAAGGCUUUUGCAA
170 1701 GGUUUUAGAAAAAUGGCAUUCCCAUCUGGU
171 1713 AGCUUCGCAGCGUGUAGCAGGUGACUCAGG
172 1751 AGUUACAACUGUCAUGUUUUUGGCCAGAGG
173 1772 CCUUUUAUGUCUAUGCUAAUGGAGGUAAAG
174 1791 ACUGUGCCCUUGCACCUAAUAUGAUGGUAA
175 1794 CAAAAGACUUAUGAAAGACAUUCUCUCUCU
176 1796 AUUGGCUGCAAUCAUGCAAUUGUUUUUCAG
177 1802 CACCCGCAAUCCUGCUAACAAUGCUGCAAU
178 1816 ACAACUAUUGUUAAUGGUGUUAGAAGGUCC
179 1820 CAUGUUUUUGGCCAGAGGUAUUGUUUUUAU
180 1845 AUACAAGGCUAUUGAUGGUGGUGUCACUCG Sequence in priority
SEQ ID NO document Sequence
181 1852 AGCAGGUGACUCAGGUUUUGCUGCAUACAG
182 1865 AAUGGAACCAAUUUAUGAUGAACCGACGAC
183 1888 CUUGGUUCACCGCUCUCACUCAACAUGGCA
184 1891 AAAUAAAUUUUUGGCUUUGUGUGCUGACUC
185 1898 AUGAAUGGACGUACCAUAUUGGGUAGUGCU
186 1901 GCAGAAUGAAUUCUCGUAACUACAUAGCAC
187 1907 CUUGUAAAACCUUCUUUUUACGUUUACUCU
188 1915 C A A AG AC AG U G C U U A A A A AG U G U A A A AG U G
189 1916 CGUUGCACUUCUUGCUGUUUUUCAGAGCGC
190 1926 CACUUGUGGCUUAGUAGAAGUUGAAAAAGG
191 1938 AGCUGGUGGCCAUAGUUACGGCGCCGAUCU
192 1954 GUAGCAGGUGACUCAGGUUUUGCUGCAUAC
193 1959 AACUACAUAGCACAAGUAGAUGUAGUUAAC
194 1975 AG AAACAC U U CCCACAGAAG U G U U AAC AG A
195 1982 ACCAUAUUGGGUAGUGCUUUAUUAGAAGAU
196 1986 AGCAGUGACAAUAUUGCUUUGCUUGUACAG
197 1989 CACUACAGUUUAAAAGACCAAUAAAUCCUA
198 1990 AGCUGUGAUCCUUCGUGGACAUCUUCGUAU
199 1991 CGUUGACAGGACACGAGUAACUCGUCUAUC
200 1995 GACAAUAUUGCUUUGCUUGUACAGUAAGUG 201 2001 CAUGCAUGCAAAUUACAUAUUUUGGAGGAA 202 2002 CACGUCAACAUCUUAAAGAUGGCACUUGUG
203 2033 ACUGCUGCAAUAUUGUUAACGUGAGUCUUG
204 2056 GUAAUGUGAAAACUACCGAAGUUGUAGGAG
205 2058 AUGGAGCUGAUGUUACUAAAAUAAAACCUC
206 2059 CUCUUAUAAUCUCUGUUACUUCUAACUACU
207 2078 ACGUACCAUAUUGGGUAGUGCUUUAUUAGA
208 2089 CUGCGGUAUGUGGAAAGGUUAUGGCUGUAG
209 2121 AACAUACGAGGGCAAUUCACCAUUUCAUCC
210 2122 CAACAUCUUAAAGAUGGCACUUGUGGCUUA 211 2131 GGAACUUCUCCUGCUAGAAUGGCUGGCAAU 212 2147 AGAGUUUCUUAGAGACGGUUGGGAAAUUGU
213 2165 CC AG A AC A A ACCC A AG G AAA U UUUGGGGAC
214 2171 GCCUUUGUAAGCACAAGCUGAUGAGUACGA
215 2174 GGGCUCUUAUAAUCUCUGUUACUUCUAACU
216 2182 CCAGAAGCUGGACUUCCCUAUGGUGCUAAC
217 2213 G G U CC AG A AC A A ACCC A AG G AAA U U U U G G G
218 2214 ACAUUUUAUUAGUAAUUCUUGGCUUAUGUG
219 2217 GAGUCUUGUAAAACCUUCUUUUUACGUUUA
220 2218 GUAGUUACAACUGUCAUGUUUUUGGCCAGA 221 2220 AGAGUGUUCAGACAUUCUUUAAGCUUGUAA 222 2221 AGGGGAACUUCUCCUGCUAGAAUGGCUGGC
223 2247 CAUUGUCUGAACAACUACGAAAACAAAUAC
224 2267 CCAGAGGUAUUGUUUUUAUGUGUGUUGAGU
225 2280 GAACAGAAAUCAAUACUGAGUCCUCUUUAU Sequence in priority
SEQ ID NO document Sequence
226 2281 AAGAACGGUAAUAAAGGAGCUGGUGGCCAU
227 2285 GCAAUUCACCAUUUCAUCCUCUAGCUGAUA
228 2308 AACCAAUUUAUGAUGAACCGACGACGACUA
229 2314 AAAACCUUCUUUUUACGUUUACUCUCGUGU
230 2316 CUUAUGUGGUUAAUAAUUAAUCUUGUACAA
231 2326 AGUGCUUUAUUAGAAGAUGAAUUUACACCU
232 2337 GAACUUCUCCUGCUAGAAUGGCUGGCAAUG
233 2338 AAGCACAAGCUGAUGAGUACGAACUUAUGU
234 2351 ACUUUUAAAGUUUCCAUUUGGAAUCUUGAU
235 2373 ACUGGUUCUAUACCUUGUAGUGUUUGUCUU
236 2374 GCUCUUAUAAUCUCUGUUACUUCUAACUAC
237 2379 GGUUAAUAAUUAAUCUUGUACAAAUGGCCC
238 2388 CUGCAAUCAUGCAAUUGUUUUUCAGCUAUU
239 2411 AACUUCUCCUGCUAGAAUGGCUGGCAAUGG
240 2447 AAUAAAGGAGCUGGUGGCCAUAGUUACGGC
241 2459 GAGCUUCGCAGCGUGUAGCAGGUGACUCAG
242 2475 ACUUGACAUUUUAUCUUACUAAUGAUGUUU
243 2498 AAUGUGAAAACUACCGAAGUUGUAGGAGAC
244 2504 AAUUCUUGGCUUAUGUGGUUAAUAAUUAAU
245 2506 GACUCAGGUUUUGCUGCAUACAGUCGCUAC
246 2509 CAGCAGUAGGGGAACUUCUCCUGCUAGAAU
247 2545 G AAAACU ACCG AAG U UG U AGG AG ACAU U AU
248 2568 CUAUUGAUGGUGGUGUCACUCGUGACAUAG
249 2579 UUCUUAGAGACGGUUGGGAAAUUGUUAAAU
250 2585 UU AUG UCAUGCAUGCAAAUU ACAU AUUUUG
251 2587 UAUAGUUUUUGAUGGUAAAUCAAAAUGUGA
252 2591 UUUAGAAAAAUGGCAUUCCCAUCUGGUAAA
253 2593 UUAGAAGAGCUUUUGGUGAAUACAGUCAUG
254 2595 UUUUGAUGGUAAAUCAAAAUGUGAAGAAUC
255 2612 UUUAGAAGAGCUUUUGGUGAAUACAGUCAU
256 2618 UAGUGCUUUAUUAGAAGAUGAAUUUACACC
257 2620 UUCUUCUUCGUAAGAACGGUAAUAAAGGAG
258 2632 UCCUCAUCACGUAGUCG C A AC AG U U C A AG A
259 2643 UGACUUUCAGGUUACUAUAGCAGAGAUAUU
260 2659 UUCAUUCCUUAAUGGUUCAUGUGGUAGUGU 261 2662 U U U UAAAAUGAAU U AUCAAG UUAAUGGUUA 262 2665 UUCAUUGCCUAUUAAUGUUAUAGUUUUUGA
263 2668 U AAC AG AG G AAG U U G U C U UGAAAAC U GG U G
264 2672 UCUUUUGGUGGUGUCAGUGUUAUAACACCA
265 2691 UUAUUCUGUUAUUUACUUGUACUUGACAUU
266 2693 UUACUCUCGUGUUAAAAAUCUGAAUUCUUC
267 2695 UGACAGGACACGAGUAACUCGUCUAUCUUC
268 2708 UGGGUGAUGCGUAUUAUGACAUGGUUGGAU
269 2714 UAGAAGGUCCUUUUAUGUCUAUGCUAAUGG
270 2716 UAUGAAUGGACGUACCAUAUUGGGUAGUGC Sequence in priority
SEQ ID NO document Sequence
271 2717 GUUAACAGAGGAAGUUGUCUUGAAAACUGG
272 2721 UCAUUGCCUAUUAAUGUUAUAGUUUUUGAU
273 2726 UGACUCAGGUUUUGCUGCAUACAGUCGCUA
274 2741 GUUUUAAAAUGAAUUAUCAAGUUAAUGGUU
275 2746 UAUGUGGAAAGGUUAUGGCUGUAGUUGUGA
276 2747 UCAUUCCUUAAUGGUUCAUGUGGUAGUGUU
277 2753 UUUUCAGCUAUUUUGCAGUACAUUUUAUUA
278 2759 UGGCGUUGCACUUCUUGCUGUUUUUCAGAG
279 2767 UUAUAAAGUUUAUUAUGGUAAUGCUUUAGA
280 2783 UUAUACCUACUAAAAAGGCUGGUGGCACUA 281 2784 UACAAUGGUUCACCAUCUGGUGUUUACCAA 282 2793 GUUAGAAGGUCCUUUUAUGUCUAUGCUAAU
283 2795 UAAUAAAGGAGCUGGUGGCCAUAGUUACGG
284 2799 UUUCCAUUUAAUAAAUGGGGUAAGGCUAGA
285 2801 U U UAAAAUGAAU U AUCAAG UUAAUGGUUAC
286 2813 UUAAAAGACCAAUAAAUCCUACUGACCAGU
287 2829 UACAACUGUCAUGUUUUUGGCCAGAGGUAU
288 2830 UGUUAGAAGGUCCUUUUAUGUCUAUGCUAA
289 2841 UGAUAGUGUUACAGUGAAGAAUGGUUCCAU
290 2867 U CC AG A AC A A ACCC A AG G AAA UUUUGGGGA
291 2868 UUUUCCAUUUAAUAAAUGGGGUAAGGCUAG
292 2870 UGGUGUCAGUGUUAUAACACCAGGAACAAA
293 2876 UACUUCUAACUACUCAGGUGUAGUUACAAC
294 2899 UCCUUUUAUGUCUAUGCUAAUGGAGGUAAA
295 2906 UAAUGGUGUUAGAAGGUCCUUUUAUGUCUA
296 2917 UCUUCUUCGUAAGAACGGUAAUAAAGGAGC
297 2921 UUCACCGCUCUCACUCAACAUGGCAAGGAA
298 2929 UCUUGAGUGUAAUG U G AAAAC U ACCG AAG U
299 2931 UGGCCAUAGUUACGGCGCCGAUCUAAAGUC
300 2933 UAUGUCAUGCAUGCAAAUUACAUAUUUUGG
301 2935 GUUUAUUCUGUUAUUUACUUGUACUUGACA
302 2950 UAAUUGUGAUACAUUCUGUGCUGGUAGUAC
303 2956 UGACAUACUAGGACCUCUUUCUGCUCAAAC
304 2962 UUGUGUAUCUACUAGUGGUAGAUGGGUACU
305 2988 UCAAAAGACUUAUGAAAGACAUUCUCUCUC
306 2992 UAAAGAUUUCAUGUCAUUGUCUGAACAACU
307 2993 UGCAGAGUGGUUUUUGGCAUAUAUUCUUUU
308 3005 UAUACCUACUAAAAAGGCUGGUGGCACUAC
309 3006 UUCUAUACCUUGUAGUGUUUGUCUUAGUGG
310 3007 UAAAAAUCUGAAUUCUUCUAGAGUUCCUGA
311 3009 GUUAAAAAUCUGAAUUCUUCUAGAGUUCCU
312 3010 UUUUGCUGCAUACAGUCGCUACAGGAUUGG
313 3017 UAACGUGAGUCUUGUAAAACCUUCUUUUUA
314 3029 UUUUGGCCAGAGGUAUUGUUUUUAUGUGUG
315 3042 UUUUAGAAAAAUGGCAUUCCCAUCUGGUAA Sequence in priority 21
SEQ ID NO document Sequence
316 3055 UCUAUACCUUGUAGUGUUUGUCUUAGUGGU
317 3103 UUCAUCUCGUUGACUUUCAGGUUACUAUAG
318 3107 UGUAGUUACAACUGUCAUGUUUUUGGCCAG
319 3113 UGCACUUCUUGCUGUUUUUCAGAGCGCUUC
320 3115 UAUUUACUUGUACUUGACAUUUUAUCUUAC
321 3141 GUUCAUUCCUUAAUGGUUCAUGUGGUAGUG
322 3158 UGUUUAUUCUGUUAUUUACUUGUACUUGAC
323 3164 UGUGGACAUGUCAAUGACAUAUGGACAACA
324 3168 G U U U ACAACAG U AG ACAACAU U AACCUCCA
325 3169 U U C AACG AG AAAAC ACACG UCCAAC U CAG U
326 3177 UGAUGAGCCUGAAGAACAUGUCCAAAUUCA
327 3183 UAGCUUGUUACAAUGGUUCACCAUCUGGUG
328 3186 UUGAUUAUGGUGCUAGAUUUUACUUUUACA
329 3190 U U ACAACAG U AG ACAACAU U AACCUCCACA
330 3193 UGUGGUUGAUUAUGGUGCUAGAUUUUACUU
331 3210 UUUGUUGAUUCAGAUGUAGAAACUAAAGAU
332 3215 UUGUUGAUUCAGAUGUAGAAACUAAAGAUG
333 3225 UGAUUCAGAUGUAGAAACUAAAGAUGUUGU
334 3227 UGAUUAUGGUGCUAGAUUUUACUUUUACAC
335 3230 UAUUGGGAACCUGAGUUUUAUGAGGCUAUG
336 3244 UCAUUCAAUCCAGAAACUAACAUUCUUCUC
337 3247 UUGUAUUAACGGGCUUAUGUUGCUCGAAAU
338 3252 UGGUACACCAGUUUGUAUUAACGGGCUUAU
339 3261 U G G AC A A A UUGUCACCUGUG C A A AG G A A A U
340 3272 GUUACAGUGAAGAAUGGUUCCAUCCAUCUU
341 3277 GUUUGUUGAUUCAGAUGUAGAAACUAAAGA
342 3285 UGUAGAGUUUCUUAGAGACGGUUGGGAAAU
343 3308 UGUAUACUGCUGCCGUGAACAUGAGCAUGA
344 3310 UGAGGCUGAAGUGCAAAUUGAUAGGUUGAU
345 3315 UUUGUAGAUGAUAUCGUAAAAACAGAUGGU
346 3327 UCAGACAUUCUUUAAGCUUGUAAAUAAAUU
347 3329 UACAGUGAAGAAUGGUUCCAUCCAUCUUUA
348 3332 UCUGAAAAGAGCUAUGAAUUGCAGACACCU
349 3336 UUGGUACACCAGUUUGUAUUAACGGGCUUA
350 3345 GUGUGGUUGAUUAUGGUGCUAGAUUUUACU
351 3355 UG U U U ACAACAG U AG ACAACAU U AACCUCC
352 3358 GUUCAGACAUUCUUUAAGCUUGUAAAUAAA
353 3363 UUUCGCUUUUCCGUUUACGAUAUAUAGUCU
354 3367 U ACACCAG U U UG U AU U AACGGGCU U AUG U U
355 3404 U AC U A A A A U A A A ACC UCAUAAUUCACAUGA
356 3405 U U U C AACG AG AAAAC ACACG UCCAAC U CAG
357 3407 UGCCACAUAGAUCAUCCAAAUCCUAAAGGA
358 3428 GCUAUAUAAACGUUUUCGCUUUUCCGUUUA
359 3440 GGUGUAUACUGCUGCCGUGAACAUGAGCAU
360 3451 CAUUCAAUCCAGAAACUAACAUUCUUCUCA Sequence in priority
SEQ ID NO document Sequence
361 3453 GUAUACUGCUGCCGUGAACAUGAGCAUGAA
362 3475 AAUGCUGCUAUCAGCGAUUAUGACUACUAU
363 3489 GGUCAUUCAAUCCAGAAACUAACAUUCUUC
364 3508 CUGUACCGUCUGCGGUAUGUGGAAAGGUUA
365 3516 CGCAAAAUAUACUCAACUGUGUCAAUAUUU
366 3520 AAGGUGUAGAGUUUCUUAGAGACGGUUGGG
367 3537 GCUUGUGAAAUUGUCGGUGGACAAAUUGUC
368 3550 AAAUUAAGGAGAGUGUUCAGACAUUCUUUA
369 3551 GGUUGAUUAUGGUGCUAGAUUUUACUUUUA
370 3554 GGACAUGUCAAUGACAUAUGGACAACAGUU
371 3557 ACACCAGUUUGUAUUAACGGGCUUAUGUUG
372 3569 AGAUGUAGUUAACUUUAAUCUCACAUAGCA
373 3575 GUGUAUACUGCUGCCGUGAACAUGAGCAUG
374 3586 ACAUGUCAAUGACAUAUGGACAACAGUUUG
375 3619 CUGAAGCAAAAUGUUGGACUGAGACUGACC
376 3642 CAGAUGGGCUAUAUAAACGUUUUCGCUUUU
377 3655 CACCUGUGCAAAGGAAAUUAAGGAGAGUGU
378 3664 AAUUGUGACACAUUAAAAGAAAUACUUGUC
379 3667 CGGUGGACAAAUUGUCACCUGUGCAAAGGA
380 3673 CUAUAUAAACGUUUUCGCUUUUCCGUUUAC
381 3686 GACCGAAAGGUAAGAUGGAGAGCCUUGUCC
382 3694 AUUGGGAACCUGAGUUUUAUGAGGCUAUGU
383 3709 GACACAUUAAAAGAAAUACUUGUCACAUAC
384 3719 AGAAACUAAAGAUGUUGUUGAAUGUCUUAA
385 3720 GUAGAGUUUCUUAGAGACGGUUGGGAAAUU
386 3726 AUAAUGAUGCACUCAACAACAUUAUCAACA
387 3741 AC A A A UUGUCACCUGUG C A A AG G A A A U U A A
388 3775 CAAGGGUUUGUUGAUUCAGAUGUAGAAACU
389 3777 GAACAUGAGCAUGAAAUUGCUUGGUACACG
390 3786 AGAUGAUAUCGUAAAAACAGAUGGUACACU
391 3803 G G AC A A A UUGUCACCUGUG C A A AG G A A A U U
392 3804 GUGGUUGAUUAUGGUGCUAGAUUUUACUUU
393 3805 CCAACUUAUUUGGAUGGAGCUGAUGUUACU
394 3829 G C A A AG G A A A UUAAGGAGAGUGUUCAGACA
395 3833 AUACUGCUGCCGUGAACAUGAGCAUGAAAU
396 3841 GAAGAAUGGUUCCAUCCAUCUUUACUUUGA
397 3856 GACUCUUCUUCCUGCUGCAGAUUUGGAUGA
398 3858 ACCGUCUGCGGUAUGUGGAAAGGUUAUGGC
399 3866 GAAAUGGUCAUGUGUGGCGGUUCACUAUAU
400 3872 CACGCCUAAACGAACAUGAAAUUUCUUGUU
401 3899 CCCUGGUUU CAACG AG AAAACAC ACG U CCA
402 3900 AGACAACAUUAACCUCCACACGCAAGUUGU
403 3905 CUUGACAAAGUUGAGGCUGAAGUGCAAAUU
404 3914 CUGUUUUGUAGAUGAUAUCGUAAAAACAGA
405 3935 CUACCCUCUUGAGUGCAUUAAAGACCUUCU Sequence in priority
SEQ ID NO document Sequence
406 3936 AAUGCUGAUCUUUAUAAGCUCAUGGGACAC
407 3948 CAACAUCAAUAUUGUUGGUGACUUUAAACU
408 3950 CCUCUUUAUGCAUUUGCAUCAGAGGCUGCU
409 3954 AAGCCAAUAUGGAUCAAGAAUCCUUUGGUG
410 3979 CAUUCAGUACGGUCGUAGUGGUGAGACACU
411 3988 C A A AG A A A UUUGACACCUUCAAUGGGGAAU
412 3998 AGCUGAUGUUACUAAAAUAAAACCUCAUAA
413 4004 AACUGGUAUGAUUUCGGUGAUUUCAUACAA
414 4018 ACUGCCGUUGCCACAUAGAUCAUCCAAAUC
415 4019 GGCAACCGGGUGUUGCUAUGCCUAAUCUUU
416 4026 C U A A A A UGUCAGAUGU A A AG U G C AC A U C AG
417 4029 CACUUAUCAACACACUUAACGAUCUAAAUG
418 4032 GGUUAUACUGAAAAAUGGGAAUCUGGAGUA
419 4082 ACAAG UUUUUGGUU U AU AU AAAAAU ACAUG
420 4105 AGCAGAACUCGAAGGCAUUCAGUACGGUCG
421 4113 GAUGGCACAACAAGUCCUAUUUCUGAACAU
422 4116 CCAAUGUUAAUGCACUUUUAUCUACUGAUG
423 4135 GCAGAUAACAACUGUUAUCUUGCCACUGCA
424 4139 AAUUACCAACUGGAGUUCAUGCUGGCACAG
425 4168 AUAACACGUUGCAAUUUAGGUGGUGCUGUC
426 4170 ACUGCCACU A A AG CAU AC A A U G U A AC AC A A
427 4171 ACGCCAAGCU U UG U U AAAAACAG UACAAU U
428 4172 AUGAAAAUGCCUUUUUACCUUUUGCUAUGG
429 4186 AGGUUUGUUACAGACACACCUAAAGGUCCU
430 4190 CCAAUUCUGCUGUCAAAUUACAGAAUAAUG
431 4213 AGGUUUGUACUUGCACUGUUAUCCGAUUUA
432 4222 AAUUACCAGUGUGGUCACUAUAAACAUAUA
433 4229 GGUUAUACCUACUAAAAAGGCUGGUGGCAC
434 4237 G AC A A AG Cl) U AU AAAAU AG AAG AAU U AU UC
435 4249 GUCAACCUAUACUGUUACUAGAUCAGGCAU
436 4277 G U ACU U U U ACU AG AAG U ACAAAU UCU AG AA
437 4282 CCUUGAAGCCCCUUUUCUCUAUCUUUAUGC
438 4287 GCUGGUGAAGCUGCUAACUUUUGUGCACUU
439 4317 CCACAAAUAGGCGUGGUAAGAGAAUUCCUU
440 4319 CGUUUUGCCUCAACUUGAACAGCCCUAUGU
441 4324 AUUUAUACUUUAU U AAAGG AU U AAACAACC
442 4325 CCACAAAUUAUGAUUUGAGUGUUGUCAAUG
443 4333 ACGCGCAGGGAAUGGAUAAUCUUGCCUGCG
444 4337 GGGGCGCGAUCAAAACAACGUCGGCCCCAA
445 4346 CUGAAGUGCAAAUUGAUAGGUUGAUCACAG
446 4377 AAUUUCAAAAAUCUUAGGGAAUUUGUGUUU
447 4397 GGUCGCACUAUUGCCUUUGGAGGCUGUGUG
448 4408 ACGCGUUCCAUGUGGUCAUUCAAUCCAGAA
449 4426 GGUGCAUCGUGUUGUCUGUACUGCCGUUGC
450 4428 GCUUUUGACAUCUACAAUGAUAAAGUAGCU Sequence in priority
SEQ ID NO document Sequence
451 4430 CCACACAGAUCUAAUGGCUGCUUAUGUAGA
452 4438 GUGCCUAUUGGGUUCCACGUGCUAGCGCUA
453 4445 GGGGGACAACCAAUCACUAAUUGUGUUAAG
454 4463 CUUCUUACAUCGUUGAUAGUGUUACAGUGA
455 4472 GCAGAAAAUUCAGUUGCUUACUCUAAUAAC
456 4510 GCUGGUAGUACAUUUAUUAGUGAUGAAGUU
457 4515 AAU U ACCU AAAG AG ACG UG U AG UCU U UAAU
458 4526 A AC UUACACCAGUUGUUCAGACUAU U G A AG
459 4537 G AAUGUCCAAAU UUUGU AU UUCCCUU AAAU
460 4538 GUCUUUAGCUAUAGAUGCUUACCCACUUAC
461 4540 GCACUUGGAAAACUUCAAGAUGUGGUCAAC
462 4549 ACGCUGCUGUUAUAAAUGGAGACAGGUGGU
463 4554 ACGCUGCUUGUCGAUUCAGAUCUUAAUGAC
464 4557 GCACUUGACCCUCUCUCAG A A AC A A AG U G U
465 4565 AUGAACUUAAGCAUGGUACAUUUACUUGUG
466 4571 GAAAGG U U UGG AU U AU AAAGCAU UCAAACA
467 4573 ACGCUGUGACAUCAAGGACCUGCCUAAAGA
468 4585 AUGAAGAAGAAGGUGAUUGUGAAGAAGAAG
469 4593 GCACUUAUCUUAGCCUACUGUAAUAAGACA
470 4605 GGCAACUUUACAAGC U G A A A A U G U A AC AG G
471 4609 GUAGAAUUCGAUCUGUCUAUCCAGUUGCGU
472 4626 CUUCUUGCAUGUGACUUAUGUCCCUGCACA
473 4647 GAAUUUGUGUUUAAGAAUAUUGAUGGUUAU
474 4656 AAUUAUAAUUACCUGUAUAGAUUGUUUAGG
475 4674 GCUGGUAAAGCUUCAUGCACUUUGUCCGAA
476 4681 AGAACGCAGUGGGGCGCGAUCAAAACAACG
477 4685 ACGG ACACAACU AU UACAG UUAAUGUUUUA
478 4712 GAUGGUACAACAUUUACUUAUGCAUCAGCA
479 4734 CCU AAAG UGAAG UAUUUAUACUUUAU U AAA
480 4760 AC A A U C A A A A AG AGUUGAUUUUUGU G G A A A
481 4776 CCUACUCAUGCCUCU A A A AG CCCC A A A AG A
482 4794 CUUGAAAACCAUUCUUCGUAAGGGUGGUCG
483 4795 CUUGAAAACUGGUGAUUUACAACCAUUAGA
484 4796 ACUGAUGUCGUAUACAGGGCUUUUGACAUC
485 4804 AUAAUCUUGCCUGCGAAGAUCUAAAACCAG
486 4821 GAAUUUCAAUUUUGUAAUGAUCCAUUUUUG
487 4827 ACAAUCACUUCUGGUUGGACCUUUGGUGCA
488 4828 AC A A U C AG AC A AC U AC U A U U C A A AC A A U U G
489 4843 CUUGAAAUUCCACGUAGGAAUGUGGCAACU
490 4869 CUGCUUACGGUUUCGUCCGUGUUGCAGCCG
491 4872 CCACGAGUGCUUUGUUAAGCGUGUUGACUG
492 4877 CUUUCAUUUGUACU U ACAAU ACAU AAG AAA
493 4879 CUUGAACGUGGUGUGUAAAACUUGUGGACA
494 4896 CU UGAAG AG AAG U U U AAGG AAGG UG U AG AG
495 4899 GCACGUAGUGUAGCUAGUCAAUCCAUCAUU Sequence in priority
SEQ ID NO document Sequence
496 4902 CCACGCGGAGUACGAUCGAGUGUACAGUGA
497 4905 GUCUGGUAACUGUGAUGUUGUAAUAGGAAU
498 4909 AACAACUUUUGAUUCUGAGUACUGUAGGCA
499 4916 CACUUGGUGCAGAAAAUUCAGUUGCUUACU
500 4931 AACUGUUUCUUGGAAUUUGCGAGAAAUGCU
501 4936 AGUUUAGCUGCCACAGUACGUCUACAAGCU
502 4940 GUAGAAGCUGUUAUGUACAUGGGCACACUU
503 4963 AUUUAACUGCUUUUGGCUUAGUUGCAGAGU
504 4964 AGGUUCCGUGGCUAUAAAGAUAACAGAACA
505 4970 GCACCUUUUUGUUAAAUAAAGAAAUGUAUC
506 4971 CCUUGAUUGGCUUGAAGAGAAGUUUAAGGA
507 4978 AGUUUAGAUAUAUGAAUUCACAGGGACUAC
508 4987 CACUUGUGAAAGAUCAGAAGCUGGUGUUUG
509 5008 CUUGACACUCGUUUAUAAAGUUUAUUAUGG
510 5042 ACAAUCUACACAACUAGGUAUAGAAUUUCU
511 5043 GCACCUACACUAGUGCCACAAGAGCACUAU
512 5083 GAUGGUGGCAGUUUGUAUGUAAAUAAACAU
513 5092 AGAAUGGAAGUUCUAUGAUGCACAGCCUUG
514 5100 CUGCUUAUGUAGACAAUUCUAGUCUUACUA
515 5108 ACGGUCGUAGUGGUGAGACACUUGGUGUCC
516 5136 AUUGUUUUUAUGUGUGUUGAGUAUUGCCCU
517 5141 AUGAAUUCAUUGAACGGUAUAAAUUAGAAG
518 5155 GCACCACUCACUGUCUUUUUUGAUGGUAGA
519 5167 AGUUUACUGUCCAAGACAUGUGAUCUGCAC
520 5171 AGCAAUGGAUACAACUAGCUACAGAGAAGC
521 5177 AACAAGCAAAUUCUAUGGUGGUUGGCACAA
522 5211 GCACCAACAAAGGUUACUUUUGGUGAUGAC
523 5215 GCUUUUCAGUAGCUGCACUUACUAACAAUG
524 5217 GGUUGCCUACGGGUACGCUGCUUGUCGAUU
525 5225 AAUUUCACAGUAUUCACUGAGACUCAUUGA
526 5238 AUGGCUACAUACUACUUAUUUGAUGAGUCU
527 5257 AUG AC A A AG A U CCA A All U U C A A AG A U C A AG
528 5260 GCACAUGGCUUUGAGUUGACAUCUAUGAAG
529 5264 AUUAUAAAGCAUUCAAACAAAUUGUUGAAU
530 5266 GAGCUUAACGGAGGGGCAUACACUCGCUAU
531 5280 AAUUACUUGUGUAUGCUGCUGACCCUGCUA
532 5284 GCACAUCAGUAGUCUUACUCUCAGUUUUGC
533 5291 AUUGUUGGUGUACUGACAUUAGAUAAUCAA
534 5320 AG C AC A A A ACC AG U U G A A AC A U C A A A U U CG
535 5347 CUUGAUGACGUAGUUUACUGUCCAAGACAU
536 5371 AUUGUUCUUUCUACCCUCCAGAUGAGGAUG
537 5381 AGAAAACCCUCACCUUAUGGGUUGGGAUUA
538 5392 AUGACAGAUGCAUUCUGCAUUGUGCAAACU
539 5399 CGUUCCAAUUAACACCAAUAGCAGUCCAGA
540 5404 GCACACUUUCUUAUGAACAAUUUAAGAAAG Sequence in priority
SEQ ID NO document Sequence
541 5419 AGCACACCUUGUAAUGGUGUUGAAGGUUUU
542 5431 G AAU UCAACAUUAGAACAGU AUG UCU UUUG
543 5447 CUUGAUGUGGCUCAGCUACUUCAUUGCUUC
544 5449 AGGUGUUGCAGGAGCCUUAAAUAAGGCUAC
545 5453 AACUGUGAUGUUGUAAUAGGAAUUGUCAAC
546 5479 ACUGACAUUAGAUAAUCAAGAUCUCAAUGG
547 5497 AGUUUACAGUCAUGUACUCAACAUCAACCA
548 5517 CUUGAUUGCCAUAGUAAUGGUGACAAUUAU
549 5557 AUGCCUAUUUUGGAAUUGCAAUGUCGAUAG
550 5563 CGGGCACGUAGUGUAGCUAGUCAAUCCAUC
551 5565 AUAACAAUUGCUUAUAUCAUUUGUAUUUCC
552 5576 GCACAAAAGUUUAACGGCCUUACUGUUUUG
553 5577 AUGACCAGUUGCUGUAGUUGUCUCAAGGGC
554 5583 CCAGACAUGUUCCUCGGAACUUGUCGGCGU
555 5598 AAUCAUCACAACUGUAGCUGCAUUUCACCA
556 5599 GCAAUUUCAAGUGUUUUAAAUGAUAUCCUU
557 5637 CCAGAGUACUCAAUGGUCUUUGUUCUUUUU
558 5650 ACGUCUACAAGCUGGUAAUGCAACAGAAGU
559 5666 ACUGAAGUCAGAGGACGCGCAGGGAAUGGA
560 5687 GUCGGUAAAUUUUGUCUAGAGGCUUCAUUU
561 5698 GGUGAUUCAACUGAAUGCAGCAAUCUUUUG
562 5703 AGCUGGUUUUGCUAAAUUCCUAAAAACUAA
563 5719 A A A A AC U C A A A AC AC UAGUUGCAACUGCAG
564 5720 AAAAGUGCCUUUUACAUUCUACCAUCUAUU
565 5729 ACGUGAAGUGCUGUCUGACAGAGAAUUACA
566 5733 GAUGUAGAAAACCCUCACCUUAUGGGUUGG
567 5749 AAUUAGAGGUGAUGAAGUCAGACAAAUCGC
568 5756 ACUGAAGAUGAUUACCAAGGUAAACCUUUG
569 5783 ACGUGCAUGGAUUGGCUUCGAUGUCGAGGG
570 5792 CGCUUCCAAGAAAAGGACGAAGAUGACAAU
571 5803 CGUGUUUAUUCUACAGGUUCUAAUGUUUUU
572 5807 G G U A A AC A AG C U AC A AAA UAUCUAGUACAA
573 5809 CCGCAAAUUGCACAAUUUGCCCCCAGCGCU
574 5811 CCAGCAUGUCACAAUUCAGAAGUAGGACCU
575 5816 AAGUUGUCUUGAAAACUGGUGAUUUACAAC
576 5839 CUUGCCGAAUACCAUAAUGAAUCUGGCUUG
577 5847 AAAUAAACAUGCAUUCCACACACCAGCUUU
578 5868 ACGUGGCUUUGGAGACUCCGUGGAGGAGGU
579 5878 ACUGAAAGACUCAAGCUUUUUGCAGCAGAA
580 5909 AACGUUCUGAAAAGAGCUAUGAAUUGCAGA
581 5913 GGUAAAAUUGUUAAUAAUUGGUUGAAGCAG
582 5918 ACAAUGUACAUUUGUGGUGAUUCAACUGAA
583 5923 AUUGUCCAGCUGUUGCUAAACAUGACUUCU
584 5930 AACUGUAACUUUGAAG C A AG G U G AAA U C A A
585 5936 AGACAUCAUGCUAAUGAGUACAGAUUGUAU Sequence in priority
SEQ ID NO document Sequence
586 5942 CCAGCUGUUGCUAAACAUGACUUCUUUAAG
587 5944 CGAGGGGUGUCAUGCUACUAGAGAAGCUGU
588 5949 G AGG ACU AU U AAGG UG U U U ACAACAG U AG A
589 5960 ACGUGUGGUAAACAAGCUACAAAAUAUCUA
590 5964 GAUGUCACAGAUGUGACUCAACUUUACUUA
591 5968 C ACC A A A U G A A U G C A ACC A A A UGUGCCUUU
592 5970 GUACCUUCCUUACCCAGAUCCAUCAAGAAU
593 5974 AUUGUCAAGUCCAUGGUAAUGCACAUGUAG
594 5991 CUUUAUGGGUAGAAUUCGAUCUGUCUAUCC
595 5994 CUCAGCUACUUCAUUGCUUCUUUCAGACUG
596 6029 AAG UUGG U AAACCU AG ACCACCACU U AACC
597 6030 GGUAAUUAUAAUUACCUGUAUAGAUUGUUU
598 6061 AUUGUAGCUAUCGUAGUAACAUGCCUUGCC
599 6109 GCAAGGUUACAAGAGUGUGAAUAUCACUUU
600 6136 AUUGUACAG A A AG U G U G U U AAA U CC AG AG A 601 6150 AAGUUGGAAAAGAUGGCUGAUCAAGCUAUG 602 6165 ACG U U G AAA UCCUUCACUGUAG A A A A AG G A
603 6188 CGGUAAAUUUUGUCUAGAGGCUUCAUUUAA
604 6190 GGGUUUUGUCGUGCCUGGUUUGCCUGGCAC
605 6193 CCAGUAACUUUAGCUUGUUUUGUGCUUGCU
606 6211 AGGUGAGUUAGGUGAUGUUAGAGAAACAAU
607 6221 AAAACACGUCUAUCAGUUACGUGCCAGAUC
608 6224 CCUACCAUUUAAUGAUGGUGUUUAUUUUGC
609 6234 CUCUCAGCCUUUUCUUAUGGACCUUGAAGG
610 6290 AAGUUGCAGUUAAAAUGUUUGAUGCUUACG 611 6292 CUGCUUUUGCAAUGAUGUUUGUCAAACAUA 612 6297 AUGAGCAGUAUAUAAAAUGGCCAUGGUACA
613 6303 GGUUACUUACCCCAAAAUGCUGUUGUUAAA
614 6310 AACUGGUACUAUCUAUACAGAACUGGAACC
615 6344 GCAACUGUACAUACAGCUAAUAAAUGGGAU
616 6355 CCAGUUACACAAUGACAUUCUCUUAGCUAA
617 6357 AUACCUUACAAUAGUGUAACUUCUUCAAUU
618 6371 AACUCGUCUAUCUUCUGCAGGCUGCUUACG
619 6381 GUGCUCAAGUAUUGAGUGAAAUGGUCAUGU
620 6388 AUGAGCUAUUAUUGUAAAUCACAUAAACCA 621 6395 GCAACUACUAGACAAGUUGUUAAUGUUGUA 622 6402 CGUGGUAAGAGAAUUCCUUACACGUAACCC
623 6411 GAUGUGCUAUUACCUCUUACGCAAUAUAAU
624 6420 AGGUCUUAUCAGAGGCACGUCAACAUCUUA
625 6433 GCAACCU U ACAAGCU AU AGCCUCAG AG U U U
626 6444 ACAAUUAUGAACCUCUAACACAAGACCAUG
627 6448 AACUGGGCCAGAAGCUGGACUUCCCUAUGG
628 6484 ACAAU U AU U AU AAG AAAG ACAAU UCU U AU U
629 6486 AGGCUGUGUGUUCUCUUAUGUUGGUUGCCA
630 6504 GCAACAUUACCUAAAGGCAUAAUGAUGAAU Sequence in priority
SEQ ID NO document Sequence
631 6510 GGGUUUUACACUUAAAAACACAGUCUGUAC
632 6512 GUGAUGGUACAACAUUUACUUAUGCAUCAG
633 6520 AUUGGCUUCGAUGUCGAGGGGUGUCAUGCU
634 6533 GAUGUGGUGGCUAUUGAUUAUAAACACUAC
635 6535 ACAAUUCACCUAAUUUAGCAUGGCCUCUUA
636 6557 AUGAGGCUGGUUCUAAAUCACCCAUUCAGU
637 6572 AUGGUUAUGUUCACACCUUUAGUACCUUUC
638 6597 GCAAAUUGAUAGGUUGAUCACAGGCAGACU
639 6603 CCAUAGUUACGGCGCCGAUCUAAAGUCAUU
640 6605 AGGUCCCAAACAAGCUAGUCUUAAUGGAGU
641 6618 ACAAUUCUGUGAUGCCAUGCGAAAUGCUGG
642 6619 CGAAAUACCAGUGGCUUACCGCAAGGUUCU
643 6620 AUUAUUGCUAUGUCUGCUUUUGCAAUGAUG
644 6625 GAACAAUGCUAGGGAGAGCUGCCUAUAUGG
645 6630 CCUACAUUACAGGUGGUGUUGUUCAGUUGA
646 6634 AUUGGCAACUAUAAAUUAAACACAGACCAU
647 6635 ACUAAGAGGUUUGAUAACCCUGUCCUACCA
648 6649 GUAUAACACGUUGCAAUUUAGGUGGUGCUG
649 6662 CCU UGUCCCUCAUGUGGGCG AAAU ACCAGU
650 6673 AUUGGAGUUACACAGAAUGUUCUCUAUGAG
651 6674 AGAAGGUUCCGAAGGUCUUAAUGACAACCU
652 6682 CACAU U AAU UGG AG AAGCCG UAAAAACACA
653 6715 CUCAGAAUAUGACUAUGUCAUAUUCACUCA
654 6719 GAGCUUUAUCACUACCAAGAGUGUGUUAGA
655 6730 CGUGCCUGGUUUGCCUGGCACGAUAUUACG
656 6758 CACAUG U UG ACACUG ACU UAACAAAGCCU U
657 6802 GCAAACUUUAAUGUUUUAUUCUCUACAGUG
658 6820 GCAAACUGGAAAGAUUGCUGAUUAUAAUUA
659 6831 CCGAACAACUGGACUUUAUUGACACUAAGA
660 6839 AAGUUCUAUGAUGCACAGCCUUGUAGUGAC 661 6882 GAACUCAUGCGUGAGCUUAACGGAGGGGCA 662 6892 AGAAAACCCAGAUAUAUUACGCGUAUACGC
663 6897 ACUAAUUAUAUGCCUUAUUUCUUUACUUUA
664 6904 AUUGCUGGACACCAUCUAGGACGCUGUGAC
665 6908 GCUGCU AAAAAG AAU AACU UACCUUU UAAG
666 6913 CACAUGGCUUUGAGUUGACAUCUAUGAAGU
667 6923 GAUGUUAGAGAAACAAUGAGUUACUUGUUU
668 6940 GGUUUCUCAAUCGAUUUACCACAACUCUUA
669 6949 GGGUGAUGUUGUUCAAGAGGGUGUUUUAAC
670 6969 ACUACAAAAGAGAUGCUCCAGCACAUAUAU
671 6976 GCAAAAGUUACUAGUGCUAUGCAGACAAUG
672 6987 AGGUAUGAGCUAUUAUUGUAAAUCACAUAA
673 7002 AG U UG U U AAUCCAG U A A U G G A ACC A A U U U A
674 7009 AUUGCUACUGUACGUGAAGUGCUGUCUGAC
675 7010 AAUUGGAACAAGCAAAUUCUAUGGUGGUUG Sequence in priority
SEQ ID NO document Sequence
676 7029 ACUACACAAACUGCUUGCACUGAUGACAAU
677 7030 CCAUGGUAAUGCACAUGUAGCUAGUUGUGA
678 7036 CCAUGGUACAUUUGGCUAGGUUUUAUAGCU
679 7039 CUUUAGCUUGUGGGUUUACAAACAAUUUGA
680 7048 AGGCUUGAUGUGGCUCAGCUACUUCAUUGC 681 7050 CCAUG U AG AAACAU U U UACCCAAAAU U ACA 682 7056 AACACU U U U ACAAG ACU UCAG AG U U U AG AA
683 7057 AGUUGUGUUUUAAGCGGACACAAUCUUGCU
684 7068 GAUGUUCUUGUUAACAACU A A ACG A AC A A U
685 7070 CCAUGUGAGUCUCAUGGAAAACAAGUAGUG
686 7075 CUUUAGCUAUAGAUGCUUACCCACUUACUA
687 7076 GCUUUGUUAAGCGUGUUGACUGGACUAUUG
688 7094 AAUUGUCAACAACACAGUUUAUGAUCCUUU
689 7132 GGGUUUAUACAACAAAAGCUAGCUCUUGGA
690 7148 AUUGCCCUAUUUUCUUCAUAACUGGUAAUA
691 7150 ACUACCAACUCAAACUGUUGAUUCAUCACA
692 7155 GCUGCCGGUACUACACAAACUGCUUGCACU
693 7157 ACUACCACACAACUGAUCCUAGUUUUCUGG
694 7158 AACACAAAGG AAU U U U U AUG AACCACAAAU
695 7163 AAGGGUGGUCGCACUAUUGCCUUUGGAGGC
696 7177 AGGUAGGUUUGUACUUGCACUGUUAUCCGA
697 7198 CCCUUGGGAUACUAUAGCUAAUUAUGCUAA
698 7201 GAACUCGUAAUCGGAGCUGUGAUCCUUCGU
699 7223 CGGUGAUGCUGCUCUUGCUUUGCUGCUGCU
700 7224 AAGUUCAAGAACUUUACUCUCCAAUUUUUC
701 7230 ACAAUUUUUAAAGAUGCUUCUGGUAAGCCA
702 7232 AUUGCAUAGACGGUGCUUUACUUACAAAGU
703 7254 GGGUU U ACAAACAAU U UG AU ACU U AU AACC
704 7259 CGGUGCACCAACAAAGGUUACUUUUGGUGA
705 7268 CCUCUUAUUGUAACAGCUUUAAGGGCCAAU
706 7281 GUAAUUUCAAAAAUCUUAGGGAAUUUGUGU
707 7283 CUUGUAGAAAGGUUCAACACAUGGUUGUUA
708 7286 AAAACAAGUAGUGUCAGAUAUAGAUUAUGU
709 7292 GGUGAGACACUUGGUGUCCUUGUCCCUCAU
710 7311 CUUUAGAACCAUUGGUAGAUUUGCCAAUAG
711 7313 GAUGUUGUAAUAGGAAUUGUCAACAACACA
712 7325 CUUGUAGGCUUGAUGUGGCUCAGCUACUUC
713 7336 AGAAUCAUCAUCUAAAUUGUGGGCUCAAUG
714 7349 AAGACCUUAAAUUCCCUCGAGGACAAGGCG
715 7351 CUUGUAGUGCGUUGUUCGUUCUAUGAAGAC
716 7360 AACCAUUACAGAUGCUGUAGACUGUGCACU
717 7374 ACUACUCCCACCCAAGAAUAGCAUAGAUGC
718 7376 CUCUCAAUGACUUCAGUAACUCAGGUUCUG
719 7381 GGGUGGUAGUUGUGUUUUAAGCGGACACAA
720 7388 CACAUCAAUCUGACAUAGAAGUUACUGGCG Sequence in priority
SEQ ID NO document Sequence
721 7399 GAUUUGUUAAAAUAUGACUUCACGGAAGAG m 7412 AGUUGUGAUCAACUCCGCGAACCCAUGCUU
123 7419 GAUGUUGUUCAAGAGGGUGUUUUAACUGCU
724 7437 AGGUACAUGUCAGCAUUAAAUCACACUAAA
725 7459 CUUUACUGGUUAUCGUGUAACUAAAAACAG
726 7482 ACUACUUUAGAUUCGAAGACCCAGUCCCUA
727 7491 GCUGCAUUACAAAUACCAUUUGCUAUGCAA
728 7513 CCCUGUUGCUAUUCAUGCAGAUCAACUUAC
729 7515 AUGAUGAUGGUGCUAGGAGAGUGUGGACAC
730 7521 ACUAGAAGGUUCUGUUGCUUAUGAAAGUUU
731 7550 ACACAACUAU UACAG UUAAUGUUUUAGCUU
732 7555 AUGCAUCAGCUGUAGUGUUACUAAUCCUUA
733 7561 CCCAAACAAGCUAGUCUUAAUGGAGUCACA
734 7599 AGUUGUCUCAAGGGCUGUUGUUCUUGUGGA
735 7610 CCCAAAUGUUAACAAAGGUGAAGACAUUCA
736 7619 AUUGAGUGAAAUGGUCAUGUGUGGCGGUUC
737 7624 GGAUGGUUAUGUUCACACCUUUAGUACCUU
738 7642 ACUAGCUAAACG U U U U AAGG AAUCACCU U U
739 7663 AGGUAAAGGCUUUUGCAAACUACACAAUUG
740 7681 AAUGUCCAAAUUUUGUAUUUCCCUUAAAUU
741 7682 GAUUUCAUACAAACCACGCCAGGUAGUGGA
742 7685 GGUGACGGUAAAAUGAAAGAUCUCAGUCCA
743 7686 AUUGACUGUAGUGCGCGUCAUAUUAAUGCG
744 7687 CUUGUCUGUUAAUCCGUAUGUUUGCAAUGC
745 7700 CUUGUCUUGUAGGCUUGAUGUGGCUCAGCU
746 7708 AUGCUGCUGACCCUGCUAUGCACGCUGCUU
747 7716 GCUGCAGCUUAUUAUGUGGGUUAUCUUCAA
748 7748 AACACAUGGCUUAAAUUUGGAAGAAGCUGC
749 7749 CCCAAUUUCACUAUUAAGGGUUCAUUCCUU
750 7790 ACACAAUCUUGCUAAACACUGUCUUCAUGU
751 7822 GUAUUAUUGCUAUGUCUGCUUUUGCAAUGA
752 7827 AC AC A A U U A A ACCG UGCUUUAACUGGAAUA
753 7830 AUUCACUGAGACUCAUUGAUGCUAUGAUGU
754 7833 GCUUUGGUUUAUGAUAAUAAGCUUAAAGCA
755 7835 G AU U U ACAACCAU U AG AACAACCU ACU AG U
756 7844 C AG AC A A A UCGCUCCAGGG C A A AC U G G AAA
757 7852 CGUAUUUGUCUUAUGGGCACAUGGCUUUGA
758 7864 CGGUUCACUAUAUGUUAAACCAGGUGGAAC
759 7869 GAUUUAACUGCUUUUGGCUUAGUUGCAGAG
760 7870 GGCUAAAUCUGAAUUUGACCGUGAUGCAGC
761 7871 AUGAUGUGUU AC A A ACG U A A U AG AG C A AC A
762 7872 CUUGUGCUGCCGGUACUACACAAACUGCUU
763 7881 CCCUG C AC A AG A A A AG A AC UUCACAACUGC
764 7933 CCCUGAUGGCUACCCUCUUGAGUGCAUUAA
765 7944 ACACACACUGGUACUGGUCAGGCAAUAACA Sequence in priority
SEQ ID NO document Sequence
766 7963 AAAAGCACACUUUCCUCGUGAAGGUGUCUU
767 8002 AGACGGUUGUAAUUCAUCAACUUGUAUGAU
768 8011 GAUUGUGCAACUGUACAUACAGCUAAUAAA
769 8024 ACUAUCUAUACAGAACUGGAACCACCUUGU
770 8026 GAUUGUGAAGAAGAAGAGUUUGAGCCAUCA
771 8027 ACACACCACUGGUUGUUACUCACAAUUUUG
772 8057 AC U A U G ACC A A UAGACAGUUUCAU C A A A A A
773 8060 CUUGUGUUCUUUGCAAUUCACAGACUUCAU
774 8063 ACACACCGCAUACAGUCUUACAGGCUGUUG
775 8064 AGCUAGUCAAUCCAUCAUUGCCUACACUAU
776 8072 AAG U U AAGCCAU U U AU AACUG AAAG UAAAC 111 8077 GAUUGUACAGAAAGUGUGUUAAAUCCAGAG
778 8101 GAUUACAUUUUAGCUAACACCUGUACUGAA
779 8106 AUUCUGUUAUGCUUACUAAUGAUAACACUU
780 8136 GGCUAACUAACAUCUUUGGCACUGUUUAUG
781 8180 CGUAUACAGGGCUUUUGACAUCUACAAUGA
782 8192 GGGUUAUCUUCAACCUAGGACUUUUCUAUU
783 8204 AUG U U U UCU ACAAAG AAAACAG U UACACAA
784 8254 GAUUGCCUUGGUGAUAUUGCUGCUAGAGAC
785 8258 AUGAUUUCGGUGAUUUCAUACAAACCACGC
786 8267 CCCUCAUGUGGGCGAAAUACCAGUGGCUUA
787 8270 AUGAUUUC U CCA A AC A A U U G C A AC A A U CC A
788 8274 CGUAGUGGUGAGACACUUGGUGUCCUUGUC
789 8285 CACAGGUGUUCUUACUGAGUCUAACAAAAA
790 8295 ACU AU U AAGG UG U U U ACAACAG U AG ACAAC
791 8313 CGUAAAACACGUCUAUCAGUUACGUGCCAG
792 8325 ACUAUUACCGUUGAAGAGCUUAAAAAGCUC
793 8371 AGCUAAAUUGUUACAUAAACCUAUUGUUUG
794 8383 ACUUUUGAAGAAGCUGCGCUGUGCACCUUU
795 8391 GCUUUGGACAUAUCAGCAUCUAUAGUAGCU
796 8396 CUUUAAUGGUGUUUCCUUUAGUACUUUUGA
797 8397 AUGAUUUUGUAGAAAACCCAGAUAUAUUAC
798 8403 GAGGUAGGUUUGUACUUGCACUGUUAUCCG
799 8408 ACUAUUGAAUAUCCUAUAAUUGGUGAUGAA
800 8411 GAUUCUUCUUCAGGUUGGACAGCUGGUGCU 801 8413 GGUACUGCUGUUAUGUCUUUAAAAGAAGGU 802 8432 CCCCGAUUUCAGCUAUGGUUAGAAUGUACA
803 8437 AUUCUACACUCCAGGGACCACCUGGUACUG
804 8457 AUGCAAAAGUAUUCUACACUCCAGGGACCA
805 8467 GAUUCUGAAGUUGUUCUUAAAAAGUUGAAG
806 8498 AAUGUCGCGCAUUGGCAUGGAAGUCACACC
807 8500 CAGACCUCGUCUAUGCUUUAAGGCAUUUUG
808 8505 AG AC A U A A AC A AG C U U U G U G A AG A A A U G C U
809 8506 GAGUCUCAUGGAAAACAAGUAGUGUCAGAU
810 8511 AGGGGCAUACACUCGCUAUGUCGAUAACAA Sequence in priority
SEQ ID NO document Sequence
811 8531 GAGUUAGGUGAUGUUAGAGAAACAAUGAGU
812 8557 CACAGGCACUAGUACUGAUGUCGUAUACAG
813 8572 ACUUUUCUAUUAAAAUAUAAUGAAAAUGGA
814 8583 GAUUAUCCUAAAUGUGAUAGAGCCAUGCCU
815 8584 ACUCAACAUCAACCAUAUGUAGUUGAUGAC
816 8586 GUGUACCUCAAGCUGAUGUAGAAUGGAAGU
817 8611 ACUCAACUCAAUUGAGUACAGACACUGGUG
818 8617 CAGACGGGCGAUUUUGUUAAAGCCACUUGC
819 8640 CCCUACUUAUUGUUAAUAACGCUACUAAUG
820 8642 AACACUAAACAUAGCAGUGGUGUUACCCGU 821 8657 CAGACGUGGUCCAGAACAAACCCAAGGAAA 822 8673 CUUUAAAAGAAGGUCAAAUCAAUGAUAUGA
823 8679 ACUCAAUGGUCUUUGUUCUUUUUUUUGUAU
824 8708 GAUUCAACUGAAUGCAGCAAUCUUUUGUUG
825 8720 GAGGACAAUCAGACAACUACUAUUCAAACA
826 8724 GUAUUAAAAUACAAGAGGGUGUGGUUGAUU
827 8726 GAUUAUUUUGUGCUGACAUCACAUACAGUA
828 8734 AAGUCUAAUCAUAAUUUCUUGGUACAGGCU
829 8736 GGUGAAACUUCAUGGCAGACGGGCGAUUUU
830 8737 CUCUAUUAUUCAAUUUCCUAACACCUACCU
831 8756 AUGCUGAUGUCUUUCAUUUGUACUUACAAU
832 8763 AAGUCUAAUCUCAAACCUUUUGAGAGAGAU
833 8797 CUUUAACUGCAGAGUCACAUGUUGACACUG
834 8837 AAUCACUGGGUUACAUCCUACACAGGCACC
835 8849 CAGACUUCAAAGUUUGCAGACAUAUGUGAC
836 8865 CUCAAUGUGUCCAGUUACACAAUGACAUUC
837 8876 CGACCCUGCUCAAUUACCUGCACCACGCAC
838 8890 AUACGCCAACUUAGGUGAACGUGUACGCCA
839 8898 CAGAGACAUUGCUGACACUACUGAUGCUGU
840 8904 CACAGAUGUGACUCAACUUUACUUAGGAGG
841 8909 AAUGCCAUUAAGUGCACCUACACUAGUGCC
842 8921 G U ACG U U G A A A UCCUUCACUGU AG A A A A AG
843 8924 GCUGACUCUAUCAUUAUUGGUGGAGCUAAA
844 8926 GCUGACUCAACUCAGGCCUAAACUCAUGCA
845 8929 CUGGAUUUUUGGUACUACUUUAGAUUCGAA
846 8932 GAGUUCAGAGUUUAUUCUAGUGCGAAUAAU
847 8936 GUCUGAUGUUGGUGAUAGUGCGGAAGUUGC
848 8937 AUGGCUCUAUUAUUCAAUUUCCUAACACCU
849 8945 ACACAUGUUAGACAUGUAUUCUGUUAUGCU
850 8950 GCUGACCCUAUACAUUCUUUAAGAGUUUGU
851 8954 CACAGACU U AG AAGG UAACU U U U AUGG ACC
852 8974 GCUGACAUCACAUACAGUAAUGCCAUUAAG
853 8982 AUAUAAAAUGGCCAUGGUACAUUUGGCUAG
854 8987 CUGGCAAUGGCGGUGAUGCUGCUCUUGCUU
855 8990 AAAU G AAG AG UGAAAAG CAAG U U G AAC AAA Sequence in priority
SEQ ID NO document Sequence
856 9006 AAUCACCUUUUGAAUUAGAAGAUUUUAUUC
857 9007 CAGAGGACGCGCAGGGAAUGGAUAAUCUUG
858 9009 CACACUUUCU U AUG AACAAU U UAAGAAAGG
859 9015 ACU U U U ACU AG AAG U ACAAAU UCU AG AAU U
860 9032 AACCAUACAGGUGUUGUUGGAGAAGGUUCC 861 9042 AGUUGCCUUUAAUACUUUACUAUUCCUUAU 862 9055 AGCUAGUUGUGAUGCAAUCAUGACUAGGUG
863 9056 AAAGG U AG ACU U AU AAU U AG AG AAAACAAC
864 9074 GCUGAACAUGUCAACAACUCAUAUGAGUGU
865 9078 CUCAAGGGCUGUUGUUCUUGUGGAUCCUGC
866 9122 CAGAGUGUGUACUUGGACAAUCAAAAAGAG
867 9125 ACACCAUCUAGGACGCUGUGACAUCAAGGA
868 9133 AUAAAUUAGAAGGCUAUGCCUUCGAACAUA
869 9142 ACUUUUAAAAGAACCUUGCUCUUCUGGAAC
870 9150 AAUUUGCGAGAAAUGCUUGCACAUGCAGAA
871 9154 CACACCUUCGGGAACGUGGUUGACCUACAC
872 9162 AG U UGCACCAGG U ACAGCUG U U U U AAG ACA
873 9175 AAAACAACUGUAGCGUCACUUAUCAACACA
874 9178 CAGAUAACAACUGUUAUCUUGCCACUGCAU
875 9179 GAAAAUAGGACCUGAGCGCACCUGUUGUCU
876 9186 GAAAAUACUCAAUAAUUUGGGUGUGGACAU
877 9203 AGACUCCGUGGAGGAGGUCUUAUCAGAGGC
878 9248 CAGAUAUAGAUUAUGUACCACUAAAGUCUG
879 9256 AUAUAAUUAAGUUAAUUUUCCUCUGGCUGU
880 9279 AGUUGAUGACCCGUGUCCUAUUCACUUCUA 881 9283 CACACACUGG U U UG U AACACAAAGG AAU U U 882 9309 CCGUGAUCCACAGACACUUGAGAUUCUUGA
883 9316 AAAAGUUAUGUGCAUGUUGUAGACGGUUGU
884 9328 GCUCUGCCUAUACAGUUGAACUCGGUACAG
885 9344 CUCUAUAGAAAUAGAGAUGUUGACACAGAC
886 9362 CACAAUUCAGAAGUAGGACCUGAGCAUAGU
887 9369 GGCUAGCAUAAAGAACUUUAAGUCAGUUCU
888 9378 CAGAUGCUGUCAUAAAAACUUUGCAACCAG
889 9391 GGCACUACUGAAAUGCUAGCGAAAGCUUUG
890 9402 AAAUGAGUUCGCCUGUGUUGUGGCAGAUGC
891 9418 CAGAUGUAAAGUGCACAUCAGUAGUCUUAC
892 9424 AGACAGGUGGUUUCUCAAUCGAUUUACCAC
893 9432 GUGGUCGCACUAUUGCCUUUGGAGGCUGUG
894 9434 GAGACACUUGGUGUCCUUGUCCCUCAUGUG
895 9443 CUCUAGUCAGUGUGUUAAUCUUACAACCAG
896 9446 ACACGAGUAACUCGUCUAUCUUCUGCAGGC
897 9476 AGAAAAGCUGUCUUUAUUUCACCUUAUAAU
898 9496 ACACGGAACGUUCUGAAAAGAGCUAUGAAU
899 9501 GAGUUUAAAUUGGCUUCACAUAUGUAUUGU
900 9503 GCUCGUGUAGAGUGUUUUGAUAAAUUCAAA Sequence in priority
SEQ ID NO document Sequence
901 9510 AAUUUGGUGCCACUUCUGCUGCUCUUCAAC
902 9516 GGCUAUAAAGAUAACAGAACAUUCUUGGAA
903 9522 CAG AU UCCAACGG U ACU AU U ACCG U UG AAG
904 9535 GCUCGUACGUGGCUUUGGAGACUCCGUGGA
905 9544 AAAAUUGUUCAACUUAGUGAAAUUAGUAUG
906 9565 GGCACUGAGAAUUUGACUAAAGAAGGUGCC
907 9572 G A AG A A A UGCUGGACAACAGGG C A ACC U U A
908 9584 GUGAUGAUUAUGUGUACCUUCCUUACCCAG
909 9589 CUAUUUUUGUACUUGUUACUUUGGCCUCUU
910 9593 GUGAUAUCAGACAACUACUAUUUGUAGUUG
911 9613 AGAAGCUGUUAUGUACAUGGGCACACUUUC
912 9622 AGACUGUGCACUUGACCCUCUCUCAGAAAC
913 9623 AAAAUUGUUAAUAAUUGGUUGAAGCAGUUA
914 9629 AAUGCACAUGUAGCUAGUUGUGAUGCAAUC
915 9652 CCGGUAGCACACCUUGUAAUGGUGUUGAAG
916 9653 C AC A AC A U G U U A A A A AC UGUUUAUAGUGAU
917 9671 CACAACAAGUCCUAUUUCUGAACAUGACUA
918 9681 GUCCU UGUCCCUCAUGUGGGCGAAAUACCA
919 9706 G A A A AG C A AG U U G A AC A A A AG AUCGCUGAG
920 9707 G AAG AAG AAG AG U U UG AGCCAU C A AC U C A A
921 9713 AAGUAUGUACAAAUACCUACAACUUGUGCU
922 9731 CGGCAGUCAAGCCUCUUCUCGUUCCUCAUC
923 9732 GGCUAUGAAGUACAAUUAUGAACCUCUAAC
924 9740 AG ACU U AU AAU U AG AG AAAACAACAG AG U U
925 9741 GCUUUAUUAGAAGAUGAAUUUACACCUUUU
926 9759 AGACUUAUGAAAACUAUAGGUCCAGACAUG
927 9760 CAGCACCACCUGCUCAGUAUGAACUUAAGC
928 9767 AAAGCUUCAUGCACUUUGUCCGAACAACUG
929 9775 CAGCACCUCAUGGUGUAGUCUUCUUGCAUG
930 9787 AGACUUAUUUAGAAAUGCCCGUAAUGGUGU
931 9812 A A U G C A AC AG A AG UGCCUGCCAAUU C A AC U
932 9818 AUGUUAACUGCACAGAAGUCCCUGUUGCUA
933 9820 GUGGACACUUAUGAAUGUCUUGACACUCGU
934 9822 AAACCUUUGGAAUUUGGUGCCACUUCUGCU
935 9846 GCUCAUGGAUGGCUCUAUUAUUCAAUUUCC
936 9857 AAUUUGUGUUUAAGAAUAUUGAUGGUUAUU
937 9858 GAAAAGAACAAUCAAGGGUACACACCACUG
938 9864 CUGGUAACUGUGAUGUUGUAAUAGGAAUUG
939 9881 AUACGUUGUCUUUGGAG C AC A A A ACC AG U U
940 9882 CUAUUUGAACUCUACUAAUGUCACUAUUGC
941 9891 GUCCUUAGACAAUGUCUUAUCUACUUUUAU
942 9895 CUGGUAAUGUUCAACUCAGGGUUAUUGGAC
943 9907 AGUUCCUGUUGUAGAUUCUUAUUAUUCAUU
944 9911 ACUUUCUUUUGAACUUCUACAUGCACCAGC
945 9912 GAGAAGGCAUUAAAAUAUUUGCCUAUAGAU Sequence in priority
SEQ ID NO document Sequence
946 9924 GUACAUUGGCGACCCUGCUCAAUUACCUGC
947 9956 AGCGUCACUUAUCAACACACUUAACGAUCU
948 9957 CAAUUUCAACUUCAAUGGUUUAACAGGCAC
949 9959 ACACUGGUAAUUACCAGUGUGGUCACUAUA
950 9969 GCUCAGAAUAUGACUAUGUCAUAUUCACUC
951 9984 AAAUGCAUUGCCUGAGACGACAGCAGAUAU
952 9999 C AG C A U U AAA U C AC AC U A A A A AG U G G AAA U
953 10042 GCUCAAUGUGUCCAGUUACACAAUGACAUU
954 10050 AAUUU UAAAG U U AC A A A AG G A A A AG C U AAA
955 10067 AGUUCAUGCUGGCACAGACUUAGAAGGUAA
956 10071 GAAGAAUCAUCUGCAAAAUCAGCGUCUGUU
957 10076 GCUCAAGUAUUGAGUGAAAUGGUCAUGUGU
958 10095 AAUUUUAACAAAGACUUCUAUGACUUUGCU
959 10096 ACACUUAUGAAUGUCUUGACACUCGUUUAU
960 10101 ACACUUAUGAUUGAACGGUUCGUGUCUUUA
961 10115 GGCAGAUGCUGUCAUAAAAACUUUGCAACC
962 10129 AAAUGCCG U UCCAAAAACCCAU U ACU U U AU
963 10130 ACACUUCGCAUGGUGGACAGCCUUUGUUAC
964 10141 AAAACAUUUUAUGUUUUACCUAAUGAUGAC
965 10166 GAUAAAAGUGUAUAUUACACUAGUAAUCCU
966 10185 GUACCUCAAGCUGAUGUAGAAUGGAAGUUC
967 10204 GGCUAUUGAUUAUAAACACUACACACCCUC
968 10216 CUAUUGAUUAUAAACACUACACACCCUCUU
969 10223 GCUAUUGGCAAAAUUCAAGACUCACUUUCU
970 10226 CGCAACAGUUCAAGAAAUUCAACUCCAGGC
971 10229 ACACUUUGAUGGACAACAGGGUGAAGUACC
972 10246 GUCUAUGACCAAGACAUCAGUAGAUUGUAC
973 10247 GGUGUUUAUUACCCUGACAAAGUUUUCAGA
974 10286 GAAGACAUUCAACUUCUUAAGAGUGCUUAU
975 10291 ACAGAAAGUGUGUUAAAUCCAGAGAAGAAA
976 10292 GGAAUGUCCAAAUUUUGUAUUUCCCUUAAA
977 10293 GCUUUACUU AC A A AG U CC U C AG A A U AC A A A
978 10303 ACAG AAAU UG ACCCU AAG UUGGACAAU U AU
979 10322 ACUUUAUUGACACUAAGAGGGGUGUAUACU
980 10324 CUGGUGAAGCUGCUAACUUUUGUGCACUUA
981 10327 GGAGUUCCUGUUGUAGAUUCUUAUUAUUCA
982 10331 GCUAUUACCUCUUACGCAAUAUAAUAGAUA
983 10334 AUACAUUAAAAAUGCAGACAUUGUGGAAGA
984 10337 GAGUGCUUUGGUUUAUGAUAAUAAGCUUAA
985 10351 ACAGAAGUAAAUGAGUUCGCCUGUGUUGUG
986 10375 CUGGUGAGUUUAAAUUGGCUUCACAUAUGU
987 10400 GAGAAAAAUAUUUGUUGAUGGUGUUCCAUU
988 10401 AAAAACACAG U UCAAU U AU U AU AAG AAAG U
989 10408 GACUUUUUGCAUUUCUUACCUAGAGUUUUU
990 10416 AUUAAAAUACAAGAGGGUGUGGUUGAUUAU Sequence in priority
SEQ ID NO document Sequence
991 10456 ACAGACACUGGUGUUGAACAUGUUACCUUC
992 10481 AAUAUUGGUGAACAGAAAUCAAUACUGAGU
993 10483 GUACGCUGCUUGUCGAUUCAGAUCUUAAUG
994 10487 CUGGUGGCACUACUGAAAUGCUAGCGAAAG
995 10509 AUAUGAGAUCUCUCAAAGUGCCAGCUACAG
996 10521 GCUAUGCAGACAAUGCUUUUCACUAUGCUU
997 10534 GGUGUUGUUCAGUUGACUUCGCAGUGGCUA
998 10544 ACAGACUUUUUCAGUGUUAGCUUGUUACAA
999 10558 AAUGAUCCAUUUUUGGGUGUUUAUUACCAC 1000 10562 AGCUGCAUUUCACCAAGAAUGUAGUUUACA 1001 10563 GCUAUGAGGCCCAAUUUCACUAUUAAGGGU 1002 10567 GCUUUAACUGGAAUAGCUGUUGAACAAGAC
1003 10568 GCUUUAACUGCAGAGUCACAUGUUGACACU
1004 10582 AAAGGGCUAUCAUCUUAUGUCCUUCCCUCA
1005 10591 GGUUUUAAUUU U UCACAAAU AU UACCAGAU
1006 10601 CAGCUGAUGCACAAUCGUUUUUAAACGGGU
1007 10606 GUCCUAUUCACUUCUAUUCUAAAUGGUAUA
1008 10607 GCUAUCUAACCUUAACUUGCCUGGUUGUGA
1009 10610 AAAUGCUGUUACGACCAUGUCAUAUCAACA
1010 10616 AGUUAUACUAAUGACAAAGCUUGCCCAUUG 1011 10631 GG U U U U ACAGG U A ACC U AC A A AG C A ACC A U 1012 10642 GGCUCAGCUACUUCAUUGCUUCUUUCAGAC
1013 10652 GCUAUCAUCUUAUGUCCUUCCCUCAGUCAG
1014 10713 GUCUUUGUUUCAAAUGGCACACACUGGUUU
1015 10730 AUUAAACAACCUAAAUAGAGGUAUGGUACU
1016 10732 CAGCUUAUGUGUCAACCUAUACUGUUACUA
1017 10749 GUGAAGUACCAGUUUCUAUCAUUAAUAACA
1018 10789 ACAGAUUGUAUCUCGAUGCUUAUAACAUGA
1019 10825 GACUUUAAACUUAAUGAAGAGAUCGCCAUU
1020 10845 AG U U AG AU AAAU AU U U U AAG AAUCAU ACAU 1021 10852 AUAUGCGCUAGUUAUCAGACUCAGACUAAU 1022 10857 AG A A AG G U U C A AC AC AU G G U U G U U A A AG C U
1023 10869 GGUUGUUAAUGCAGCCAAUGUUUACCUUAA
1024 10879 CAAUGGCGGUGAUGCUGCUCUUGCUUUGCU
1025 10899 CUGGUUCUAAAUCACCCAUUCAGUACAUCG
1026 10909 AAUUGUGUUAAUUGUGAUACAUUCUGUGCU
1027 10922 AGCUAUCGUAGUAACAUGCCUUGCCUACUA
1028 10924 AAUGUGGCAACUUUACAAGCUGAAAAUGUA
1029 10926 GCUAGUGAGUACACUGGUAAUUACCAGUGU
1030 10939 AUACUAUAGCUAAUUAUGCUAAGCCUUUUC
1031 10962 AAUGUAAACAGAUUUAAUGUUGCUAUUACC
1032 10994 GCUAGGAGAGUGUGGACACUUAUGAAUGUC
1033 10996 G A A AC A UUUGUCACGCACU C A A AG G G A U U G
1034 11003 AAAUAAGGGACACUUUGAUGGACAACAGGG
1035 11006 ACAGCCUUUGUUACUAAUGUGAAUGCGUCA Sequence in priority
SEQ ID NO document Sequence
1036 11020 GCUAGCGCUAACAUAGGUUGUAACCAUACA
1037 11026 GUAGUCUUGUAGUGCGUUGUUCGUUCUAUG
1038 11028 GAAAUUAGUAUGGACAAUUCACCUAAUUUA
1039 11029 CAAUGCCAGAUUACGUGCUAAGCACUAUGU
1040 11032 GGCAGUUUGUAUGUAAAUAAACAUGCAUUC
1041 11042 CUGGUUUUAAGCUAAAAGACUGUGUUAUGU
1042 11050 GCUAGAUUUUACUUU U ACACCAG U AAAACA
1043 11054 GUAGUCUUUAAUGGUGUUUCCUUUAGUACU
1044 11061 GCUAGAUUCCCUAAGAGUGAUGGAACUGGU
1045 11069 AGUUACACAGAAUGUUCUCUAUGAGAACCA
1046 11103 GCUUGUGUUCUUUGCAAUUCACAGACUUCA
1047 11116 CUUUUUUGAUGGUAGAGUUGAUGGUCAAGU
1048 11138 A A AG G C U U U U G C A A AC U AC AC A A U U G G A A U
1049 11149 CUAUGUGAUAGACGUGCCACAUGCUUUUCC
1050 11157 CAAUGACAUAUGGACAACAGUUUGGUCCAA
1051 11159 CAGGCAAUAACAGUUACACCGGAAGCCAAU
1052 11174 AACAUGCCUUGCCUACUAUUUUAUGAGGUU
1053 11176 ACAGCUGGUGCUGCAGCUUAUUAUGUGGGU
1054 11182 GGAUCCUGCUGCAAAUUUGAUGAAGACGAC
1055 11187 ACAGCUGUUUUAAGACAGUGGUUGCCUACG
1056 11196 GAUAAUAUCAAAUUUGCUGAUGAUUUAAAC
1057 11206 AUAUGGUUGAUACUAGUUUGUCUGGUUUUA
1058 11209 AAUUGCUAUCGCAAUGGCUUGUCUUGUAGG
1059 11227 ACUUGUUCUUACCUUUCUUUUCCAAUGUUA
1060 11228 GGCAUACACUCGCUAUGUCGAUAACAACUU 1061 11230 CAAUCUUCAUCCAGAUUCUGCCACUCUUGU 1062 11254 AG G A A U AC A A A UCCAAUUCAGUUGUCUUCC
1063 11273 ACUUGUUACUUUGGCCUCUUUUGUUUACUC
1064 11282 AGUUAAGAGACACACUUUCUCUAACUACCA
1065 11287 GACUUAUGUCCCUGCACAAGAAAAGAACUU
1066 11294 AACGUGGUUGACCUACACAGGUGCCAUCAA
1067 11317 CUAUGUACACACCGCAUACAGUCUUACAGG
1068 11322 GGUUGACCUACACAGGUGCCAUCAAAUUGG
1069 11333 CUAUGUAACACAUGGCUUAAAUUUGGAAGA
1070 11393 GUCCCUUGGGAUACUAUAGCUAAUUAUGCU
1071 11411 CAAUCCAUCAUUGCCUACACUAUGUCACUU
1072 11426 AAGAAUAAUAAUGAGGCUUUGGCUUUGCUG
1073 11452 GGAAUUGCUAUCGCAAUGGCUUGUCUUGUA
1074 11466 GUCUCUAUAGAAAUAGAGAUGUUGACACAG
1075 11470 GUGAAUAUCACUUUUGAACUUGAUGAAAGG
1076 11479 GACUUAAAAGGUAAGUAUGUACAAAUACCU
1077 11481 ACAGGCUGGUAAUGUUCAACUCAGGGUUAU
1078 11488 AGGAAUGUGGCAACUUUACAAGCUGAAAAU
1079 11496 CUGUACUGCCGUUGCCACAUAGAUCAUCCA
1080 11516 AAU U U U U AUG AACCACAAAUCAU U ACU ACA Sequence in priority
SEQ ID NO document Sequence
1081 11517 AGUGUUUGUCUUAGUGGUUUAGAUUCUUUA
1082 11530 CUCUGGGACCAAUGGUACUAAGAGGUUUGA
1083 11542 CUGUAGACAUCAUGCUAAUGAGUACAGAUU
1084 11550 GCUUGUAUUGACUGUAGUGCGCGUCAUAUU
1085 11554 CAAUAU U U A A AC AC A U U A AC A U UAGCUGUA
1086 11571 CAGGGUUUAAAUGGUUACACUGUAGAGGAG
1087 11598 GGCUGAACAUGUCAACAACUCAUAUGAGUG
1088 11606 GUCUAGCUGUCCACGAGUGCUUUGUUAAGC
1089 11624 CUAUGCUUUAAGGCAUUUUGAUGAAGGUAA
1090 11639 GUAUAUUACACUAGUAAUCCUACCACAUUC
1091 11650 CAAUAGUGUUUAUAACACUUUGCUUCACAC
1092 11656 CGAUUUUGUUAAAGCCACUUGCGAAUUUUG
1093 11667 AGUGUUGGUUUUAACAUAGAUUAUGACUGU
1094 11676 GCUAAUGGACAAGUUUUUGGUUUAUAUAAA
1095 11677 AUAAAGAUUGUACAAAUGUUAAGUGACACA
1096 11682 GUGGACAUUGCUGCUAAUACUGUGAUCUGG
1097 11683 AAAUAUAAGGGUAUUAAAAUACAAGAGGGU
1098 11713 AUAUUACACUAGUAAUCCUACCACAUUCCA
1099 11716 AUUAGGUUUGAAAACCCUUGCUACUCAUGG
1100 11720 GCUAAUGACCCUGUGGGUUUUACACUUAAA 1101 11728 CUAUGCCUUCGAACAUAUCGUUUAUGGAGA 1102 11761 ACAGUACAG U U AAAAACU AU U UCAU AACAG
1103 11766 AUAUUAGAGUAGGAGCUAGAAAAUCAGCAC
1104 11790 CCGGCUGUUUUGUAGAUGAUAUCGUAAAAA
1105 11808 CUAUGCAGAUUCAUUUGUAAUUAGAGGUGA
1106 11843 AACCCUAAAGCUAUUAAGUGUGUACCUCAA
1107 11857 GACUGGACAAAUGCUGGUGAUUACAUUUUA
1108 11861 AAUGGUGACAAUUAUGCUUUGCUGUAUGAC
1109 11865 CAAUAACAGUUACACCGGAAGCCAAUAUGG
1110 11880 AUGGACAAUUCACCUAAUUUAGCAUGGCCU 1111 11882 GGUGUUACCCGUGAACUCAUGCGUGAGCUU 1112 11896 ACUUGGUAGUUUAGCUGCCACAGUACGUCU
1113 11904 ACAGUCUAAAAUGUCAGAUGUAAAGUGCAC
1114 11910 AAUGGCCUACAUUACAGGUGGUGUUGUUCA
1115 11921 GCUAAGCGCAACAUUAAACCAGUACCAGAG
1116 11935 AGUGUUACUAAUCCUUAUGACAGCAAGAAC
1117 11940 ACAGUGAACAAUGCUAGGGAGAGCUGCCUA
1118 11941 GCUAAGCACUAUGUGUACAUUGGCGACCCU
1119 11945 CUGUAUUAAUGCUAACCAAGUCAUCGUCAA
1120 11976 GUAGGUACAUGUCAGCAUUAAAUCACACUA 1121 11981 CAGUAACCAGAAUGGAGAACGCAGUGGGGC 1122 11987 AGUGUUAAAGGUUUACAACCAUCUGUAGGU
1123 11990 AGCGAUAAUGUUACUGACUUUAAUGCAAUU
1124 11991 CCUCAGAAUACAAAGGUCCUAUUACGGAUG
1125 12015 AC A A A A AG A AG A AG G CU G A U G A A AC U C A AG Sequence in priority
SEQ ID NO document Sequence
1126 12046 GUAUACAGCUUGCUCUCAUGCCGCUGUUGA
1127 12047 ACUUGGACAAUCAAAAAGAGUUGAUUUUUG
1128 12056 ACAGUUAAAAACUAUUUCAUAACAGAUGCG
1129 12061 CG G CCC A A A U G U U A AC A A AG GUGAAGACAU
1130 12067 GCUAACAAAGACGGCAUCAUAUGGGUUGCA
1131 12068 AAACUGUGAAAGGUUUGGAUUAUAAAGCAU
1132 12081 GAUACUAUAGCUAAUUAUGCUAAGCCUUUU
1133 12082 AAGCCAG U ACCAU AU UG U U AUG AU ACCAAU
1134 12097 AAUUCUAACAAUCUUGAUUCUAAGGUUGGU
1135 12108 GUGAUGCGUAUUAUGACAUGGUUGGAUAUG
1136 12114 AAACAGAUUUAAUGUUGCUAUUACCAGAGC
1137 12120 CUAUGACCAAGACAUCAGUAGAUUGUACAA
1138 12128 CCUCACUUGUUCUUGCUCGCAAACAUACAA
1139 12151 CUAUGAAGUACAAUUAUGAACCUCUAACAC
1140 12167 AUAAACUUUGUAAGAAUAAUAAUGAGGCUU
1141 12171 G C U A A ACC ACCG CCUGGAGAUCAAUUU AAA
1142 12199 AAACCU AG ACCACCACU U AACCG AAAU U AU
1143 12207 CUAUCUUCUGCAGGCUGCUUACGGUUUCGU
1144 12229 CAAGUCCAUGGUAAUGCACAUGUAGCUAGU
1145 12240 GG AAAU ACCCACAAG UUAAUGGUU UAACU U
1146 12262 CAGUCAAGCCUCUUCUCGUUCCUCAUCACG
1147 12268 GUCCAGUUACACAAUGACAUUCUCUUAGCU
1148 12269 GGAGUAUGGCUACAUACUACUUAUUUGAUG
1149 12299 GCGUUGUUCGUUCUAUGAAGACUUUUUAGA
1150 12315 CGCGAUCAAAACAACGUCGGCCCCAAGGUU
1151 12322 CAAGUAGACUUAUUUAGAAAUGCCCGUAAU
1152 12339 AGAGGAGG C A A AG ACAGUGCUU A A A A AG U G
1153 12342 G AU AG AAG UGCAAGG U U ACAAG AG UG UG AA
1154 12355 GAUAGACGUGCCACAUGCUUUUCCACUGCU
1155 12368 G G A AG A AG C U A A A A AG G U A A A ACC A AC AG U
1156 12392 GAUAGAGCCAUGCCUAACAUGCUUAGAAUU
1157 12394 GAAACUUCAUGGCAGACGGGCGAUUUUGUU
1158 12400 AGGACCUGAGCAUAGUCUUGCCGAAUACCA
1159 12401 AGUGUCUCCUACUAAAUUAAAUGAUCUCUG
1160 12433 G G U G U G U A A A AC UUGUGGACAACAGCAGAC 1161 12437 GCUUGCUGCUGUUUACAGAAUAAAUUGGAU 1162 12439 ACUUGCACUGUUAUCCGAUUUACAGGAUUU
1163 12446 AAACCUUCAGUUGAACAGAGAAAACAAGAU
1164 12459 G U ACGCCAAGCU U UG U U A A A A AC AG U AC A A
1165 12462 GCGUGUUUUACAGAAGGCCGCUAUAACAAU
1166 12482 AACAUCUGUUACACACCAUCAAAACUUAUA
1167 12493 GGACAACAGCAGACAACCCUUAAGGGUGUA
1168 12494 CUAUCCAGUUGCGUCACCAAAUGAAUGCAA
1169 12498 GGUUUUUGGCAUAUAUUCUUUUCACUAGGU
1170 12505 CAGUGAGGACAAUCAGACAACUACUAUUCA Sequence in priority
SEQ ID NO document Sequence
1171 12519 AACCCUGCUUGGAGAAAAGCUGUCUUUAUU
1172 12520 AGUGUCAGAUAUAGAUUAUGUACCACUAAA
1173 12536 ACAUAUCAGCAUCUAUAGUAGCUGGUGGUA
1174 12540 CUGUGAAUUUCAAUUUUGUAAUGAUCCAUU
1175 12551 CUGAUAGAGACCUUUAUGACAAGUUGCAAU
1176 12556 CUAUCAUCUUAUGUCCUUCCCUCAGUCAGC
1177 12557 GACUCAACUUUACUUAGGAGGUAUGAGCUA
1178 12561 GACUCAACAAUUAAUUAGAGCUGCAGAAAU
1179 12566 GGACAACCAAUCACUAAUUGUGUUAAGAUG
1180 12576 CUAUCAGUUACGUGCCAGAUCAGUUUCACC 1181 12584 AAGAAGCUGCUCGGUAUAUGAGAUCUCUCA 1182 12602 GGAUGAGGCUGGUUCUAAAUCACCCAUUCA
1183 12610 GCGUGGAUGAGGCUGGUUCUAAAUCACCCA
1184 12627 GACUAUUGACUAUACAGAAAUUUCAUUUAU
1185 12646 GGUCACUAUAAACAUAUAACUUCUAAAGAA
1186 12653 AGUGUAGCUAGUCAAUCCAUCAUUGCCUAC
1187 12654 A AG A AG C U A A A A AG G U A A A ACC A AC AG U G G
1188 12675 AGCUGCACUUACUAACAAUGUUGCUUUUCA
1189 12680 GCGUGAUCUCCCUCAGGGUUUUUCGGCUUU
1190 12686 AGCCUUGAAUACACCAAAAGAUCACAUUGG
1191 12711 CAAGGAAGACCUUAAAUUCCCUCGAGGACA
1192 12725 AUAAACCAAAUACCUGGUGUAUACGUUGUC
1193 12729 CAGUGUGUUAAUCUUACAACCAGAACUCAA
1194 12730 GACUAUGGUGAUGCUGUUGUUUACCGAGGU
1195 12737 GCUUGCAUACGUAGACCAUUCUUAUGUUGU
1196 12745 CAGUGUUAU A AC ACC AG G A AC A A A U AC U U C
1197 12746 AAUCUUGAUUACAUCAUAAACCUCAUAAUU
1198 12765 CUUUUGUACUGUAAAUGCAUUGCCUGAGAC
1199 12770 CAAGCUGUCACGGCCAAUGUUAAUGCACUU
1200 12786 ACAUCGAUAUCGGUAAUUAUACAGUUUCCU 1201 12813 CUAUAUGCCUGCUAGUUGGGUGAUGCGUAU 1202 12822 AGCCUUAAAUAAGGCUACUAACAAUGCCAU
1203 12858 CAGUUAGGUGGUUUACAUCUACUGAUUGGA
1204 12865 AUAAACAGGCUAGAUCUGAGGACAAGAGGG
1205 12873 GCGUAUAAAGAUUGUACAAAUGUUAAGUGA
1206 12878 CAAGCGUGGCAACCGGGUGUUGCUAUGCCU
1207 12897 CGCGCAUUGGCAUGGAAGUCACACCUUCGG
1208 12903 AUGGUGUUGUUUGUACAGAAAUUGACCCUA
1209 12904 GAUAGUGCAACAUUACCUAAAGGCAUAAUG
1210 12907 GAUAGUGCGGAAGUUGCAGUUAAAAUGUUU 1211 12916 AGACAAUUCUAGUCUUACUAUUAAGAAACC 1212 12918 A A AC U A A AG CCA U AG U U U C A AC U A U AC AG C
1213 12920 GGAAAGGGCUAUCAUCUUAUGUCCUUCCCU
1214 12925 AG AAGCCG U AAAAACACAG UUCAAU U AU U A
1215 12932 CAAGCCUCUUCUCGUUCCUCAUCACGUAGU Sequence in priority
SEQ ID NO document Sequence
1216 12944 AUUAACAUCACUAGGUUUCAAACUUUACUU
1217 12946 CAGUUCUUUAUUAUCAAAACAAUGUUUUUA
1218 12947 ACAUCUUCGUAUUGCUGGACACCAUCUAGG
1219 12954 ACAUCUUCUUUGCAUCAUUUUAUUAUGUAU
1220 12984 AGUGGUGAGACACUUGGUGUCCUUGUCCCU 1221 13005 GUACAGUGAACAAUGCUAGGGAGAGCUGCC 1222 13009 GAAGCUGCUAACUUUUGUGCACUUAUCUUA
1223 13022 ACAUGACCUAUAGAAGACUCAUCUCUAUGA
1224 13039 CCGUGUUGCAGCCGAUCAUCAGCACAUCUA
1225 13066 AUCAAAGUAGCCACUGUACAGUCUAAAAUG
1226 13067 GGUAGAUGGGUACUUAACAAUGAUUAUUAC
1227 13098 GACUACUCCCACCCAAGAAUAGCAUAGAUG
1228 13107 G U AAAACU UG UGG ACAACAGCAG ACAACCC
1229 13131 GGCCAUAGUUACGGCGCCGAUCUAAAGUCA
1230 13146 GAAGCUGUUGAAGCUCCAUUGGUUGGUACA
1231 13167 CUGAUCAAGCUAUGACCCAAAUGUAUAAAC
1232 13196 G U G G U A A AC A AG C U AC A A A A UAUCUAGUAC
1233 13208 CUGUGUGGAAACUAAAGCCAUAGUUUCAAC
1234 13216 CAGUUUGUAUGUAAAUAAACAUGCAUUCCA
1235 13230 GUAAAAGUGCCUUUUACAUUCUACCAUCUA
1236 13243 GACUACCAACUCAAACUGUUGAUUCAUCAC
1237 13245 GGCUGUAUUAAUGCUAACCAAGUCAUCGUC
1238 13251 CGAUUCAGAUCUUAAUGACUUUGUCUCUGA
1239 13252 CUGUGUGUUCUCUUAUGUUGGUUGCCAUAA
1240 13279 CAG U U U U UG U ACACAAU UAAACCGUGCU U U
1241 13283 AAUCUGGAGUAAAAGACUGUGUUGUAUUAC
1242 13287 CAUAAAAACUUUGCAACCAGUAUCUGAAUU
1243 13292 ACAUGGGCACACUUUCUUAUGAACAAUUUA
1244 13293 AGGAGACAUUAUACUUAAACCAGCAAAUAA
1245 13296 AUCAAGAAUCCUUUGGUGGUGCAUCGUGUU
1246 13302 GCGGCACAGGCACUAGUACUGAUGUCGUAU
1247 13320 GGUUGGCACAACAUGUUAAAAACUGUUUAU
1248 13321 GUGGUAAAAUUGUUAAUAAUUGGUUGAAGC
1249 13339 AUCAAGAUGCACUUUUCGCAUAUACAAAAC
1250 13352 GACUACAAAAGAGAUGCUCCAGCACAUAUA
1251 13371 GGUGUCAUGCUACUAGAGAAGCUGUUGGUA
1252 13383 CAUAACAAGAGAAGUGGGUUUUGUCGUGCC
1253 13385 ACAUGUCAGCAUUAAAUCACACUAAAAAGU
1254 13386 GCGGAAGUUGCAGUUAAAAUGUUUGAUGCU
1255 13394 CU U U UGCAAACU ACACAAU UGGAAUUGUGU
1256 13412 GAUAUCAGACAACUACUAUUUGUAGUUGAA
1257 13420 CUAUAAUCCGUUUAUGAUUGAUGUUCAACA
1258 13438 AAUGGUGUUCUUAUUACAGAAGGUAGUGUU
1259 13441 AUUAACGGGCUUAUGUUGCUCGAAAUCAAA
1260 13448 CUCUUUUUGUUACAUGCACCAUAUGGAAUU Sequence in priority
SEQ ID NO document Sequence
1261 13465 GGUGUCAGUGUUAUAACACCAGGAACAAAU
1262 13486 ACAAAGGACUUCCUUGGAAUGUAGUGCGUA
1263 13497 CUGUUAAUCCGUAUGUUUGCAAUGCUCCAG
1264 13501 AGUGGAGUUCCUGUUGUAGAUUCUUAUUAU
1265 13540 GGUGUCACUCGUGACAUAGCAUCUACAGAU
1266 13546 CAUAAUGAUGAAUGUCGCAAAAUAUACUCA
1267 13556 CUAUAAAGAUAACAGAACAUUCUUGGAAUG
1268 13578 ACUUCCUUGGAAUGUAGUGCGUAUAAAGAU
1269 13608 AGUGGAAAAUCCUACCAUACAGAAAGACGU
1270 13616 AAAAGACUGUGUUGUAUUACACAGUUACUU
1271 13622 GGCCCUGAUGGCUACCCUCUUGAGUGCAUU
1272 13648 CAUACACUCGCUAUGUCGAUAACAACUUCU
1273 13649 AGCCUCAAAGAUUUUGGGACUACCAACUCA
1274 13651 GCGCGUCAUAUUAAUGCGCAGGUAGCAAAA
1275 13657 CUUUUGAGUACUACCACACAACUGAUCCUA
1276 13662 GGAAACUGUGAAAGGUUUGGAUUAUAAAGC
1277 13693 CAACUUUACAAGCUGAAAAUGUAACAGGAC
1278 13698 G CG CG A U C A A A AC A ACG U CG G CCCC A AG G U
1279 13701 CAUACCAGACUAUAACACAUAUAAAAAUAC
1280 13717 AUACCACUUCAGAGAGCUAGGUGUUGUACA 1281 13719 ACUUCCCUAUGGUGCUAACAAAGACGGCAU 1282 13729 CAUACCUAAGGACAUGACCUAUAGAAGACU
1283 13738 CCUAUUUCUGAACAUGACUACCAGAUUGGU
1284 13743 CUGUUAUGGCCAGUAACUUUAGCUUGUUUU
1285 13745 CUUUUGACAUCUACAAUGAUAAAGUAGCUG
1286 13771 AGUGCUGCUAAAAAGAAUAACUUACCUUUU
1287 13776 CAUACUAAUUGUUACGACUAUUGUAUACCU
1288 13781 GUAUACGUUGUCUUUGGAGCACAAAACCAG
1289 13806 AAGAGUCAUUUUGCUAUUGGCCUAGCUCUC
1290 13807 AAUCUAUUACUAGAUAAACGCACUACGUGC
1291 13819 GAUAUGUACGACCCUAAGACUAAAAAUGUU
1292 13822 ACAUUCUAUGCAAAAUUGUGUACUUAAGCU
1293 13825 GGCCGGCUGUUUUGUAGAUGAUAUCGUAAA
1294 13856 AAUCUAUCAAACUUCUAACUUUAGAGUCCA
1295 13857 CUAGUGGCUAGCAUAAAGAACUUUAAGUCA
1296 13861 GUGGUAGUUGUGUUUUAAGCGGACACAAUC
1297 13862 CAUACUUUGCAUAAUGUCUGAUAGAGACCU
1298 13870 GGACACUUAUGAAUGUCUUGACACUCGUUU
1299 13876 ACAAAUACCUACAACUUGUGCUAAUGACCC
1300 13921 AUCACCGGUGGAAUUGCUAUCGCAAUGGCU
1301 13926 AGUGCGUUGUUCGUUCUAUGAAGACUUUUU
1302 13946 ACAAAU AGG AG AG U ACACCU U UG AAAAAGG
1303 13964 ACAUUGCUGCUAAUACUGUGAUCUGGGACU
1304 13975 AGGAGCUAGAAAAUCAGCACCUUUAAUUGA
1305 13977 AGUGCGUAUAAAGAUUGUACAAAUGUUAAG Sequence in priority
SEQ ID NO document Sequence
1306 13986 AAAGUGAGUUCAGAGUUUAUUCUAGUGCGA
1307 13998 AGUGCGCGUCAUAUUAAUGCGCAGGUAGCA
1308 14001 ACAUUGGCGACCCUGCUCAAUUACCUGCAC
1309 14009 AAUGUUCAACUCAGGGUUAUUGGACAUUCU
1310 14012 G G A A AC U A A AG CCA U AG U U U C A AC U A U AC A
1311 14017 AGCUUAUUUUAAUAUGGUCUAUAUGCCUGC
1312 14019 GCGAUUUUGUUAAAGCCACUUGCGAAUUUU
1313 14022 CAUAGUCAGUUAGGUGGUUUACAUCUACUG
1314 14035 GUAGUCUUCUUGCAUGUGACUUAUGUCCCU
1315 14084 GGCUUACCGCAAGGUUCUUCUUCGUAAGAA
1316 14085 AUGUACAAAUACCUACAACUUGUGCUAAUG
1317 14110 CAACU All AAAU U AAACACAG ACCAU UCCAG
1318 14119 CAACUAGCACUCUCCAAGGGUGUUCACUUU
1319 14122 CCUGACGGCGUAAAACACGUCUAUCAGUUA
1320 14135 AUAAUUAAUAACUAAUUACUGUCGUUGACA
1321 14144 ACAUUUACUUGUGCUAGUGAGUACACUGGU
1322 14145 GGCUUAGUAGAAGUUGAAAAAGGCGUUUUG
1323 14153 GAUAUUGCUGCUAGAGACCUCAUUUGUGCA
1324 14165 ACAUUUAUUAGUGAUGAAGUUGCGAGAGAC
1325 14166 CAUAUAUUCUUUUCACUAGGUUUUUCUAUG
1326 14169 CAUAUCAACAUCACAUAAAUUAGUCUUGUC
1327 14189 CCUGUUGCACUACGACAGAUGUCUUGUGCU
1328 14197 AGAGUGUGGACACUUAUGAAUGUCUUGACA
1329 14200 ACAAAUGCUGGUGAUUACAUUUUAGCUAAC
1330 14203 G ACG G U A A A A U G A A AG A U CUCAGUCCAAGA
1331 14212 AUGGAAAGUGAGUUCAGAGUUUAUUCUAGU
1332 14221 CAACGUCUUACUAAAUACACAAUGGCAGAC
1333 14233 ACAUUUGGCUAGGUUUUAUAGCUGGCUUGA
1334 14240 CUGUUGCUAAUGGUGAUUCUGAAGUUGUUC
1335 14250 ACAAAUGGCCCCGAUUUCAGCUAUGGUUAG
1336 14260 CUAGGUUUUAUAGCUGGCUUGAUUGCCAUA
1337 14267 AUUAUCCUAAAUGUGAUAGAGCCAUGCCUA
1338 14271 ACAUUUGUGGUGAUUCAACUGAAUGCAGCA
1339 14280 AAUUGCCGUUUUAGAUAUGUGUGCUUCAUU
1340 14283 AUCAGACAUACCACCCAAAUUGUGUUAACU
1341 14310 GUCUAAGGGUUUCUUUAAGGAAGGAAGUUC
1342 14318 CUGUUGGGGCUUGUGUUCUUUGCAAUUCAC
1343 14320 GUCAUGCUACUAGAGAAGCUGUUGGUACCA
1344 14322 GGACAGCCUUUGUUACUAAUGUGAAUGCGU
1345 14341 GCUUCAUUAAAAGAAUUACUGCAAAAUGGU
1346 14343 GGUGUAGAUGCUGUAAAUUUACUUACUAAU
1347 14345 AC A A A UGUUAAGUGACACACUU A A A A A U C U
1348 14346 AAGAGAGGUUAAAACUCUUUGACCGUUAUU
1349 14358 CAUAUUAAUGCGCAGGUAGCAAAAAGUCAC
1350 14360 CAACCUUACAAGCUAUAGCCUCAGAGUUUA Sequence in priority
SEQ ID NO document Sequence
1351 14366 AAUGGAUAAUCUUGCCUGCGAAGAUCUAAA
1352 14395 GCGAAUAAUUGCACUUUUGAAUAUGUCUCU
1353 14401 AAUUCAUCAACUUGUAUGAUGUGUUACAAA
1354 14403 CAUAUUCACUCAAACCACUGAAACAGCUCA
1355 14405 GAGCCUUGAAU AC ACC A A A AG AUCACAUUG
1356 14417 AGGAGGUCUUAUCAGAGGCACGUCAACAUC
1357 14431 ACCAAACCAACCAUAUCCAAACGCAAGCUU
1358 14441 AGCUAGAAAAUCAGCACCUUUAAUUGAAUU
1359 14442 CAACCUAUACUGUUACUAGAUCAGGCAUUA
1360 14444 AGGAGGUGUUGCAGGAGCCUUAAAUAAGGC
1361 14456 GAUCAACUCCGCGAACCCAUGCUUCAGUCA
1362 14469 GCGAAAUACCAGUGGCUUACCGCAAGGUUC
1363 14483 AGAGUUGAUGGUCAAGUAGACUUAUUUAGA
1364 14492 CAACCGGGUGUUGCUAUGCCUAAUCUUUAC
1365 14499 AAUAGGUUUUUGUAUAUAAUUAAGUUAAUU
1366 14507 CUGUUGUUCUUGUGGAUCCUGCUGCAAAUU
1367 14509 GUAUCUACUAGUGGUAGAUGGGUACUUAAC
1368 14514 ACAAAUUCUAGAAUUAAAGCAUCUAUGCCG
1369 14528 GUACUGACAUUAGAUAAUCAAGAUCUCAAU
1370 14537 CUAGCUGUCCACGAGUGCUUUGUUAAGCGU
1371 14543 AAUAGGUUUCCUAUUCCUUACAUGGAUUUG
1372 14547 GCCUUUUACAUUCUACCAUCUAUUAUCUCU
1373 14550 AUGGAAAAGUUAUGUGCAUGUUGUAGACGG
1374 14559 CUGUUUAAUAGGGGCUGAACAUGUCAACAA
1375 14579 CUGUUUACUACAGUCAGCUUAUGUGUCAAC
1376 14582 AGUGAUGUGCUAUUACCUCUUACGCAAUAU
1377 14590 AAUCGGAGCUGUGAUCCUUCGUGGACAUCU
1378 14603 GGUAACAACUUUUGAUUCUGAGUACUGUAG
1379 14609 CCUAUUCUGGACAAUCUACACAACUAGGUA
1380 14625 GCCUUUCAACUCUCAUGAAGUGUGAUCAUU
1381 14630 AAAGUACAAAUAGGAGAGUACACCUUUGAA
1382 14691 GAAGGUGUCUUUGUUUCAAAUGGCACACAC
1383 14699 G U AAAG AUGGCCAUG U AG AAACAU U U U ACC
1384 14731 GUGGCGGUUCACUAUAUGUUAAACCAGGUG
1385 14750 GUAGCUAGUCAAUCCAUCAUUGCCUACACU
1386 14754 CCU AU UCACUUCU AU UCU AAAUGGU AU AU U
1387 14761 CAUCAUCUGAAGCAUUUUUAAUUGGAUGUA
1388 14767 CUAGCAUAAAGAACUUUAAGUCAGUUCUUU
1389 14777 GAUCAGACAUACCACCCAAAUUGUGUUAAC
1390 14787 CAACCAAAAUGCACAAGCUUUAAACACGCU
1391 14803 CAUCAUUCUAUUGGAUUUGAUUACGUCUAU
1392 14805 GGUUAUUUAAAACUUACUGACAAUGUAUAC
1393 14835 ACC A A U G G A A A A AC U C A A A AC AC U AG U U G C
1394 14843 ACCAAUGGUACUAAGAGGUUUGAUAACCCU
1395 14879 AGGAGUUAGAUAAAUAUUUUAAGAAUCAUA Sequence in priority
SEQ ID NO document Sequence
1396 14881 CUAGAUUCCCUAAGAGUGAUGGAACUGGUA
1397 14887 AUAGAAUUUCUUAAGAGAGGUGAUAAAAGU
1398 14907 AAAGUAUGAGCAGUAUAUAAAAUGGCCAUG
1399 14909 ACCAAUUUACCUUUACAGCUAGGUUUUUCU
1400 14921 CUAGAUCUGAGGACAAGAGGGCAAAAGUUA
1401 14942 AAUAGGAAUUGUCAACAACACAGUUUAUGA
1402 14983 AC A AC A AC U U AC A A A U U AAA UGUUGGUGAU
1403 14991 CUAGAGGCUUCAUUUAAUUAUUUGAAGUCA
1404 14998 AACCUAAAUUGGGUAGUCUUGUAGUGCGUU
1405 15016 AAUAGCUGUUGAACAAGACAAAAACACCCA
1406 15028 GCCUGGUUUGCCUGGCACGAUAUUACGCAC
1407 15050 ACCACAUAUAUCACGUCAACGUCUUACUAA
1408 15054 GAAGUACCAG UUUCUAUCAU UAAUAACACU
1409 15068 AG U G AC A A AG C U U A U A A A A U AG A AG A A U U A
1410 15078 C A U CG U C A AC A ACC U AG AC A A A U C AG C U G G
1411 15092 GCCUGGAAUAUUGGUGAACAGAAAUCAAUA
1412 15109 CCU AU U ACGG AUG U U U U C U AC A A AG A A A AC
1413 15119 GAUCAUUGUGGUGAAACUUCAUGGCAGACG
1414 15121 GUGUAGACUUAUGAAAACUAUAGGUCCAGA
1415 15138 GGACAUCUUCGUAUUGCUGGACACCAUCUA
1416 15145 GCCUGCCAAUUCAACUGUAUUAUCUUUCUG
1417 15148 A A AC A AG C U AC A A A A UAUCUAGU AC A AC AG
1418 15150 AUCAUGACGUUCGUGUUGUUUUAGAUUUCA
1419 15174 GCUUAUGUUGCUCGAAAUCAAAGACACAGA
1420 15187 AACCUACAAAGCAACCAUGAUCUGUAUUGU
1421 15188 GAUCCACAGACACUUGAGAUUCUUGACAUU
1422 15195 GACCUUGGUGCUUGUAUUGACUGUAGUGCG
1423 15208 CAUCUCGCAAAGGCUCUCAAUGACUUCAGU
1424 15237 ACCACUAAAGUCUGCUACGUGUAUAACACG
1425 15245 GACCUUCAAAAUUAUGGUGAUAGUGCAACA
1426 15258 ACCACUAGUGAGAAAAAUAUUUGUUGAUGG
1427 15260 GAAGUAUUUAUACUUUAUUAAAGGAUUAAA
1428 15269 CAACAAGACGGCAGUGAGGACAAUCAGACA
1429 15285 A U G U AAA U A A AC A U G C A U U CC AC AC ACC AG
1430 15289 CAACAACUCAUAUGAGUGUGACAUACCCAU
1431 15308 GUAUAAUGCUAGUUUAUUGUUUCUUAGGCU
1432 15310 CAACAACCUAGACAAAUCAGCUGGUUUUCC
1433 15331 CAACAACACAG UUUAUGAUCCU U UGCAACC
1434 15335 CUUAAAUUGUCACAUCAAUCUGACAUAGAA
1435 15342 CUUAAAUUUGGAAGAAGCUGCUCGGUAUAU
1436 15358 CUCUGAUGCAGAUUCAACUUUGAUUGGUGA
1437 15362 AAAGUGCACAUCAGUAGUCUUACUCUCAGU
1438 15365 AUAAGUUUGUUCGCAUUCAACCAGGACAGA
1439 15367 ACCACUUAAAGUGGGUGGUAGUUGUGUUUU
1440 15378 C A AC A A AC U G U U G G U C A AC A AG ACGGCAGU Sequence in priority
SEQ ID NO document Sequence
1441 15382 GGCUUGUGUUCUUUGCAAUUCACAGACUUC
1442 15394 GUGACAUACCCAUUGGUGCAGGUAUAUGCG
1443 15445 AGUCUUUAAUGGUGUUUCCUUUAGUACUUU
1444 15460 ACAACAGCAGACAACCCUUAAGGGUGUAGA
1445 15477 AAUCCUACCACAUUCCACCUAGAUGGUGAA
1446 15478 GCCUAUUGGGUUCCACGUGCUAGCGCUAAC
1447 15479 AGUCUUGUAGUGCGUUGUUCGUUCUAUGAA
1448 15481 CUACUUCUUGCAGAGUAUAAACUUUGUAAG
1449 15490 CGAAUGUACAACUAUUGUUAAUGGUGUUAG
1450 15501 CAUCUUUUUCUGCUUCCACAAGUGCUUUUG
1451 15517 GGAAAAUCCUACCAUACAGAAAGACGUUCU
1452 15524 ACAACAGGAGUCACCUUUUGUUAUGAUGUC
1453 15527 AGUCUUCUUGCAUGUGACUUAUGUCCCUGC
1454 15535 ACCAGAGGUGAAAAUACUCAAUAAUUUGGG
1455 15541 ACAACAGGGCAACCUUACAAGCUAUAGCCU
1456 15547 CACUAACUGAGAAUAAAUAUUCUCAAUUAG
1457 15548 CUUUUAAUGUUGUAAAUAAGGGACACUUUG
1458 15549 GUCAGUGUUAUAACACCAGGAACAAAUACU
1459 15552 ACAACAGGGUGAAGUACCAGUUUCUAUCAU
1460 15558 GCUUAUGAAAAUUUUAAUCAGCACGAAGUU
1461 15571 CUACUUAGCUGUCUUUGAUAAAAAUCUCUA
1462 15581 ACAACAGUACUUUUAAAAGAACCUUGCUCU
1463 15598 CACUAAGAAAUCUGCUGCUGAGGCUUCUAA
1464 15600 CUGAUGUUGGUGAUAGUGCGGAAGUUGCAG
1465 15601 GGUAGUGUUGGUUUUAACAUAGAUUAUGAC
1466 15611 AGUCUUACUCUCAGUUUUGCAACAACUCAG
1467 15630 GAUCCUUCGUGGACAUCUUCGUAUUGCUGG
1468 15632 CAAAUUACAGAAUAAUGAGCUUAGUCCUGU
1469 15658 GGACAUUGCUGCUAAUACUGUGAUCUGGGA
1470 15666 ACAACAGUUUGGUCCAACUUAUUUGGAUGG
1471 15694 ACCAGGAACUAAUCAGACAAGGAACUGAUU
1472 15696 ACUUACAAUACAUAAGAAAGCUACAUGAUG
1473 15729 A A A AC AG G G U A A U U U C A A A A A UCUUAGGGA
1474 15744 CAAAUGGAAAUUGAUUUCUUAGAAUUAGCU
1475 15762 AAUAGAGCAACAAGAGUCGAAUGUACAACU
1476 15783 CUGCGUUAUAGCUUGGAAUUCUAACAAUCU
1477 15784 ACUUAAUGAGAAGUGCUCUGCCUAUACAGU
1478 15803 CAUGAUGGAAAAGCACACUUUCCUCGUGAA
1479 15809 AACAGUUUACUCACACCUUUUGCUCGUUGC
1480 15819 AUACAGCUUGCUCUCAUGCCGCUGUUGAUG
1481 15829 GAAGUGCUGUCUGACAGAGAAUUACAUCUU
1482 15830 AACCUAGUAAUAGGUUUCCUAUUCCUUACA
1483 15834 GAAAGAUCAGAAGCUGGUGUUUGUGUAUCU
1484 15863 GUGCUGACUCUAUCAUUAUUGGUGGAGCUA
1485 15871 CUUAAUGACAACCUUCUUGAAAUACUCCAA Sequence in priority
SEQ ID NO document Sequence
1486 15887 CAAAUCAAUGAUAUGAUUUUAUCUCUUCUU
1487 15888 ACUUAAGCUUAAGGUUGAUACAGCCAAUCC
1488 15894 GUCAGGGUUUAAAUGGUUACACUGUAGAGG
1489 15903 GUACUGCUGUUAUGUCUUUAAAAGAAGGUC
1490 15906 ACCAGUUUCUAUCAUUAAUAACACUGUUUA
1491 15909 AG AAAU U U ACAAG AAU U U AAACCCAGG AG U
1492 15912 A AG A A AC UAAGUUCCU C AC AG A A A AC U U G U
1493 15913 AAGAGAAUUCCUUACACGUAACCCUGCUUG
1494 15914 GUGCUUCAUUAAAAGAAUUACUGCAAAAUG
1495 15927 AAA U C A A A A UGUGAAGAAUCAUCUG C A A A A
1496 15939 CUUAAUGGAGUCACAUUAAUUGGAGAAGCC
1497 15963 ACUUAACAAUGAUUAUUACAGAUCUUUACC
1498 15968 GGUAGUUAUACUAAUGACAAAGCUUGCCCA
1499 15984 ACAACAUUUACUUAUGCAUCAGCAUUGUGG
1500 16000 GCCGGCUGUUUUGUAGAUGAUAUCGUAAAA
1501 16012 AGCCACUGUACAGUCUAAAAUGUCAGAUGU
1502 16018 GGCUUUGGAGACUCCGUGGAGGAGGUCUUA
1503 16019 CACGUAGUGUAGCUAGUCAAUCCAUCAUUG
1504 16021 CAUGCCUUCUUACUGUACUGGUUACAGAGA
1505 16024 AAAUUGAUUUCUUAGAAUUAGCUAUGGAUG
1506 16025 CUCCUACUAAAUUAAAUGAUCUCUGCUUUA
1507 16034 GGAGGAGGUCUUAUCAGAGGCACGUCAACA
1508 16050 ACAACCAAUCACUAAUUGUGUUAAGAUGUU
1509 16057 ACCAUAUUGUUAUGAUACCAAUGUACUAGA
1510 16073 GUGCUGUAGACAUAAACAAGCUUUGUGAAG
1511 16076 CUUUGUUUCAAAUGGCACACACUGGUUUGU
1512 16082 AAAAGAUGGCUGAUCAAGCUAUGACCCAAA
1513 16088 CGGCGUUGUCCUGCUGAAAUUGUUGACACU
1514 16096 AAAGUUGAGGGUUGUAUGGUACAAGUAACU
1515 16101 CUGAACAACUACGAAAACAAAUACGUAGUG
1516 16107 CAUGCUACUAGAGAAGCUGUUGGUACCAAU
1517 16114 GGUGGUGACGGUAAAAUGAAAGAUCUCAGU
1518 16123 AG A U C A A U U U A A AC ACC UCAUACCACUUAU
1519 16126 CAAAGUGACUAUUGACUAUACAGAAAUUUC
1520 16142 GAUCUCAUUAUUAGUGAUAUGUACGACCCU
1521 16164 GAUCUCCCUCAGGGUUUUUCGGCUUUAGAA
1522 16166 CUACUACCGAAGAGCUACCAGACGAAUUCG
1523 16172 GGCUUUUAAUGUUGUAAAUAAGGGACACUU
1524 16190 CUACUAAUUUGGUUAAAAACAAAUGUGUCA
1525 16204 GGCGCGAUCAAAACAACGUCGGCCCCAAGG
1526 16234 CUACUAACAAUGCCAUGCAAGUUGAAUCUG
1527 16236 CACUACUGAAAUGCUAGCGAAAGCUUUGAG
1528 16238 CUACUAACAAUCUAGUUGUAAUGGCCUACA
1529 16242 AAGAGAAUCAGCAACUGUGUUGCUGAUUAU
1530 16247 GCCCUUUUGGUGAAGUUUUUAACGCCACCA Sequence in priority
SEQ ID NO document Sequence
1531 16252 CUGAUAAUGGACCCCAAAAUCAGCGAAAUG
1532 16255 CAUGGAAGUCACACCUUCGGGAACGUGGUU
1533 16265 AUAAUGGUUAUCUUACUUCUUCUUCUAAAA
1534 16268 GCCCUUGCACCUAAUAUGAUGGUAACAAAC
1535 16271 AG U CG C A AC AG U U C A AG A A A U U C A AC U CC A
1536 16274 CUUACAGGCUGUUGGGGCUUGUGUUCUUUG
1537 16280 GAAGUUAUCACCUUUGACAAUCUUAAGACA
1538 16287 G G ACCAG G AAC U AAU CAG ACAAG G AAC U G A
1539 16290 CUUUGUUCUUUUUUUUGUAUGAAAAUGCCU
1540 16296 GAUCUGCACCUCUGAAGACAUGCUUAACCC
1541 16315 A AG UCACACCUUCG G G A ACG UGGUUGACCU
1542 16348 GAUCUGGGACUACAAAAGAGAUGCUCCAGC
1543 16403 AUGUAAACUUACAUAGCUCUAGACUUAGUU
1544 16428 GGUGGUAGUUAUACUAAUGACAAAGCUUGC
1545 16431 GUGUAGAAGCUGUUAUGUACAUGGGCACAC
1546 16433 CACGGCCAAUGUUAAUGCACUUUUAUCUAC
1547 16436 A A A ACC A AC AG UGGUUGUUAAUG CAG CCA A
1548 16449 AGUUUUCUGUGGUGUAGAUGCUGUAAAUUU
1549 16450 CACGGCACUUGUGAAAGAUCAGAAGCUGGU
1550 16471 CUUACCGCAAGGUUCUUCUUCGUAAGAACG
1551 16478 AUUAUCUUUCUGUGCUUUUGCUGUAGAUGC
1552 16501 GGGAAAUCCAACAGGUUGUAGAUGCAGAUA
1553 16530 GUCUCCU ACU AAAU UAAAUGAUCUCUGCUU
1554 16540 CACUAGUACUGAUGUCGUAUACAGGGCUUU
1555 16583 CAAACUGGAAAGAUUGCUGAUUAUAAUUAU
1556 16589 AGACAUUUAAACUGUCUUAUGGUAUUGCUA
1557 16591 CGCACUAUUGCCUUUGGAGGCUGUGUGUUC
1558 16594 CUUUGUGUGCUGACUCUAUCAUUAUUGGUG
1559 16608 CUUACUAAAUACACAAUGGCAGACCUCGUC
1560 16609 CAUGUACUCAACAUCAACCAUAUGUAGUUG
1561 16634 CAUGUAGUUGCCUUUAAUACUUUACUAUUC
1562 16645 GAAAUCCAACAGGUUGUAGAUGCAGAUAGU
1563 16649 GAAGUUGGUAAACCUAGACCACCACUUAAC
1564 16653 C AC U A U A A AC A UAU AAC U U C U A A AG A A AC U
1565 16675 CCUUACUGUUUUGCCACCUUUGCUCACAGA
1566 16681 CUUACUAUUAAGAAACCUAAUGAAUUAUCU
1567 16682 GACCAGGAACUAAUCAGACAAGGAACUGAU
1568 16697 GUCAGAUAUAGAUUAUGUACCACUAAAGUC
1569 16708 CAUGUCUAAACAUACUGACUUUUCAAGUGA
1570 16717 CUUACUCUCAGUUUUGCAACAACUCAGAGU
1571 16720 CAAACCUUGUAUCAAAGUAGCCACUGUACA
1572 16745 CCUUAGACAAUGUCUUAUCUACUUUUAUUU
1573 16769 CAAACCCGG U AAU U U U AACAAAG ACU UCU A
1574 16774 CUGAACAUGUCAACAACUCAUAUGAGUGUG
1575 16781 ACCCCAAAAUCAGCGAAAUGCACCCCGCAU Sequence in priority
SEQ ID NO document Sequence
1576 16794 CGACGAGCUUGGCACUGAUCCUUAUGAAGA
1577 16802 AACCUCAUCAGGAGAUGCCACAACUGCUUA
1578 16804 CAAACCACGCGAACAAAUAGAUGGUUAUGU
1579 16815 GGACCCUCAGAUUCAACUGGCAGUAACCAG
1580 16846 CAUGUGUGGCGGUUCACUAUAUGUUAAACC
1581 16849 AAAUCACAU AAACCACCCAU U AG U U U UCCA
1582 16864 GGUUUACAUCUACUGAUUGGACUAGCUAAA
1583 16866 CAUGUUAACAAUGCAACUAAUAAAGCCACG
1584 16868 CUGCUACGUGUAUAACACGUUGCAAUUUAG
1585 16869 CAAACAUAAGCAUGCAUUUCUCUGUUUGUU
1586 16873 GACCAAUGG U ACU AAG AGG U U UG AU AACCC
1587 16909 AUCCUGCUGCAAAUUUGAUGAAGACGACUC
1588 16914 CAAACAGCACAAGCAGCUGGUACGGACACA
1589 16921 CAUGUUAUGGUUGAGCUGGUAGCAGAACUC
1590 16926 AACGUUAAAGAUUUCAUGUCAUUGUCUGAA
1591 16934 AGCAUUUGAGCUUUGGGCUAAGCGCAACAU
1592 16943 GAUGAACUGAAGAUUAAUGCGGCUUGUAGA
1593 16956 ACAACUACACUUAACGGUCUUUGGCUUGAU
1594 16959 GUGACCUUCAAAAUUAUGGUGAUAGUGCAA
1595 16970 ACAACU ACU AACAU AG U U ACACGG UG U U U A
1596 16976 CAAACAAAU U U ACAAAACACCACCAAU U AA
1597 16985 AGUCACCUUUUGUUAUGAUGUCAGCACCAC
1598 16986 AAACUUACAUAGCUCUAGACUUAGUUUUAA
1599 16990 GGUAGUUGUGUUUUAAGCGGACACAAUCUU
1600 17003 AAAAUCCUACCAUACAGAAAGACGUUCUUG 1601 17008 AGUCACAUUAAUUGGAGAAGCCGU A A A A AC 1602 17014 G CC A U C A A A U U G G A U G AC A A AG A U CCA A A U
1603 17026 CAAAAUUCAAGACUCACUUUCUUCCACAGC
1604 17027 CACGCACUCAAAGGGAUUGUACAGAAAGUG
1605 17037 CACUAUUCUGACCAGACCGCUUCUAGAAAG
1606 17040 G AAG U U U U U AACGCCACCAG AU U UGCAUCU
1607 17063 CACUAUUGCAACCUACUGUACUGGUUCUAU
1608 17080 AUGCUACUCCUUCAGAUUUUGUUCGCGCUA
1609 17083 GAUGAAGUCAGACAAAUCGCUCCAGGGCAA
1610 17088 AAAUUGUUAAAUUUAUCUCAACCUGUGCUU 1611 17092 GGACCUAAAAAGUCUACUAAUUUGGUUAAA 1612 17118 CAUUAAAAUAUUUGCCUAUAGAUAAAUGUA
1613 17125 GGGACAACCAAUCACUAAUUGUGUUAAGAU
1614 17131 GAUGAAGUUGCGAGAGACUUGUCACUACAG
1615 17134 CUACAUACUACUUAUUUGAUGAGUCUGGUG
1616 17152 GGUGGCUAUUGAUUAUAAACACUACACACC
1617 17169 ACCCUAUAAUAUGAGAGUUAUACAUUUUGG
1618 17179 CAAAAGUUACUAGUGCUAUGCAGACAAUGC
1619 17206 AACUUUUAUGGACCUUUUGUUGACAGGCAA
1620 17208 ACCCUCAGAUUCAACUGGCAGUAACCAGAA Sequence in priority
SEQ ID NO document Sequence
1621 17211 CACGAUAUUACGCACAACUAAUGGUGACUU
1622 17228 AGUCAAAUGGAAAUUGAUUUCUUAGAAUUA
1623 17232 GCCAGCUACAGUUUCUGUUUCUUCACCUGA
1624 17237 G AACG UG U ACGCCAAGCU U UG U UAAAAACA
1625 17243 CUUAGUAGAAGUUGAAAAAGGCGUUUUGCC
1626 17250 CAUUAAUGCUUCAGUUGUAAACAUUCAAAA
1627 17269 AAAAGCUAAAAAAGGUGCCUGGAAUAUUGG
1628 17271 GACAUUGACAUCACUUUCUU A A AG A A AG A U
1629 17284 GCCAGAUCAGUUUCACCUAAACUGUUCAUC
1630 17289 AAGGUAAUCACUGGGUUACAUCCUACACAG
1631 17316 GCCAGAAGCUGGACUUCCCUAUGGUGCUAA
1632 17319 AG AUGCAG AU AG U AAAAU UG U UCAACU U AG
1633 17323 CUUAGUGGUUUAGAUUCUUUAGACACCUAU
1634 17343 GAUGACACUGUGAUAGAAGUGCAAGGUUAC
1635 17344 GCCACUUCUGCUGCUCUUCAACCUGAAGAA
1636 17364 CUUAGUUGCAGAGUGGUUUUUGGCAUAUAU
1637 17379 AGAUGCCACAACUGCUUAUGCUAAUAGUGU
1638 17393 CAUUACUUCAGGUGAUGGCACAACAAGUCC
1639 17415 GCCACUCCAUGGCACUAUUCUGACCAGACC
1640 17440 GCCACUACUUGUGGUUACUUACCCCAAAAU
1641 17450 GAAAUUGUCGGUGGACAAAUUGUCACCUGU
1642 17468 AUAGAUUGUUUAGGAAGUCUAAUCUCAAAC
1643 17471 GAAUACAGUCAUGUAGUUGCCUUUAAUACU
1644 17485 CAUUAGUGUCUGAUGUUGGUGAUAGUGCGG
1645 17503 GAAAUCAUAGGAUACAAGGCUAUUGAUGGU
1646 17504 A U U A A U G C U A ACC A AG U C A U CG U C A AC A AC
1647 17515 AG AAU UG U U UG AAAAU AAAACAACAU U ACC
1648 17536 GCCACAUGCUUUUCCACUGCUUCAGACACU
1649 17566 AAUGCUUUAGAUCAAGCCAUUUCCAUGUGG
1650 17567 CACCUUUUGUUAUGAUGUCAGCACCACCUG
1651 17568 CUUAUACCCAACACUCAAUAUCUCAGAUGA
1652 17570 CAAAAACGUACUGCCACUAAAGCAUACAAU
1653 17577 CUACAAGCUGGUAAUGCAACAGAAGUGCCU
1654 17579 AGAUGCUGCUAAAGCUUACAAAGAUUAUCU
1655 17580 AUUAUGACAUGGUUGGAUAUGGUUGAUACU
1656 17585 GCU U A A A A AG U G U A A A AG U G CC U U U U ACAU
1657 17604 GUCACUCGUGACAUAGCAUCUACAGAUACU
1658 17610 AGAUGCUGUAAAUUUACUUACUAAUAUGUU
1659 17612 AG G C A A AG AC AG U G C U U A A A A AG U G U A A A A
1660 17615 GCCAAUUCUGCUGUCAAAUUACAGAAUAAU 1661 17627 GUAUGAUGAUGGUGCUAGGAGAGUGUGGAC 1662 17635 AG AAACAU U U U ACCCAAAAU U ACAAUCU AG
1663 17656 AG ACAU U AU ACU U AAACCAGCAAAU AAU AG
1664 17671 AAAU UUACUUACUAAUAUGUU U ACACCACU
1665 17672 A AC U U U G A AG C A AG G U G AAA U C A AG G A U G C Sequence in priority
SEQ ID NO document Sequence
1666 17687 CUUAUAGGUUUAAUGGUAUUGGAGUUACAC
1667 17689 GUGAUGUUGUUCAAGAGGGUGUUUUAACUG
1668 17691 CAUUCACUGUACUCUGUUUAACACCAGUUU
1669 17753 AUUUUUGGUGCUGACCCUAUACAUUCUUUA
1670 17754 AUUUUUGGUACUACUUUAGAUUCGAAGACC
1671 17763 G U ACACACCACUGG U UG U U ACUCACAAU U U
1672 17789 GACAUCUCUGGCAUUAAUGCUUCAGUUGUA
1673 17795 CUUAUCAGAGGCACGUCAACAUCUU A A AG A
1674 17797 ACUGUAGGCACGGCACUUGUGAAAGAUCAG
1675 17802 AAUACACUUCAGUGUAUAAUGCUAGUUUAU
1676 17806 CAUUCCCAUCUGGUAAAGUUGAGGGUUGUA
1677 17816 GUGAUCAUUGUGGUGAAACUUCAUGGCAGA
1678 17817 CUAAUUUAGGCAUGCCUUCUUACUGUACUG
1679 17825 GUACUUAACAAUGAUUAUUACAGAUCUUUA
1680 17832 GCCAACAGACAAUUAUAUAACCACUUACCC 1681 17845 GUGUACUUGGACAAUCAAAAAGAGUUGAUU 1682 17846 GUACUUAAGCUUAAGGUUGAUACAGCCAAU
1683 17855 AGUAUGGCUACAUACUACUUAUUUGAUGAG
1684 17865 CCGCUAUAACAAUACUAGAUGGAAUUUCAC
1685 17869 GGUUUAGAUUCUUUAGACACCUAUCCUUCU
1686 17870 CUUUGGCUUUGCUGGAAAUGCCGUUCCAAA
1687 17879 GUACACACACUGGUACUGGUCAGGCAAUAA
1688 17880 CACUCGUGACAUAGCAUCUACAGAUACUUG
1689 17881 GAGUACACUGGUAAUUACCAGUGUGGUCAC
1690 17885 CUUUGGCUUGAUGACGUAGUUUACUGUCCA
1691 17893 AUGUGAUAAUAUCAAAUUUGCUGAUGAUUU
1692 17898 AUGGUAAUGCUGCUAUCAGCGAUUAUGACU
1693 17900 CCUAUAUAAUUCCGCAUCAUUUUCCACUUU
1694 17909 AGUAUGCUGAUGUCUUUCAUUUGUACUUAC
1695 17915 CUUAUCUACUUUUAUUUCAGCAGCUCGGCA
1696 17919 GCUGUUGUUCUUGUGGAUCCUGCUGCAAAU
1697 17945 G U G U A A A AC UUGUGGACAACAGCAG AC A AC
1698 17953 GACAUCAAGGACCUGCCU A A AG AAA U C AC U
1699 17965 AGAUGGGUACUUAACAAUGAUUAUUACAGA
1700 17977 CGCUACAGGAUUGGCAACUAUAAAUUAAAC
1701 17986 GAAUAGUUUUAGUGGUUAUU UAAAACU U AC
1702 18008 AAUACAAAUCCAAUUCAGUUGUCUUCCUAU
1703 18018 AAAAACAGAUGGUACACUUAUGAUUGAACG
1704 18021 AAAUUUCCCCUUAAAUUAAGGGGUACUGCU
1705 18027 GACAUAGCAUCUACAGAUACUUGUUUUGCU
1706 18042 AACUUUAGCUUGUUUUGUGCUUGCUGCUGU
1707 18048 ACC U A A A A AG UCUACUAAU UUGGU UAAAAA
1708 18085 G AAAU UGU U AAAU UUAUCUCAACCUGUGCU
1709 18088 GACAUACCCAUUGGUGCAGGUAUAUGCGCU
1710 18096 ACUGUAAAUGCAUUGCCUGAGACGACAGCA Sequence in priority
SEQ ID NO document Sequence
1711 18126 G U AGAUGCUG U AAAU UU ACU U ACU AAU AUG
1712 18146 AUUUUGUGACUUAAAAGGUAAGUAUGUACA
1713 18154 AUGGUACAAGUAACUUGUGGUACAACUACA
1714 18155 AUUUUGUGAAAAUAGGACCUGAGCGCACCU
1715 18157 AUCUAAAGUUGCGUAGUGAUGUGCUAUUAC
1716 18164 GAAUAUCACUUUUGAACUUGAUGAAAGGAU
1717 18184 CUUUGGAG C AC A A A ACC AG U U G A A AC A U C A
1718 18210 CAUUGAUUUAGAUGAGUGGAGUAUGGCUAC
1719 18214 CUUAUGGGCACAUGGCUUUGAGUUGACAUC
1720 18215 GAUGAUGAUUAUUUCAAUAAAAAGGACUGG
1721 18220 ACCUACAGGUUAUGUUGAUACACCUAAUAA
1722 18227 AUAAUGCUAGUUUAUUGUUUCUUAGGCUAU
1723 18230 CUUUGGAGACUCCGUGGAGGAGGUCUUAUC
1724 18234 AACUUUAAUUUUAGCCAUGGCAGAUUCCAA
1725 18248 CUUAUGGUAUUGCUACUGUACGUGAAGUGC
1726 18254 AAAAC U U G U G G AC AACAG CAG ACAACCC U U
1727 18292 AUGCUCGAACUGCACCUCAUGGUCAUGUUA
1728 18301 G U A AC U A A A A AC AG U A A AG U ACAAAU AGG A
1729 18311 AGGCACGGCACUUGUGAAAGAUCAGAAGCU
1730 18313 GCAUUGAUUUAGAUGAGUGGAGUAUGGCUA
1731 18330 GUGGUCACUAUAAACAUAUAACUUCUAAAG
1732 18349 ACUGGUUACAGAGAAGGCUAUUUGAACUCU
1733 18356 AUCUACUAGUGGUAGAUGGGUACUUAACAA
1734 18370 GAAAUCAAGGAUGCUACUCCUUCAGAUUUU
1735 18382 AG A AG U U G A A A A AG GCGUUUUGCCUCAACU
1736 18411 CUUUGCUGG AAA U G CCG U U CC A A A A ACCC A
1737 18427 CUUAUGUUGC U CG A A A U C A A AG AC AC AG A A
1738 18440 AAUGUAGUGCGUAUAAAGAUUGUACAAAUG
1739 18442 CUAAUCUCAAACCUUUUGAGAGAGAUAUUU
1740 18452 GGGAUUUGUUAAAAUAUGACUUCACGGAAG
1741 18476 GAUGAUUAUGUGUACCUUCCUUACCCAGAU
1742 18478 AGAAUUCGAUCUGUCUAUCCAGUUGCGUCA
1743 18523 CACUGAGAAUUUGACUAAAGAAGGUGCCAC
1744 18531 ACCUCAAGCUGAUGUAGAAUGGAAGUUCUA
1745 18536 CUAAUCAUAAUUUCUUGGUACAGGCUGGUA
1746 18555 AACUUGUGGUACAACUACACUUAACGGUCU
1747 18563 GCAUUAAAGACCUUCUAGCACGUGCUGGUA
1748 18570 AAAAUGAAAGAUCUCAGUCCAAGAUGGUAU
1749 18577 CACUGAUAACACUCGCUACUUGUGAGCUUU
1750 18579 CUGAUGAAACUCAAGCCUUACCGCAGAGAC
1751 18586 GCAUGUUGUAGACGGUUGUAAUUCAUCAAC
1752 18599 ACUGGUCAGGCAAU AACAG UUACACCGGAA
1753 18600 ACCUCAUGAAUUUUGCUCUCAACAUACAAU
1754 18639 ACUGGUAUGAUUUUGUAGAAAACCCAGAUA
1755 18647 GGUGCUUGCAUACGUAGACCAUUCUUAUGU Sequence in priority
SEQ ID NO document Sequence
1756 18650 CACUGAUCCUUAUGAAGAUUUUCAAGAAAA
1757 18652 AG U AGU ACU U UCU UUUGAACU UCU ACAUGC
1758 18660 AACUUGUCGGCGUUGUCCUGCUGAAAUUGU
1759 18663 GUAACUUCUUCAAUUGUCAUUACUUCAGGU
1760 18692 AAAUCCAACAGGUUGUAGAUGCAGAUAGUA
1761 18732 GAUGCAAUCAUGACUAGGUGUCUAGCUGUC
1762 18751 GAACGUGGUUGACCUACACAGGUGCCAUCA
1763 18764 GUACAAUCACUUCUGGUUGGACCUUUGGUG
1764 18765 AUUUUAGUGGAGCAAUGGAUACAACUAGCU
1765 18785 GCAUGGAUUGGCUUCGAUGUCGAGGGGUGU
1766 18798 GCUUUUGUUAAUU U AAAACAAU U ACCAU U U
1767 18809 AUCUCAUUAUUAGUGAUAUGUACGACCCUA
1768 18813 ACUGGUAAGAGUCAUUUUGCUAUUGGCCUA
1769 18818 ACCUCUUUCUGCUCAAACUGGAAUUGCCGU
1770 18828 AUACAACUAGCUACAGAGAAGCUGCUUGUU
1771 18830 GCUUUUGUGGAAACUGUGAAAGGUUUGGAU
1772 18836 GACACUUUGAUGGACAACAGGGUGAAGUAC
1773 18838 CAUUUAUUGAAGAUCUACUUUUCAACAAAG
1774 18850 GGUCAACCAAAAUGCACAAGCUUUAAACAC
1775 18864 GACACUUGCAGAUGCUGGCUUCAUCAAACA
1776 18871 AACUCAGGUUCUGAUGUUCUUUACCAACCA
1777 18882 ACCUGAGCAUAGUCU UGCCGAAU ACCAU AA
1778 18891 AUGGUACUGAAGAUGAUUACCAAGGUAAAC
1779 18893 ACCUGAGCGCACCUGUUGUCUAUGUGAUAG
1780 18894 AAUGGUGUUGAAGGUUUUAAUUGUUACUUU
1781 18899 AUCUCGAUGCUUAUAACAUGAUGAUCUCAG
1782 18902 AUGUCUUUUGUACUGUAAAUGCAUUGCCUG
1783 18908 GACACUUCGCAUGGUGGACAGCCUUUGUUA
1784 18925 AAUUGCAAUGUCGAUAGAUAUCCUGCUAAU
1785 18934 GAUGCAGCCAUG C A ACG U A AG U U G G A A A AG
1786 18985 GGUGCUGUCUGUAGACAUCAUGCUAAUGAG
1787 18989 CAUUUGACUUAGGCGACGAGCUUGGCACUG
1788 18990 ACCUGCCUAAAGAAAUCACUGUUGCUACAU
1789 19002 GGAGCAAUGGAUACAACUAGCUACAGAGAA
1790 19006 AGGCAUACUUUGCAUAAUGUCUGAUAGAGA
1791 19039 GGCAAACCUUGUAUCAAAGUAGCCACUGUA
1792 19049 AGUAGAAUUAUACCUGCACGUGCUCGUGUA
1793 19052 CGAUAGUUGUAAUAACUAUAUGCUCACCUA
1794 19059 AUGGUACUUGGUAGUUUAGCUGCCACAGUA
1795 19065 GCAUCGUGUUGUCUGUACUGCCGUUGCCAC
1796 19069 CUAAGGGUUUCUUUAAGGAAGGAAGUUCUG
1797 19075 CUGCUCGUGUUGUACGAUCAAUUUUCUCCC
1798 19085 AUACAGGGCUUUUGACAUCUACAAUGAUAA
1799 19104 GUAUGCCUAUUUUGGAAUUGCAAUGUCGAU
1800 19108 AUCUGAAUUACUUACACCACUGGGCAUUGA Sequence in priority
SEQ ID NO document Sequence
1801 19110 AAAGAUUGCUGAUUAUAAUUAUAAAUUACC
1802 19114 AGAAAAAGGAAUCUAUCAAACUUCUAACUU
1803 19117 AGUACUUUCUUUUGAACUUCUACAUGCACC
1804 19122 AAA UUUUGGGGACCAGGAACUAAUCAGACA
1805 19133 AUUUGUUUAUGAGAAUCUUCACAAUUGGAA
1806 19139 GAUGCCAUGCGAAAUGCUGGUAUUGUUGGU
1807 19151 AGAAUUAUACCUGCACGUGCUCGUGUAGAG
1808 19156 AAAUUUUGUCUAGAGGCUUCAUUUAAUUAU
1809 19175 CUUCACAUAUGUAUUGUUCUUUCUACCCUC
1810 19190 GUCAAUUUCAACUUCAAUGGUUUAACAGGC 1811 19192 GGCGGUUCACUAUAUGUUAAACCAGGUGGA 1812 19220 CACCUACACACCUCAGUGUUGACACUAAAU
1813 19223 AUUUGUUAAAAUAUGACUUCACGGAAGAGA
1814 19236 GAAUCUGGAGUAAAAGACUGUGUUGUAUUA
1815 19240 CACCUAAUUUUUCUAAACUGAUAAAUAUUA
1816 19256 CUAAGCGCAACAUUAAACCAGUACCAGAGG
1817 19300 AUUUGUCUUCUACAAUUUGCCUAUGCCAAC
1818 19302 AUUUGUCUUAUGGGCACAUGGCUUUGAGUU
1819 19318 CUUUGAUGAAAUUUCAAUGGCCACAAAUUA
1820 19329 AGUACUAUGACCAAUAGACAGUUUCAUCAA 1821 19333 GGUACAACUACACUUAACGGUCUUUGGCUU 1822 19340 CAUUUUGAUGAAGGUAAUUGUGACACAUUA
1823 19345 CGAUAGAUAUCCUGCUAAUUCCAUUGUUUG
1824 19349 CAUUUUGCUAUUGGCCUAGCUCUCUACUAC
1825 19350 AGCUGGUGGUAUUGUAGCUAUCGUAGUAAC
1826 19354 CAUUUUGCUGAAUAAGCAUAUUGACGCAUA
1827 19367 GGGCGAAAUACCAGUGGCUUACCGCAAGGU
1828 19380 GUCUCUUUUUGUUACAUGCACCAUAUGGAA
1829 19385 CCUUCCCUCAGUCAGCACCUCAUGGUGUAG
1830 19409 GAUGCGUAUUAUGACAUGGUUGGAUAUGGU
1831 19410 GCUGUCUGUAGACAUCAUGCUAAUGAGUAC
1832 19413 GCUGUCUGACAGAGAAUUACAUCUUUCAUG
1833 19417 AGUACGAUCGAGUGUACAGUGAACAAUGCU
1834 19425 GCAUACACUCGCUAUGUCGAUAACAACUUC
1835 19430 CUGCUGAAUGUACAAUUUUUAAAGAUGCUU
1836 19432 CUUUGAUAAAAAUCUCUAUGACAAACUUGU
1837 19436 ACAAGGCGUUCCAAUUAACACCAAUAGCAG
1838 19439 CUUUGAGUUGACAUCUAUGAAGUAUUUUGU
1839 19446 AGAUUCUUAUUAUUCAUUGUUAAUGCCUAU
1840 19449 A AC U A A A A AC AG U A A AG U AC A A A U AG G AG A
1841 19453 ACCUUCCUUACCCAGAUCCAUCAAGAAUCC
1842 19474 AAACAUUUCUCAAUGAUGAUACUCUCUGAC
1843 19492 CUUCAUCAAACAAUAUGGUGAUUGCCUUGG
1844 19504 ACCUUGAAGG A A A AC AG G G UAAU UUCAAAA
1845 19517 AAUAAGACAGUAGGUGAGUUAGGUGAUGUU Sequence in priority
SEQ ID NO document Sequence
1846 19538 GUGCUAAUGGACAAGUUUUUGGUUUAUAUA
1847 19563 CUUCAUGUUGUCGGCCCAAAUGUUAACAAA
1848 19564 AG AU UG AU U AAACG AACAUG AAAAU U AU UC
1849 19575 AGUACAUUUAUUAGUGAUGAAGUUGCGAGA
1850 19582 AACAAAAUUGCCGAUAAGUAUGUCCGCAAU
1851 19602 GACACACUUAAAAAUCUCUCUGACAGAGUC
1852 19608 GCAGUUGGUAACAUCUGUUACACACCAUCA
1853 19610 A AC A A AC A A UACCUUCACACU C A A AG G CG G
1854 19612 AACUUCUUCAAUUGUCAUUACUUCAGGUGA
1855 19625 GUACUUGGACAAUCAAAAAGAGUUGAUUUU
1856 19653 GUGGAAACUAAAGCCAUAGUUUCAACUAUA
1857 19667 GAAUGAGUUUUACGCAUAUUUGCGUAAACA
1858 19683 CUAACUAACAUCUUUGGCACUGUUUAUGAA
1859 19693 ACCUUUCUGGAUAACAAUUGCUUAUAUCAU
1860 19730 AAUAACUAUAUGCUCACCUAUAACAAAGUU 1861 19742 ACCUUUGGUGCAGGUGCUGCAUUACAAAUA 1862 19763 G UCAAU AU U U AAACACAU U AACAU U AGCUG
1863 19780 AAUUAUCUUGGCAAACCACGCGAACAAAUA
1864 19784 CUUUGAAUGUGGCUAAAUCUGAAUUUGACC
1865 19800 G C AG U G A A A AG A AC A A UCAAGGGUACACAC
1866 19802 GGGCUCAAUGUGUCCAGUUACACAAUGACA
1867 19803 GUAUGCUGCUGACCCUGCUAUGCACGCUGC
1868 19808 ACCUUUUGUUGACAGG C A A AC AG C AC A AG C
1869 19822 CUAACAUAAUAAGAGGCUGGAUUUUUGGUA
1870 19827 GGUAAGAGAAUUCCUUACACGUAACCCUGC
1871 19832 AGAUUGUACAAUGUACAUUUGUGGUGAUUC
1872 19834 ACAAGUAACUUGUGGUACAACUACACUUAA
1873 19839 GCUUUUGCUGUAGAUGCUGCUAAAGCUUAC
1874 19846 AGCUUGUCACACCGUUUCUAUAGAUUAGCU
1875 19851 AUUUGAUUACGUCUAUAAUCCGUUUAUGAU
1876 19856 AGUAAUUGGAACAAGCAAAUUCUAUGGUGG
1877 19863 A A A AC U U C A AG A U G U G G U C A ACC A A A A U G C
1878 19869 GGUAUUGUAGCUAUCGUAGUAACAUGCCUU
1879 19872 CCAAAUUCACACAAUCGACGGUUCAUCCGG
1880 19875 ACUGCUGUUAUGUCUUUAAAAGAAGGUCAA 1881 19879 AGUUUCUAAGGUUGUCAAAGUGACUAUUGA 1882 19892 GACAAUUAUGCUUUGCUGUAUGACCAGUUG
1883 19908 CUUCCUAUUCUUUAUUUGACAUGAGUAAAU
1884 19909 CCAAAU UUUGUAUUUCCCU U AAAU UCCAU A
1885 19916 C U A AC A A A A AG UUUCUGCCUUU CCA AC A A U
1886 19917 CCUAAACUCAUGCAGACCACACAAGGCAGA
1887 19921 GAUGCUGCUCUUGCUUUGCUGCUGCUUGAC
1888 19925 CUCAUGGAAAACAAGUAGUGUCAGAUAUAG
1889 19928 CCUAGCUCUCUACUACCCUUCUGCUCGCAU
1890 19935 CCAACAAUUACCUGAAACUUACUUUACUCA Sequence in priority
SEQ ID NO document Sequence
1891 19944 AACAGGAAGAGAAUCAGCAACUGUGUUGCU
1892 19948 ACGAAGAUGACAAUUUAAUUGAUUCUUACU
1893 20003 GCUGUAGACAU A A AC A AG CUUUGUGAAGAA
1894 20005 ACAAG U AU U U U AG UGG AGCAAUGG AU ACAA
1895 20009 CCAACCAACAGAAUCUAUUGUUAGAUUUCC
1896 20010 GGAACCUCAUCAGGAGAUGCCACAACUGCU
1897 20013 GCAGGUGCUGCAUUACAAAUACCAUUUGCU
1898 20046 AACAGCUUUAAGGGCCAAUUCUGCUGUCAA
1899 20047 GCAGGUAUAUGCGCUAGUUAUCAGACUCAG
1900 20060 AU UACACAG U U ACU UCACU UCAG ACU AU U A
1901 20063 AACAAAUACUUCUAACCAGGUUGCUGUUCU
1902 20071 GAUGCUGUUGUUUACCGAGGUACAACAACU
1903 20078 CUAAAUCUGAAUUUGACCGUGAUGCAGCCA
1904 20082 AUUUGAAAUGGGCUAGAUUCCCUAAGAGUG
1905 20085 ACGACCCUAAGACUAAAAAUGUUACAAAAG
1906 20094 CACUGUUUAUGAAAAACUCAAACCCGUCCU
1907 20097 GAAUGCGUCAUCAUCUGAAGCAUUUUUAAU
1908 20106 CUUCGAUGUCGAGGGGUGUCAUGCUACUAG
1909 20124 GCAGGCUGUUUAAUAGGGGCUGAACAUGUC
1910 20128 AGUAAGGUAAUCACUGGGUUACAUCCUACA
1911 20154 CGAUAACAACUUCUGUGGCCCUGAUGGCUA
1912 20155 CCAACUCAGUUUGCCUGUUUUACAGGUUCG
1913 20240 CCAAGACAUGUGAUCUGCACCUCUGAAGAC
1914 20253 CUGACAGAGAAUUACAUCUUUCAUGGGAAG
1915 20265 AUUUCUACUACCUAGGAACUGGGCCAGAAG
1916 20280 AGUAACAUGCCUUGCCUACUAUUUUAUGAG
1917 20283 CCAAGAUGGUAUUUCUACUACCUAGGAACU
1918 20288 AGAUUUGACACUAGAGUGCUAUCUAACCUU
1919 20319 CUUCUAAGAAGCCUCGGCAAAAACGUACUG
1920 20327 AGAUUUGCCAAUAGGUAUUAACAUCACUAG
1921 20337 AGACCAUUCUUAUGUUGUAAAUGCUGUUAC
1922 20340 ACGAUCAAUUUUCUCCCGCACUCUUGAAAC
1923 20342 GAUGGAACUGGUACUAUCUAUACAGAACUG
1924 20349 ACGAUCGAGUGUACAGUGAACAAUGCUAGG
1925 20360 CUUCUACAAUUUGCCUAUGCCAACAGGAAU
1926 20373 CGCCGAUCUAAAGUCAUUUGACUUAGGCGA
1927 20376 AUUUCCCUUAAAUUCCAUAAUCAAGACUAU
1928 20385 GUAGACUUAUGAAAACUAUAGGUCCAGACA
1929 20396 AUUUCCACAAAGCAUUUCUAUUGGUUCUUU
1930 20398 AAAGAUGGCCAUGUAGAAACAUUUUACCCA
1931 20403 AGCAGAGGCGGCAGUCAAGCCUCUUCUCGU
1932 20405 AAAU ACCCACAAG UUAAUGGUU UAACUUCU
1933 20416 GG U AAU U U UAAAG U U AC A A A AG G A A A AG C U
1934 20418 AACCAGAAUGGAGAACGCAGUGGGGCGCGA
1935 20421 GCUGGUUCUGAUAAAGGAGUUGCACCAGGU Sequence in priority
SEQ ID NO document Sequence
1936 20430 GAAUGGAUAAUCUUGCCUGCGAAGAUCUAA
1937 20435 AUGUAAUUAUCUUGGCAAACCACGCGAACA
1938 20458 C U A A ACG A AC U AAA UAU UAUAUUAGUUUUU
1939 20468 AACAACAAAG AU AGCACU UAAGGGUGG U AA
1940 20496 A A AC A U U C A A A A AG AAA UUGACCGCCU C A A
1941 20500 C U A A AC A UACUGACUUUU C A AG U G A A A U C A
1942 20504 AGUAAAAGACUGUGUUGUAUUACACAGUUA
1943 20505 AGUUUCAACUGGAUACCACUUCAGAGAGCU
1944 20506 GACAACCAAUCACUAAUUGUGUUAAGAUGU
1945 20514 AGAUUUUAGUCAUAGUCAGUUAGGUGGUUU
1946 20556 U A AC A A AC A A UACCUUCACACU C A A AG G CG
1947 20557 U U A A A A AC A A A U G U G U C A A U U U C A AC U U C A
1948 20558 U A AC A A A A UUGCCGAUAAGUAUGUCCGCAA
1949 20569 UAAAUUUUGUCUAGAGGCUUCAUUUAAUUA
1950 20577 UAUGGUACUUGGUAGUUUAGCUGCCACAGU
1951 20582 UUUUACUAUUAAGUGUUUGCCUAGGUUCUU
1952 20583 UG U U U ACCG AGG U ACAACAACU U ACAAAU U
1953 20587 UGUUUACCAAUGUGCUAUGAGGCCCAAUUU
1954 20593 UUGUCAUACCAGACUAUAACACAUAU A A A A
1955 20603 U AAAU UUAUCUCAACCUGUGCUUGUG AAAU
1956 20605 UAAGAGAAUUCCU UACACG U AACCCUGCU U
1957 20607 UAAGAGACACACUUUCUCUAACUACCAACA
1958 20613 UGGGAUUAUCCUAAAUGUGAUAGAGCCAUG
1959 20615 U UAAAAAU U ACAG AAG AGG U UGGCCACACA
1960 20618 UUUUUACUAUUAAGUGUUUGCCUAGGUUCU
1961 20650 GUUAGCUUGUUACAAUGGUUCACCAUCUGG
1962 20657 UUUCCAACCCACUAAUGGUGUUGGUUACCA
1963 20661 UGUUUAAACCGUGUUUGUACUAAUUAUAUG
1964 20662 UUAAAACUCUUUGACCGUUAUUUUAAAUAU
1965 20668 UAUGAUACCAAUGUACUAGAAGGUUCUGUU
1966 20683 UAAGAGUCAUUUUGCUAUUGGCCUAGCUCU
1967 20689 UG U UGU UUGU ACAG AAAU UGACCCUAAGUU
1968 20690 UGUUGUUUGUAACAGUUUACUCACACCUUU
1969 20700 UAAGAGUGUCGGUAAAUUUUGUCUAGAGGC
1970 20705 GUUACUAAUCCUUAUGACAGCAAGAACUGU
1971 20708 UAUGGUUGAGCUGGUAGCAGAACUCGAAGG
1972 20718 UCCUGUUGUAGAUUCUUAUUAUUCAUUGUU
1973 20732 UGUUGUUGGAGAAGGUUCCGAAGGUCUUAA
1974 20762 UGUUGUUCAGUUGACUUCGCAGUGGCUAAC
1975 20763 UAAGAUGUUGUGUACACACACUGGUACUGG
1976 20774 UACUUGGUUCCAUGCUAUACAUGUCUCUGG
1977 20779 UUGUCUGGUUUUAAGCUAAAAGACUGUGUU
1978 20781 G UGU UUCAAU AGCACU UAUGCAUCUCAAGG
1979 20789 UAUGAGCUAUUAUUGUAAAUCACAUAAACC
1980 20794 UAUGUACAUGGGCACACUUUCUUAUGAACA Sequence in priority
SEQ ID NO document Sequence
1981 20799 UUGUCUUAGUGGUUUAGAUUCUUUAGACAC
1982 20829 UACUUGGUAGUUUAGCUGCCACAGUACGUC
1983 20835 GUUGUCUGUACUGCCGUUGCCACAUAGAUC
1984 20840 UUUUAAGCUAAAAGACUGUGUUAUGUAUGC
1985 20856 UUGGGAUUAUCCUAAAUGUGAUAGAGCCAU
1986 20858 UAUGUAUGCAUCAGCUGUAGUGUUACUAAU
1987 20874 UAAAUCCAGAGAAGAAACUGGCCUACUCAU
1988 20879 UUAAACCGUGUUUGUACUAAUUAUAUGCCU
1989 20890 UAAAUCAAAAUGUGAAGAAUCAUCUGCAAA
1990 20914 UGUUGUCCAACAAUUACCUGAAACUUACUU
1991 20915 UUGGG AAAU UGU U AAAU UUAUCUCAACCUG
1992 20918 UUGUGAUGGUGGCAGUUUGUAUGUAAAUAA
1993 20921 UUGUGAUGUCACAGAUGUGACUCAACUUUA
1994 20927 UAAGCCAGUACCAUAUUGUUAUGAUACCAA
1995 20933 U A AG CCAUUUAU A AC U G A A AG U A A ACC U U C
1996 20971 UGUUGUACAUAAUCAGGAUGUAAACUUACA
1997 20987 UAAAUAAAGAAAUGUAUCUAAAGUUGCGUA
1998 21002 UAUGUCUUUAAAAGAAGGUCAAAUCAAUGA
1999 21007 GUUACCCGUGAACUCAUGCGUGAGCUUAAC
2000 21009 UG U UGG U U ACCAACCAU ACAG AG U AG U AG U 2001 21016 UAAAGUUGAGGGUUGUAUGGUACAAGUAAC 2002 21017 GUUCUUAUUACAGAAGGUAGUGUUAAAGGU
2003 21023 GUUGUUCAGUUGACUUCGCAGUGGCUAACU
2004 21025 UGUUGGUGGCAAACCUUGUAUCAAAGUAGC
2005 21028 U AAGCG UGU UGACUGGACU AU UGAAU AUCC
2006 21037 UUAUCUUACUUCUUCUUCUAAAACACCUGA
2007 21039 UUAUGUGUUGACAUACCUGGCAUACCUAAG
2008 21046 UUUCAUCAACUUUUAACGUACCAAUGGAAA
2009 21060 UAUGUGCAUGUUGUAGACGGUUGUAAUUCA
2010 21074 UAUGUGCUCAUGGAUGGCUCUAUUAUUCAA 2011 21083 UUGUGGACCUAAAAAGUCUACUAAUUUGGU 2012 21090 GUUACCACAGAAAUUCUACCAGUGUCUAUG
2013 21105 GUUGUCCAACAAUUACCUGAAACUUACUUU
2014 21109 U U C ACC U A A AC UGUUCAUCAGACAAGAGGA
2015 21117 UAAAGGUUUACAACCAUCUGUAGGUCCCAA
2016 21120 UGUUGGAGAAGGUUCCGAAGGUCUUAAUGA
2017 21122 UUUUAGUGCAGUUGGUAACAUCUGUUACAC
2018 21126 UUUUAACGCCACCAGAUUUGCAUCUGUUUA
2019 21159 U A A AG G C U U U U G C A A AC U AC AC A A U U G G A A
2020 21169 UUAUCUUCAACCUAGGACUUUUCUAUUAAA 2021 21176 UUGGCCACACAGAUCUAAUGGCUGCUUAUG 2022 21192 UUAUUUUGCUUCCACUGAGAAGUCUAACAU
2023 21193 UUGGCAUGUUAACAAUGCAACUAAUAAAGC
2024 21196 UGUUGCUAUGCCUAAUCUUUACAAAAUGCA
2025 21211 UAAAGCUUCAUGCACUUUGUCCGAACAACU Sequence in priority
SEQ ID NO document Sequence
2026 21220 UAAAGCUGCAUUAUUAGCAGACAAAUUCCC
2027 21221 UUUUAACAUUUGUCAAGCUGUCACGGCCAA
2028 21231 GUUACAUCCUACACAGGCACCUACACACCU
2029 21236 UAUGUUCACACCUUUAGUACCUUUCUGGAU
2030 21239 UAUCUUGCCACUGCAUUGUUAACACUCCAA
2031 21243 UAAAGCCACUUGCGAAUUUUGUGGCACUGA
2032 21256 UUUUAACAUAGAUUAUGACUGUGUCUCUUU
2033 21262 UAUGUUGAUACACCUAAUAAUACAGAUUUU
2034 21264 U U G G C AC A AC A U G U U A A A A AC UGUUUAUAG
2035 21265 UAUCUUCAACCUAGGACUUUUCUAUUAAAA
2036 21268 UGUUGCAGGAGCCUUAAAUAAGGCUACUAA
2037 21275 UAUCUUACUUCUUCUUCUAAAACACCUGAA
2038 21276 GUUGUCAAUGCCAGAUUACGUGCUAAGCAC
2039 21283 GUUGUUGGAGAAGGUUCCGAAGGUCUUAAU
2040 21314 UUGGAUUAUAAAGCAUUCAAACAAAUUGUU
2041 21316 UUGUGUUCCCUUGAACAUAAUACCUCUUAC
2042 21332 UUUUAUAGCUGGCUUGAUUGCCAUAGUAAU
2043 21333 UUAAAUGGUUACACUGUAGAGGAGGCAAAG
2044 21347 GUUAAGAUGUUGUGUACACACACUGGUACU
2045 21358 UGUUGAUGUAGAAUUGUUUGAAAAUAAAAC
2046 21364 UUGGAUGACAGAUGCAUUCUGCAUUGUGCA
2047 21377 UU AAAU UGGCUUCACAUAUGU AU UGUUCUU
2048 21378 U UG U U AAAGCUGCAU U AU U AGCAG ACAAAU
2049 21393 UUGGAUAUGGUUGAUACUAGUUUGUCUGGU
2050 21408 UUUCAGAUCCUCAGUUUUACAUUCAACUCA
2051 21416 UAUUAAAAUACAAGAGGGUGUGGUUGAUUA
2052 21437 G U UG U AU UACACAG U U ACU UCACU UCAG AC
2053 21442 UGAGCUGGUAGCAGAACUCGAAGGCAUUCA
2054 21454 UAUUAAAGUCUGUGAAUUUCAAUUUUGUAA
2055 21479 UUGUUAAUGCAGCCAAUGUUUACCUUAAAC
2056 21481 GUUGUAUGGUACAAGUAACUUGUGGUACAA
2057 21484 UAUUAACAUCACUAGGUUUCAAACUUUACU
2058 21516 UUAACAGGCACAGGUGUUCUUACUGAGUCU
2059 21518 UGUUGAAUGUCUUAAAUUGUCACAUCAAUC
2060 21523 G U U A U A AC ACC AG G A AC A A A UACUUCUAAC 2061 21524 UAUCGUGUAACU A A A A AC AG U A A AG U AC A A 2062 21535 UGUUGAAGGUUUUAAUUGUUACUUUCCUUU
2063 21545 UGAGGCUUUUGAGUACUACCACACAACUGA
2064 21548 U U U C U AC A A AG A A A ACAG U U ACACAACAAC
2065 21553 UAAGUAUGUACAAAUACCUACAACUUGUGC
2066 21554 UGUUGAACAUGUUACCUUCUUCAUCUACAA
2067 21567 U UG U U ACAG ACACACCU AAAGG UCCU AAAG
2068 21568 UGAGGGUUGUAUGGUACAAGUAACUUGUGG
2069 21575 U U AUG AAAAACUCAAACCCG UCCU UGAUUG
2070 21582 UUUCACUACUUUCUGUUUUGCUUUCCAUGC Sequence in priority
SEQ ID NO document Sequence
2071 21584 UGAGGUUCAACCUCAAUUAGAGAUGGAACU
2072 21592 UGUUCUUGUGGAUCCUGCUGCAAAUUUGAU 207B 21594 UUGGACCUUUGGUGCAGGUGCUGCAUUACA
2074 21598 GUUGUUUGUACAGAAAUUGACCCUAAGUUG
2075 21609 UGAGACACUUGGUGUCCUUGUCCCUCAUGU
2076 21612 UGUUCUUAUUACAGAAGGUAGUGUUAAAGG
2077 21618 UUGGACAGCUGGUGCUGCAGCUUAUUAUGU
2078 21623 UGUUCUUACUGAGUCUAACAAAAAGUUUCU
2079 21638 GUGUGUGUUCUGUUAUUGAUUUAUUACUUG
2080 21641 UGUUCUUAAAAAGUUGAAGAAGUCUUUGAA 2081 21657 U A AG UGACACACUU A A A A A UCUCUCUGACA 2082 21677 UUAACGGCCUUACUGUUUUGCCACCUUUGC
2083 21683 UGGGAAAUUGUUAAAUUUAUCUCAACCUGU
2084 21688 UGAGUAUUGCCCUAUUUUCUUCAUAACUGG
2085 21689 UUGUUACUCACAAUUUUGACUUCACUUUUA
2086 21695 GUUGUUUUAGAUUUCAUCUAAACGAACAAA
2087 21702 UGACUUUUUGCAUUUCUUACCUAGAGUUUU
2088 21720 UAAACCUUUGGAAUUUGGUGCCACUUCUGC
2089 21721 UGUUCGUUCUAUGAAGACUUUUUAGAGUAU
2090 21723 UUGGAACUUUAAUUUUAGCCAUGGCAGAUU
2091 21737 UGACUUUAAACUUAAUGAAGAGAUCGCCAU
2092 21738 UUUGCCACCUUUGCUCACAGAUGAAAUGAU
2093 21765 UGACUUCGCAGUGGCUAACUAACAUCUUUG
2094 21790 UUAACUUCUAUUAAAUGGGCAGAUAACAAC
2095 21795 UGAGUUAGGUGAUGUUAGAGAAACAAUGAG
2096 21808 UAUCCGAUUUACAGGAUUUGAAAUGGGCUA
2097 21820 UGUUCCAUUUGUAGUUUCAACUGGAUACCA
2098 21822 UGAGU UU AAAU UGGCUUCACAUAUGU AU UG
2099 21825 UGACUGGACUAUUGAAUAUCCUAUAAUUGG
2100 21828 UGGUCAACAAGACGGCAGUGAGGACAAUCA 2101 21845 UGAUAAAAGUGUAUAUUACACUAGUAAUCC 2102 21860 UUAAGAAUAUUGAUGGUUAUUUUAAAAUAU
2103 21862 UGUUCAGUUGACUUCGCAGUGGCUAACUAA
2104 21869 U AAACCU AG ACCACCACU U AACCG AAAU U A
2105 21880 GUUGUAGCUUGUCACACCGUUUCUAUAGAU
2106 21894 GUUUAAACCGUGUUUGUACUAAUUAUAUGC
2107 21901 UGACUAUGGUGAUGCUGUUGUUUACCGAGG
2108 21903 UGUUCAGAUACCUUGUACGUGUGGUAAACA
2109 21906 UGUUCAGACUAUUGAAGUGAAUAGUUUUAG
2110 21910 UGUUCACUUUGUUUGCAACUUGCUGUUGUU 2111 21937 GUGUUUUAACUGCUGUGGUUAUACCUACUA 2112 21943 UGUUCAAGAGGGUGUUUUAACUGCUGUGGU
2113 21952 GUUUAAAUGGUUACACUGUAGAGGAGGCAA
2114 21965 UG AU ACACCU AAU AAU ACAG AU U U U UCCAG
2115 21969 UGAUACAGCCAAUCCUAAGACACCUAAGUA Sequence in priority
SEQ ID NO document Sequence
2116 21979 U G ACG G U A A A A U G A A AG A U CUCAGUCCAAG
2117 21982 UG U U AU U UCU AG UGAUGU UCU UGUUAACAA
2118 21984 UUUUUCUAUGUACUUGGAUUGGCUGCAAUC
2119 21988 UACUCACAAUUUUGACUUCACUUUUAGUUU
2120 21989 GUUCUUACUGAGUCUAACAAAAAGUUUCUG 2121 21991 UGAUACUAGUUUGUCUGGUUUUAAGCUAAA 2122 22002 UUGCUGUUCUUUAUCAGGAUGUUAACUGCA
2123 22021 UAAACCAGGUGGAACCUCAUCAGGAGAUGC
2124 22022 GUUAACUGCACAGAAGUCCCUGUUGCUAUU
2125 22025 UAAUAACGCUACUAAUGUUGUUAUUAAAGU
2126 22028 GUUUAAGAAUAUUGAUGGUUAUUUUAAAAU
2127 22042 UGUUAUUAAAGUCUGUGAAUUUCAAUUUUG
2128 22045 UGAUAGUGCAACAUUACCUAAAGGCAUAAU
2129 22047 UGAUAGUGCGGAAGUUGCAGUUAAAAUGUU
2130 22088 UGACCUACACAGGUGCCAUCAAAUUGGAUG
2131 22089 UAUCAGACUCAGACUAAUUCUCCUCGGCGG
2132 22097 UUAAGGAAGGUGUAGAGUUUCUUAGAGACG
2133 22118 GUUGUACGAUCAAUUUUCUCCCGCACUCUU
2134 22128 UAUUAUUGCUAUGUCUGCUUUUGCAAUGAU
2135 22145 UGAUAUUGCUGCUAGAGACCUCAUUUGUGC
2136 22157 UGUUAUCACGCAUGAUGUUUCAUCUGCAAU
2137 22161 UAUCACGCAUGAUGUUUCAUCUGCAAUUAA
2138 22164 UAUCACCUUUGACAAUCUUAAGACACUUCU
2139 22169 GUGUGUUCUGUUAUUGAUUUAUUACUUGAU
2140 22181 UAAUAAUUAAUCUUGUACAAAUGGCCCCGA
2141 22182 UGAUCACAGGCAGACUUCAAAGUUUGCAGA
2142 22184 UUUUUCUACAGGUGUUAACCUAGUUGCUGU
2143 22190 U AAU AAU UGG U UG AAGCAG UUAAU UAAAG U
2144 22211 UAAUACACUUCAGUGUAUAAUGCUAGUUUA
2145 22218 UUUGGACCACUAGUGAGAAAAAUAUUUGUU
2146 22221 UGACAUGUGCAACUACUAGACAAGUUGUUA
2147 22245 UGACAUCUCUGGCAUUAAUGCUUCAGUUGU
2148 22247 UGACAUCUAUGAAGUAUUUUGUGAAAAUAG
2149 22264 GUUGACUGGACUAUUGAAUAUCCUAUAAUU
2150 22275 U AAU ACG U U U UCAUCAACU U U UAACG U ACC
2151 22278 UGACAUACCUGGCAUACCUAAGGACAUGAC
2152 22279 UG U U AG U ACAACU ACU AACAU AG U UACACG
2153 22287 UGGUAUUGUAGCUAUCGUAGUAACAUGCCU
2154 22296 GUUUACAAACAAUUUGAUACUUAUAACCUC
2155 22299 UAAACAGGGUGAUGAUUAUGUGUACCUUCC
2156 22307 UGACAGGCAAACAGCACAAGCAGCUGGUAC
2157 22318 UGAUGAACUGAAGAUUAAUGCGGCUUGUAG
2158 22333 UGAUGAAGUCAGACAAAUCGCUCCAGGGCA
2159 22338 U AG AGG U ACAACAG U ACU U U UAAAAGAACC
2160 22344 UGACACUGUGAGUGCUUUGGUUUAUGAUAA Sequence in priority
SEQ ID NO document Sequence
2161 22345 GUUAUCACGCAUGAUGUUUCAUCUGCAAUU
2162 22353 UGAUGACACUGUGAUAGAAGUGCAAGGUUA
2163 22355 UGACACUGACUUAACAAAGCCUUACAUUAA
2164 22359 UGAUGACCCGUGUCCUAUUCACUUCUAUUC
2165 22373 UUUCAAACUUUACUUGCUUUACAUAGAAGU
2166 22378 UUUCUCAAUCGAUUUACCACAACUCUUAAU
2167 22382 UGACACUAAAUUCAAAACUGAAGGUUUAUG
2168 22383 UGUUAGACAAUGCUCAGGUGUUACUUUCCA
2169 22395 UGUUACUU U CCA A AG U G C AG U G A A A AG A AC
2170 22417 UGACACAGACUUUGUGAAUGAGUUUUACGC
2171 22437 UG U U ACUCACAAU U U UG ACU UCACU U U U AG
2172 22443 UGACAAUUAUGCUUUGCUGUAUGACCAGUU
2173 22467 UGAUGAUUAUGUGUACCUUCCUUACCCAGA
2174 22478 UAAUAGUGUCCCUUGGGAUACUAUAGCUAA
2175 22492 UGAUGCACUAUGUGAGAAGGCAUUAAAAUA
2176 22504 UGUUACCCGUGAACUCAUGCGUGAGCUUAA
2177 22531 U A A AC A AG C U AC A A A A UAUCUAGUACAACA
2178 22541 UGAUGCGUAUUAUGACAUGGUUGGAUAUGG
2179 22547 UAUAUUAGAGUAGGAGCUAGAAAAUCAGCA
2180 22565 GUUGGUUUUAACAUAGAUUAUGACUGUGUC 2181 22566 GUUUACCAAUGUGCUAUGAGGCCCAAUUUC 2182 22567 GUUACAAACGUAAUAGAGCAACAAGAGUCG
2183 22577 UGAUGCUGCUCUUGCUUUGCUGCUGCUUGA
2184 22582 UGAUGCUGUUGUUUACCGAGGUACAACAAC
2185 22590 GUUAUCUUCAACCUAGGACUUUUCUAUUAA
2186 22597 UGUUAAUGUUGU A AC A AC A A AG A U AG C AC U
2187 22608 UUCAAACUUUACUUGCUUUACAUAGAAGUU
2188 22616 UGAUGGCACAACAAGUCCUAUUUCUGAACA
2189 22618 UAUUGAUUUAUUACUUGAUGAUUUUGUUGA
2190 22620 U ACU UCACU UCAGACUAUUACCAGCUGU AC
2191 22629 UUAAUAAUUAAUCUUGUACAAAUGGCCCCG
2192 22634 UGUUAAUGCAGCCAAUGUUUACCUUAAACA
2193 22638 UGAAUGUCUUAAAUUGUCACAUCAAUCUGA
2194 22639 UUGUUCGCAUUCAACCAGGACAGACUUUUU
2195 22645 UUUUGCUAAAUUCCUAAAAACUAAUUGUUG
2196 22648 UGUUAAUCCAGUAAUGGAACCAAUUUAUGA
2197 22651 UAAAAUUUAUUGUCCAGCAUGUCACAAUUC
2198 22658 UGAUGGUCAAGUAGACUUAUUUAGAAAUGC
2199 22662 UCCCUUCCAUCAUAUGCAGCUUUUGCUACU
2200 22672 UAAAAUUGUUAAUAAUUGGUUGAAGCAGUU 2201 22675 UUGCGCGUACGCGUUCCAUGUGGUCAUUCA 2202 22685 UGAUGGUGUUCCAUUUGUAGUUUCAACUGG
2203 22686 UGAUGGUGUUGAUGUAGAAUUGUUUGAAAA
2204 22687 UGAUGGUGUUGUCCAACAAUUACCUGAAAC
2205 22691 UAUAUGCGCUAGUUAUCAGACUCAGACUAA Sequence in priority
SEQ ID NO document Sequence
2206 22698 UAUUGCUACUGUACGUGAAGUGCUGUCUGA
2207 22705 UAAUCACUGGGUUACAUCCUACACAGGCAC
2208 22709 UGAUGUAGAAUUGUUUGAAAAUAAAACAAC
2209 22710 UUAAUAGGGGCUGAACAUGUCAACAACUCA
2210 22711 UGAAUCUGAUGAUUACAUAGCUACUAAUGG 2211 22712 G U UGG U U ACCAACCAU ACAG AG U AG U AG U A 2212 22718 UGAAUCCUGUGGUAAUUUUAAAGUUACAAA
2213 22723 UUGUUCUAUGACUGACAUAGCCAAGAAACC
2214 22731 UAUUGGACAUUCUAUGCAAAAUUGUGUACU
2215 22734 UAUAUGAGAUCUCUCAAAGUGCCAGCUACA
2216 22742 GUGUCAUGCUACUAGAGAAGCUGUUGGUAC
2217 22744 UAUUGGAGUUACACAGAAUGUUCUCUAUGA
2218 22761 UCCCUUGAACAUAAUACCUCUUACAACAGC
2219 22766 UGUUAACUGCACAGAAGUCCCUGUUGCUAU
2220 22769 UUGCCUGUUUUACAGGUUCGCGACGUGCUC 2221 22772 UAAUCCAGUAAUGGAACCAAUUUAUGAUGA 2222 22773 UGUUAACCUAGUUGCUGUACCUACAGGUUA
2223 22774 UGAAUACAGUCAUGUAGUUGCCUUUAAUAC
2224 22777 UGAUGUGGUGGCUAUUGAUUAUAAACACUA
2225 22780 UUGCCUGGCACGAUAUUACGCACAACUAAU
2226 22785 GUGUUCACUUUGUUUGCAACUUGCUGUUGU
2227 22788 UAAUCCGUAUGUUUGCAAUGCUCCAGGUUG
2228 22801 UGAAG U U U U U AACGCCACCAG AU U UGCAUC
2229 22802 UAAAAUGUUUGAUGCUUACGUUAAUACGUU
2230 22809 UGAAGUUUAAUCCACCUGCUCUACAAGAUG
2231 22811 UUUUUGUAUAUAAUUAAGUUAAUUUUCCUC
2232 22815 UGAUGUUAGAGAAACAAUGAGUUACUUGUU
2233 22823 UUAAUCCACCUGCUCUACAAGAUGCUUAUU
2234 22831 UUUUUCGGCUUUAGAACCAUUGGUAGAUUU
2235 22835 UGAAGUUAUCACCUUUGACAAUCUUAAGAC
2236 22845 UUGCCUACGGGUACGCUGCUUGUCGAUUCA
2237 22855 UG U U AAAGCUGCAU U AU U AGCAG ACAAAU U
2238 22868 UGAUGUUGUUCAAGAGGGUGUUUUAACUGC
2239 22870 UAAUCUAUUACUAGAUAAACGCACUACGUG
2240 22881 UAUUGUAGCUAUCGUAGUAACAUGCCUUGC
2241 22882 GUUGGUGGCAAACCUUGUAUCAAAGUAGCC
2242 22889 UG AAG U ACCAG UUUCUAUCAU U AAU AACAC
2243 22896 UGAAGGUUUUAAUUGUUACUUUCCUUUACA
2244 22910 UAAUCUUACAACCAGAACUCAAUUACCCCC
2245 22914 UGUUAAAAUUUAUUGUCCAGCAUGUCACAA
2246 22916 UAAAAUGAAAGAUCUCAGUCCAAGAUGGUA
2247 22920 GUUAAUUGUGAUACAUUCUGUGCUGGUAGU
2248 22930 UUUAUUGCCACUAGUCUCUAGUCAGUGUGU
2249 22931 UGAUUACAUUUUAGCUAACACCUGUACUGA
2250 22967 UUGCCAUAACAAGUGUGCCUAUUGGGUUCC Sequence in priority
SEQ ID NO document Sequence
2251 22969 UGUGUUUUAAGCGGACACAAUCUUGCUAAA
2252 22974 UGAAGCUGCUAACUUUUGUGCACUUAUCUU
2253 22978 UGAAGCUCCAUUGGUUGGUACACCAGUUUG
2254 22982 UUUAUUCUCUACAGUGUUCCCACCUACAAG
2255 23000 UGAUUAUUUUGUGCUGACAUCACAUACAGU
2256 23003 UGAUUCAACUGAAUGCAGCAAUCUUUUGUU
2257 23012 UGAAGCAGUUAAUUAAAGUUACACUUGUGU
2258 23017 UGAUUCAUCACAGGGCUCAGAAUAUGACUA
2259 23031 UAAAAUAUGACUUCACGGAAGAGAGGUUAA
2260 23034 UAUUGUUGGUGUACUGACAUUAGAUAAUCA 2261 23040 UUUCUGGGUAGGUACAUGUCAGCAUUAAAU 2262 23046 UUGCCAAGAAUUUAAAUGAAUCUCUCAUCG
2263 23054 UGAUUCUGAAGUUGUUCUUAAAAAGUUGAA
2264 23064 UAUUGUUUUUAUGUGUGUUGAGUAUUGCCC
2265 23065 UGAUUCUUCUUCAGGUUGGACAGCUGGUGC
2266 23070 UAUUUAAAACUUACUGACAAUGUAUACAUU
2267 23081 GUUAUGGAGUGUCUCCUACUAAAUUAAAUG
2268 23087 UGAUUGCCUUGGUGAUAUUGCUGCUAGAGA
2269 23092 UGAAGAGCUUAAAAAGCUCCUUGAACAAUG
2270 23097 GUUGAAGGUUUUAAUUGUUACUUUCCUUUA
2271 23110 UGAAGACAUUCAACUUCUUAAGAGUGCUUA
2272 23112 UUCAAAUGGCACACACUGGUUUGUAACACA
2273 23119 GUUGGUAGCGAUAAUGUUACUGACUUUAAU
2274 23126 U G A AG A AG U U AC A AC A AC U C U G G A AG A A AC
2275 23128 UGAUUGUGAAGAAGAAGAGUUUGAGCCAUC
2276 23130 UGAAGAAGUCUUUGAAUGUGGCUAAAUCUG
2277 23132 UGAUUGUGCAACUGUACAUACAGCUAAUAA
2278 23139 UGUGUUCCCUUGAACAUAAUACCUCUUACA
2279 23146 U A A U G C A AC AG A AG UGCCUGCCAAUU C A AC
2280 23159 UAAUGCACAUGUAGCUAGUUGUGAUGCAAU 2281 23163 GUUUUAAAUGAUAUCCUUUCACGUCUUGAC 2282 23164 UG AU U U ACAACCAU U AG AACAACCU ACU AG
2283 23170 UAAUGCACUUUUAUCUACUGAUGGUAACAA
2284 23174 UAAUGCAGCCAAUGUUUACCUUAAACAUGG
2285 23177 UGAUUUAGGUGACAUCUCUGGCAUUAAUGC
2286 23183 U U UCUGUGGUG UAGAUGCUGU AAAU UU ACU
2287 23187 UGAACUCGGUACAGAAGUAAAUGAGUUCGC
2288 23191 UUAAUGGUAUUGGAGUUACACAGAAUGUUC
2289 23193 UAGAGUGGUAACAACUUUUGAUUCUGAGUA
2290 23203 UGAUUUCAUACAAACCACGCCAGGUAGUGG
2291 23210 UGAACGUGU ACG CC A AG C U U U G U U A A A A AC
2292 23223 UAAUGCCUAUAUUAACCUUGACCAGGGCUU
2293 23225 UGUGUGUUUCAAUAGCACUUAUGCAUCUCA
2294 23228 GUUUAUAACACUUUGCUUCACACUCAAAAG
2295 23250 UUUACGCAUAUUUGCGUAAACAUUUCUCAA Sequence in priority
SEQ ID NO document Sequence
2296 23268 UGAACAUGUUACCUUCUUCAUCUACAAUAA
2297 23277 GUUUAUACAACAAAAGCUAGCUCUUGGAGG
2298 23279 UAAUGCUGCUAUCAGCGAUUAUGACUACUA
2299 23283 GUUAUGUAUGCAUCAGCUGUAGUGUUACUA
2300 23284 U G A AC AG AG A A A AC A AG A U GAU A AG A A A A U
2301 23285 UAGCAGAACUCGAAGGCAUUCAGUACGGUC
2302 23287 UGAACAGAAAUCAAUACUGAGUCCUCUUUA
2303 23294 UUGCAGACAUAUGUGACUCAACAAUUAAUU
2304 23295 UUUGUUACAGACACACCUAAAGGUCCUAAA
2305 23298 UAUUUCUACUACCUAGGAACUGGGCCAGAA
2306 23300 UAUUUCUAGUGAUGUUCUUGUUAACAACUA
2307 23306 UGAUUUUUGUGGAAAGGGCUAUCAUCUUAU
2308 23310 UAAUGCUUUAGAUCAAGCCAUUUCCAUGUG
2309 23312 U G A AC A AG AC A A A A AC ACCC A AG A AG U U U U
2310 23319 UGGUAUGCAAAAGUAUUCUACACUCCAGGG
2311 23324 UGAACAAAAGAUCGCUGAGAUUCCUAAAGA
2312 23327 UACUUAUAAAUUGGAUGGUGUUGUUUGUAC
2313 23346 UAUAGCUUGGAAUUCUAACAAUCUUGAUUC
2314 23361 UAUUUGACUCCUGGUGAUUCUUCUUCAGGU
2315 23381 GUGUUAAAUCCAGAGAAGAAACUGGCCUAC
2316 23385 UGAAAUCCUUCACUGUAGAAAAAGGAAUCU
2317 23390 UGAAAUCAAGGAUGCUACUCCUUCAGAUUU
2318 23391 UGGGGCUUGUGUUCUUUGCAAUUCACAGAC
2319 23406 UGAAAUAAUAAAAUCCCAAGAUUUAUCUGU
2320 23408 UUCAACACAUGGUUGUUAAAGCUGCAUUAU
2321 23417 GUUGGGAUUAUCCUAAAUGUGAUAGAGCCA
2322 23419 UUUCUUAGGAAUCAUCACAACUGUAGCUGC
2323 23421 UGCAAAUUAUCAAAAGGUUGGUAUGCAAAA
2324 23458 UCCGAAGGUCUUAAUGACAACCUUCUUGAA
2325 23469 UUGCAAUGCUCCAGGUUGUGAUGUCACAGA
2326 23480 UGAAACUUCAUGGCAGACGGGCGAUUUUGU
2327 23490 UGCAACUGAGGGAGCCUUGAAUACACCAAA
2328 23492 U G C A AC UGCAGAAGCUGAACUUG C A A AG A A
2329 23514 UCCUGAUCUUCUGGUCUAAACGAACUAAAU
2330 23517 UUUAUGUGUUGACAUACCUGGCAUACCUAA
2331 23520 U G A A AC A UUUGUCACGCACU C A A AG G G A U U
2332 23523 UGAAACAUCAAAUUCGUUUGAUGUACUGAA
2333 23532 UUGCAACUUGCUGUUGUUGUUUGUAACAGU
2334 23533 UAGAGUUGAUGGUCAAGUAGACUUAUUUAG
2335 23537 UUGCAACUGAGGGAGCCUUGAAUACACCAA
2336 23538 UAUUUUAAAAUAUAUUCUAAGCACACGCCU
2337 23547 UAUUUUAAAUAUUGGGAUCAGACAUACCAC
2338 23551 UAAAACUCUUUGACCGUUAUUUUAAAUAUU
2339 23565 UAAUGGUUUAACUUCUAUUAAAUGGGCAGA
2340 23569 UGCAAUAUGGCAGUUUUUGUACACAAUUAA Sequence in priority
SEQ ID NO document Sequence
2341 23582 UGAAAAUACUCAAUAAUUUGGGUGUGGACA
2342 23593 UAAUGUAGCAUUUGAGCUUUGGGCUAAGCG
2343 23594 UAUAGAAUUUCUUAAGAGAGGUGAUAAAAG
2344 23603 UGAAAAGAAAAAGCUUGAUGGCUUUAUGGG
2345 23617 UGAAAACAUGACACCCCGUGACCUUGGUGC
2346 23619 UUUUGUUACCUUCUCUUGCCACUGUAGCUU
2347 23631 UUCAACAUGCCAAUUUAGAUUCUUGCAAAA
2348 23636 UGCAAUUUACAAGUCUUGAAAUUCCACGUA
2349 23637 UGCAAUUUAGGUGGUGCUGUCUGUAGACAU
2350 23638 UGAAAAAGGCGUUUUGCCUCAACUUGAACA
2351 23639 UGCAAUUUCAAGUGUUUUAAAUGAUAUCCU
2352 23640 UACUUACCCCAAAAUGCUGUUGUUAAAAUU
2353 23641 GUUUAUGAUUACUUAGUUUCUACACAGGAG
2354 23648 UGUGUACACACACUGGUACUGGUCAGGCAA
2355 23654 UCUUUUUUUUGUAUGAAAAUGCCUUUUUAC
2356 23682 UUACAAACAAUUUGAUACUUAUAACCUCUG
2357 23698 U G U G U A A A AC UUGUGGACAACAGCAG AC A A
2358 23701 UGCACCAACAAAGGUUACUUUUGGUGAUGA
2359 23714 UGCACCAGGUACAGCUGUUUUAAGACAGUG
2360 23715 UAUACUGAAAAAUGGGAAUCUGGAGUAAAA
2361 23734 U A A A ACC A AC AG UGGUUGUUAAUGCAGCCA
2362 23740 UAAAACAUUUUAUGUUUUACCUAAUGAUGA
2363 23747 UUACAACCAUCUGUAGGUCCCAAACAAGCU
2364 23754 UAAUGUUCAACUCAGGGUUAUUGGACAUUC
2365 23756 UGCACUACGACAGAUGUCUUGUGCUGCCGG
2366 23760 UAUACUAAUGACAAAGCUUGCCCAUUGAUU
2367 23774 UCUUUGUUCUUUUUUUUGUAUGAAAAUGCC
2368 23780 UUACAAGAGUGUGAAUAUCACUUUUGAACU
2369 23782 U AAUG U UG U AACAACAAAG AU AGCACU U AA
2370 23786 UAUUUUUGGUGCUGACCCUAUACAUUCUUU
2371 23804 GUUUUAAUGUCUAAUUUAGGCAUGCCUUCU
2372 23806 G U U U AU U ACC AC A A A A AC A AC A A A AG UUGG
2373 23810 G U U U AU U ACCCUG ACAAAG U U UUCAGAUCC
2374 23812 UCUUUGGCUUGAUGACGUAGUUUACUGUCC
2375 23816 UGCAGAAAAUUCAGUUGCUUACUCUAAUAA
2376 23823 UAAUGUUUUAGCUUGGUUGUACGCUGCUGU
2377 23840 UAAUUAAAGUUACACUUGUGUUCCUUUUUG
2378 23859 UUUUAUGUCUGAAGCAAAAUGUUGGACUGA
2379 23871 UCUUUGCAAUUCACAGACUUCAUUAAGAUG
2380 23891 UAAUUACCAGUGUGGUCACUAUAAACAUAU
2381 23897 UUACACAAAAGUUGAUGGUGUUGAUGUAGA
2382 23922 UCUUUCUACCCUCCAGAUGAGGAUGAAGAA
2383 23925 GUUUAUUCUACAGGUUCUAAUGUUUUUCAA
2384 23939 UAAUUAUAAUUACCUGUAUAGAUUGUUUAG
2385 23947 UUGAUGUACUGAAGUCAGAGGACGCGCAGG Sequence in priority
SEQ ID NO document Sequence
2386 23951 UUACACCACUAAUUCAACCUAUUGGUGCUU
2387 23956 UGCAGCCGAUCAUCAGCACAUCUAGGUUUC
2388 23965 UUUUAUGUGUGUUGAGUAUUGCCCUAUUUU
2389 23981 UCUUUAUUAUCAAAACAAUGUUUUUAUGUC
2390 23992 UUCAACCUCAAUUAGAGAUGGAACUUACAC
2391 24000 UCUUUAUCAGGAUGUUAACUGCACAGAAGU
2392 24002 UACUUAACAAUGAUUAUUACAGAUCUUUAC
2393 24010 UGCAGGAGCCUUAAAUAAGGCUACUAACAA
2394 24015 UCUUUAGUAAUUACCUAAAGAGACGUGUAG
2395 24036 UUUUGUACACAAUUAAACCGUGCUUUAACU
2396 24045 UUGAUGCUUACGUUAAUACGUUUUCAUCAA
2397 24047 U AG AU AAAU AU U U U AAG AAUCAU ACAUCAC
2398 24051 UCUUUACCAACCACCACAAACCUCUAUCAC
2399 24053 UGCAGGUAUAUGCGCUAGUUAUCAGACUCA
2400 24055 UUACACUGUAGAGGAGGCAAAGACAGUGCU
2401 24059 UGCAGGUGCUGCAUUACAAAUACCAUUUGC
2402 24076 UUACAGAAUAAAUUGGAUCACCGGUGGAAU
2403 24081 UGUGGCAGAUGCUGUCAUAAAAACUUUGCA
2404 24103 UUACAGAGAAGGCUAUUUGAACUCUACUAA
2405 24106 UUAUGAGAAUCUUCACAAUUGGAACUGUAA
2406 24108 UGCAGUUAAAAUGUUUGAUGCUUACGUUAA
2407 24109 GUUUAUUUUGCUUCCACUGAGAAGUCUAAC
2408 24113 UGGUGACGGUAAAAUGAAAGAUCUCAGUCC
2409 24121 U C U U G U U A AC A AC U A A ACG A AC A A U G U U U G
2410 24127 UUCACCAUCUGGUGUUUACCAAUGUGCUAU
2411 24130 GUGUUGGUGGCAAACCUUGUAUCAAAGUAG
2412 24131 UCUUGUGGAUCCUGCUGCAAAUUUGAUGAA
2413 24143 GUUAUUGGACAUUCUAUGCAAAAUUGUGUA
2414 24150 UUCAACUAUACAGCGUAAAUAUAAGGGUAU
2415 24153 UCAAAUCAAUGAUAUGAUUUUAUCUCUUCU
2416 24175 UGUGGACAUUGCUGCUAAUACUGUGAUCUG
2417 24187 G U G U U A A U C U U AC A ACC AG A AC U C A A U U AC
2418 24216 UGCAUCGUGUUGUCUGUACUGCCGUUGCCA
2419 24239 UUGAUCACAGGCAGACUUCAAAGUUUGCAG
2420 24246 UCAACAAGACGGCAGUGAGGACAAUCAGAC
2421 24248 U AAU UG UG ACACAU U AAAAG AAAU ACU UG U
2422 24249 UUUGCUAACAAACAUGCUGAUUUUGACACA
2423 24255 UCAACAAUGGGGUUUUACAGGUAACCUACA
2424 24273 UCAACACAUGGUUGUUAAAGCUGCAUUAUU
2425 24276 UUACAGUCAUGUACUCAACAUCAACCAUAU
2426 24280 GUUUCAAUAGCACUUAUGCAUCUCAAGGUC
2427 24284 UCUUGCUCG C A A AC A U AC A ACG UGUUGUAG
2428 24292 U AAU U U AAAACAAU U ACCAU UUUUCUAUUA
2429 24294 UUUGCU AAAU UCCUAAAAACU AAU UGUUGU
2430 24302 UAUAAUCUACCAACAAUGUGUGAUAUCAGA Sequence in priority
SEQ ID NO document Sequence
2431 24326 UUCAACUGGAUACCACUUCAGAGAGCUAGG
2432 24330 UCAACCAAAAUGCACAAGCUUUAAACACGC
2433 24337 GUUCUGUUAUUGAUUUAUUACUUGAUGAUU
2434 24338 U U U AUG AU AAU AAGCU U AAAGCACAU AAAG
2435 24370 UUACAUCCUACACAGGCACCUACACACCUC
2436 24373 UGGUGACUUUAAACUUAAUGAAGAGAUCGC
2437 24374 UAAUUUCAAAAAUCUUAGGGAAUUUGUGUU
2438 24375 UUGAUACUAGUUUGUCUGGUUUUAAGCUAA
2439 24382 UUACAUCUACUGAUUGGACUAGCUAAACGU
2440 24390 UCAACCUCAAUUAGAGAUGGAACUUACACC
2441 24396 UUGAUACAGCCAAUCCUAAGACACCUAAGU
2442 24400 UUUGUGCUUGCUGCUGUUUACAGAAUAAAU
2443 24404 U A A A A AC UGUUUAUAGUGAUGU AG A A A ACC
2444 24412 UUUGAAAACCCUUGCUACUCAUGGUUUAGC
2445 24419 UUUUCUUGUUUUAUUGCCACUAGUCUCUAG
2446 24421 UUUAUGAGGCUAUGUACACACCGCAUACAG
2447 24422 U A A A A AC UAUUUCAUAACAGAUGCG C A A AC
2448 24442 UUGAUAACCCUGUCCUACCAUUUAAUGAUG
2449 24450 UCCCACCUACAAGUUUUGGACCACUAGUGA
2450 24455 UCAACUCAGGGUUAUUGGACAUUCUAUGCA
2451 24473 UGGUAGUUGUGUUUUAAGCGGACACAAUCU
2452 24487 U AAU U U U AAAG U U AC A AAAG G A A A AG C U A A
2453 24489 UAAAAACAGUACAAUUCUGUGAUGCCAUGC
2454 24493 UAAUUUUAACAAAGACUUCUAUGACUUUGC
2455 24497 UGCCAAGAAUUUAAAUGAAUCUCUCAUCGA
2456 24501 UCAACUUAGUGAAAUUAGUAUGGACAAUUC
2457 24527 U A A A A AC A A A U G U G U C A A UUUCAACUUCAA
2458 24535 UCAAGAAAUUCAACUCCAGGCAGCAGUAGG
2459 24536 U U ACCAACCAU ACAG AG U AG U AG U ACU U UC
2460 24541 UCAAGAACUUUACUCUCCAAUUUUUCUUAU
2461 24542 UAAUUUUCCUCUGGCUGUUAUGGCCAGUAA
2462 24561 UCUUCGGAAUGUCGCGCAUUGGCAUGGAAG
2463 24566 UGCCACUACUUGUGGUUACUUACCCCAAAA
2464 24574 UUACCAAUGUGCUAUGAGGCCCAAUUUCAC
2465 24583 UGGUAGUUAUACUAAUGACAAAGCUUGCCC
2466 24588 UGCCACUUCUGCUGCUCUUCAACCUGAAGA
2467 24594 UCAAGAGGGUGUUUUAACUGCUGUGGUUAU
2468 24604 U A U A AG A A ACC U G C U U C A AG AG AG C U U AAA
2469 24627 U AC A A A AG A A A A U G ACU C U A A AG AG G G U U U
2470 24635 U AC A A A AG G A A A AG C U A A A A A AG G U G CC U G
2471 24636 UGCCAUAACAAGUGUGCCUAUUGGGUUCCA
2472 24652 U G CC A U C A A A U U G G A U G AC A A AG A U CCA A A
2473 24653 UCUUCACGACAUUGGUAACCCUAAAGCUAU
2474 24665 UGUGAUGUCACAGAUGUGACUCAACUUUAC
2475 24669 UACAAACGUAAUAGAGCAACAAGAGUCGAA Sequence in priority
SEQ ID NO document Sequence
2476 24676 UGUGAUGGUGGCAGUUUGUAUGUAAAUAAA
2477 24684 UUACCCAAUAAUACUGCGUCUUGGUUCACC
2478 24696 UGUGAUGCAAUCAUGACUAGGUGUCUAGCU
2479 24700 UGUGAUGAUGAUUAUUUCAAUAAAAAGGAC
2480 24714 UUGAGCUGGUAGCAGAACUCGAAGGCAUUC
2481 24719 U All AACACCAGGAACAAAU ACU UCU AACCA
2482 24723 UCUUAUUACAGAAGGUAGUGUUAAAGGUUU
2483 24725 UGUGAUCAACUCCGCGAACCCAUGCUUCAG
2484 24737 UUGAGCCAUCAACUCAAUAUGAGUAUGGUA
2485 24769 UAUAAAUUAGAAGGCUAUGCCUUCGAACAU
2486 24773 UCUUAUCAGAGGCACGUCAACAUCUUAAAG
2487 24775 U U ACCG AGG UACAACAACU U AC AAAU U AAA
2488 24782 UACAACAACUCUGGAAGAAACUAAGUUCCU
2489 24783 UACAACAACU UACAAAUUAAAUGUUGGUGA
2490 24793 UAUAAAUGGAGACAGGUGGUUUCUCAAUCG
2491 24801 UCAAG U AG ACU U AU U U AG AAAUGCCCG U AA
2492 24815 UACAACAGUACUUUUAAAAGAACCUUGCUC
2493 24842 UACAACAUUUACUUAUGCAUCAGCAUUGUG
2494 24866 UCUUACUGAGUCUAACAAAAAGUUUCUGCC
2495 24891 UCUUACCUUUCUUUUCCAAUGUUACUUGGU
2496 24892 UACAACUACACUUAACGGUCUUUGGCUUGA
2497 24914 UUACCUUAAACAUGGAGGAGGUGUUGCAGG
2498 24926 UGCCUACGGGUACGCUGCUUGUCGAUUCAG
2499 24933 UUGUUUUUCUUGUUUUAUUGCCACUAGUCU
2500 24944 UAGCACACCUUGUAAUGGUGUUGAAGGUUU
2501 24947 UUGUUUUUGUUACCUUCUCUUGCCACUGUA
2502 24965 UACAAGAGUGUGAAUAUCACUUUUGAACUU
2503 24977 UCU UAAUGACAACCU UCU UG AAAU ACUCCA
2504 24981 UCCUUUUUGUUGCUGCUAUUUUCUAUUUAA
2505 24985 UUGACCUACACAGGUGCCAUCAAAUUGGAU
2506 25005 UGUCUUUGUUUCAAAUGGCACACACUGGUU
2507 25019 UGUCUUUGGAG C AC A A A ACC AG U U G A A AC A
2508 25021 UGUCUUUGAUGAAAUUUCAAUGGCCACAAA
2509 25039 UACAAGUAACUUGUGGUACAACUACACUUA
2510 25054 GUUUCCUUUAGUACUUUUGAAGAAGCUGCG
2511 25060 UGCCUGGAAUAUUGGUGAACAGAAAUCAAU
2512 25061 UUACGCCCUGACACACGUUAUGUGCUCAUG
2513 25074 UCUUAAAAAGUUGAAGAAGUCUUUGAAUGU
2514 25084 UGUCUUGAAAACUGGUGAUUUACAACCAUU
2515 25085 GUUGCUGAUUAUUCUGUCCUAUAUAAUUCC
2516 25094 GUUUUAACUGCUGUGGUUAUACCUACUAAA
2517 25099 UGUCUUCCUAUUCUUUAUUUGACAUGAGUA
2518 25117 UACAAUCACUUCUGGUUGGACCUUUGGUGC
2519 25134 UGGUGAUAGUGCGGAAGUUGCAGUUAAAAU
2520 25136 UCUGUUGCUUAUGAAAGUUUACGCCCUGAC Sequence in priority
SEQ ID NO document Sequence
2521 25142 UACAAUGCCACUUGGCUAUGUAACACAUGG
2522 25149 UGCCUUUAAUACUUUACUAUUCCUUAUGUC
2523 25154 UCAAUUAUUAUAAGAAAGUUGAUGGUGUUG
2524 25160 UGGCUAUUGAUUAUAAACACUACACACCCU
2525 25161 UCUGUUAUUGAUUUAUUACUUGAUGAUUUU
2526 25174 UCUGUUAGAGUGGUAACAACUUUUGAUUCU
2527 25186 UGUCUGUACUGCCGUUGCCACAUAGAUCAU
2528 25212 UAGUUUAGCUGCCACAGUACGUCUACAAGC
2529 25220 UGCGAGAGACUUGUCACUACAGUUUAAAAG
2530 25234 GUUGCUAUGCCUAAUCUUUACAAAAUGCAA
2531 25240 U ACACAACAACCAU AAAACCAG U U ACU U AU
2532 25254 UACACAAUGACAUUCUCUUAGCUAAAGAUA
2533 25257 UUUGUCGUGCCUGGUUUGCCUGGCACGAUA
2534 25266 UAGUUGUGUUUUAAGCGGACACAAUCUUGC
2535 25274 UACACACCACUGGUUGUUACUCACAAUUUU
2536 25275 UACACACCAUCAAAACUUAUAGAGUACACU
2537 25289 UACACAGAAUGUUCUCUAUG AG A ACC A A A A
2538 25320 UGUCUCAAGGGCUGUUGUUCUUGUGG AUCC
2539 25330 UCCUCGGAACUUGUCGGCGUUGUCCUGCUG
2540 25337 UCACACCUUUAGUACCUUUCUGGAUAACAA
2541 25338 UG UCU AUG UGAUAGACGUGCCACAUGCUUU
2542 25364 UUUAUAUAAAAAUACAUGUGUUGGUAGCGA
2543 25369 UGCGGCAAUAGUGUUUAUAACACUUUGCUU
2544 25374 UUACUACAGUCAGCUUAUGUGUCAACCUAU
2545 25377 UUUUCUGUUUGGAACUUUAAUUUUAGCCAU
2546 25378 UGUCUAGCUGUCCACGAGUGCUUUGUUAAG
2547 25384 UUGAAGCAGUUAAUUAAAGUUACACUUGUG
2548 25385 UUUAAAUGAUAUCCUUUCACGUCUUGACAA
2549 25405 UUUAAAUGGUUACACUGUAGAGGAGGCAAA
2550 25406 UACACCGGAAGCCAAUAUGGAUCAAGAAUC
2551 25407 UUCAAGCUUUUUGGAAAUGAAGAGUGAAAA
2552 25437 UGCGUAGUGAUGUGCUAUUACCUCUUACGC
2553 25451 U G CG U C ACC A A A U G A AU G C A ACC A A A U G U G
2554 25452 UCACAUCUGAUUUGGCUACUAACAAUCUAG
2555 25462 UUACUAUAGCAGAGAUAUUACUAAUUAUUA
2556 25463 UACACGGAACGUUCUGAAAAGAGCUAUGAA
2557 25470 UACACGGUGUUUAAACCGUGUUUGUACUAA
2558 25472 UUUAUAGCUGGCUUGAUUGCCAUAGUAAUG
2559 25482 UGUCGGCCCAAAUGUUAACAAAGGUGAAGA
2560 25490 GUGUUGCUAUGCCUAAUCUUUACAAAAUGC
2561 25496 UGUCGCUUCCAAGAAAAGGACGAAGAUGAC
2562 25498 GUUCACUUUGUUUGCAACUUGCUGUUGUUG
2563 25511 UUUAACAGGCACAGGUGUUCUUACUGAGUC
2564 25520 UUUAACAUAGAUUAUGACUGUGUCUCUUUU
2565 25526 UCCCAAACAAGCUAGUCUUAAUGGAGUCAC Sequence in priority
SEQ ID NO document Sequence
2566 25529 UAGUUAUACUAAUGACAAAGCUUGCCCAUU
2567 25543 UCACCAUCUGGUGUUUACCAAUGUGCUAUG
2568 25555 UGCUAAACAUGACUUCUUUAAGUUUAGAAU
2569 25559 UUACUCAACCGCUACUUUAGACUGACUCUU
2570 25567 UUACUCACACCUUUUGCUCGUUGCUGCUGG
2571 25569 UGUCCUUGUCCCUCAUGUGGGCGAAAUACC
2572 25573 UACACUGUAGAGGAGGCAAAGACAGUGCUU
2573 25585 UGCUAACAAAGACGGCAUCAUAUGGGUUGC
2574 25589 UCACCGCUCUCACUCAACAUGGCAAGGAAG
2575 25593 UACACUUAUGAUUGAACGGUUCGUGUCUUU
2576 25610 U U G A A A A U A A A AC A AC A UUACCUGUUAAUG
2577 25613 UACACUUGUGUUCCUUUUUGUUGCUGCUAU
2578 25617 GUUCAGAUACCUUGUACGUGUGGUAAACAA
2579 25623 UUGAAAAGAAAAAGCUUGAUGGCUUUAUGG
2580 25626 UUGAAAACCCUUGCUACUCAUGGUUUAGCU
2581 25653 UUCUUUUUUAGCACAUAUUCAGUGGAUGGU
2582 25659 UACAGAAGUAAAUGAGUUCGCCUGUGUUGU
2583 25665 UUUAUACAACAAAAGCUAGCUCUUGGAGGU
2584 25670 UGGUAGCGAUAAUGUUACUGACUUUAAUGC
2585 25674 UUUAACUGCUGUGGUUAUACCUACUAAAAA
2586 25685 UACAGACACACCUAAAGGUCCUAAAGUGAA
2587 25693 UAGUGUUGGUUUUAACAUAGAUUAUGACUG
2588 25697 UUUAACUUCUAUUAAAUGGGCAGAUAACAA
2589 25707 UUAUGAUAAUAAGCUUAAAGCACAUAAAGA
2590 25713 UACAGAGAAGGCUAUUUGAACUCUACUAAU
2591 25720 UGCUAAUGGUGAUUCUGAAGUUGUUCUUAA
2592 25721 UGUCCAACAAU U ACCUG AAACU U ACU U U AC
2593 25740 UUUAAGACAGUGGUUGCCUACGGGUACGCU
2594 25750 UGCUACAUCACGAACGCUUUCUUAUUACAA
2595 25759 UGUCAUGCUACUAGAGAAGCUGUUGGUACC
2596 25766 UAGUGUUAAAGGUUUACAACCAUCUGUAGG
2597 25771 UGUCAUCUCGCAAAGGCUCUCAAUGACUUC
2598 25788 G UG U U AG AGG U ACAACAG U ACU U U UAAAAG
2599 25792 U C AC U A U A A AC A UAUAACUUCU A A AG A A AC
2600 25797 UCACUAUAUGUUAAACCAGGUGGAACCUCA 2601 25810 UGUCAUACCAGACUAUAACACAUAU A A A A A 2602 25819 UCUGAUGUUCUU U ACCAACCACCAC AAACC
2603 25826 UUUAAGCGGACACAAUCUUGCUAAACACUG
2604 25830 UGUCAGUGUUAUAACACCAGGAACAAAUAC
2605 25831 UUCUUUAGUAAUUACCUAAAGAGACGUGUA
2606 25833 UUUAAGCUAAAAGACUGUGUUAUGUAUGCA
2607 25835 UGCUAGAUUUUACUUU U ACACCAG U AAAAC
2608 25845 UGCUAGGAGAGUGUGGACACUUAUGAAUGU
2609 25846 UUUAUAAGGGUGUUAUCACGCAUGAUGUUU
2610 25850 UACAGCGUAUAAUGGUUAUCUUACUUCUUC Sequence in priority
SEQ ID NO document Sequence
2611 25852 UUUAAGGAAUCACCUUUUGAAUUAGAAGAU
2612 25854 UUUAAGGAAUUACUUGUGUAUGCUGCUGAC
2613 25856 UUACUGUCCAAGACAUGUGAUCUGCACCUC
2614 25866 GUGUUCUCUUAUGUUGGUUGCCAUAACAAG
2615 25878 UACAGCUGUUUUAAGACAGUGGUUGCCUAC
2616 25894 UGUCACUCGUGACAUAGCAUCUACAGAUAC
2617 25931 UUACUUACCCCAAAAUGCUGUUGUUAAAAU
2618 25949 UACAGGCUGGUAAUGUUCAACUCAGGGUUA
2619 25963 UCCAUUUGUAGUUUCAACUGGAUACCACUU
2620 25965 UUCUUGGAAUUUGCGAGAAAUGCUUGCACA 2621 25969 UGCUAUGCCUAAUCUUUACAAAAUGCAAAG 2622 25991 UGUCAAUGCCAGAUUACGUGCUAAGCACUA
2623 25996 UGCUAUUACCAGAGCAAAAGUAGGCAUACU
2624 26005 UCACUUUGUUUGCAACUUGCUGUUGUUGUU
2625 26011 UGCUAUUCAUGCAGAUCAACUUACUCCUAC
2626 26012 GUUAAAGGUUUACAACCAUCUGUAGGUCCC
2627 26029 UGGCUGUAUUAAUGCUAACCAAGUCAUCGU
2628 26041 G U U U U AAGCGG ACACAAUCU UGCU AAACAC
2629 26050 UAGUGGAGUUCCUGUUGUAGAUUCUUAUUA
2630 26056 GUUAAUCU U ACAACCAG AACUCAAU UACCC
2631 26067 UCUCUUAUGUUGGUUGCCAUAACAAGUGUG
2632 26068 UGUCAAAGUGACUAUUGACUAUACAGAAAU
2633 26096 UUCAAUAGCACUUAUGCAUCUCAAGGUCUA
2634 26115 UUACUUUUGGUGAUGACACUGUGAUAGAAG
2635 26121 GUUCAUCAAACGUUCGGAUGCUCGAACUGC
2636 26122 GUUUUUUCACUUACAUUUGUGGGUUUAUAC
2637 26131 UAGUGCUAAACCACCGCCUGGAGAUCAAUU
2638 26152 UUAGAAAAUGUGGCUUUUAAUGUUGUAAAU
2639 26156 U G C U CG A A A U C A A AG AC AC AG A A A AG U AC U
2640 26170 UUCUUCACCUGAUGCUGUUACAGCGUAUAA
2641 26182 UACAUAAACCUAUUGUUUGGCAUGUUAACA
2642 26206 UCAGACUAUUGAAGUGAAUAGUUUUAGUGG
2643 26215 UCUCUAUGAGAACCAAAAAUUGAUUGCCAA
2644 26253 UUAGAAUAGACGGUGACAUGGUACCACAUA
2645 26256 UUCUUAGGCUAUUUUUGUACUUGUUACUUU
2646 26270 UUAGAAUGUACAUCUUCUUUGCAUCAUUUU
2647 26271 UGUAUUACACAGUUACUUCACUUCAGACUA
2648 26279 UCAGAGUUUAUUCUAGUGCGAAUAAUUGCA
2649 26291 UCAGAUACCUUGUACGUGUGGUAAACAAGC
2650 26295 UACAUCCUACACAGGCACCUACACACCUCA
2651 26304 UGCUGACCCUAUACAUUCUUUAAGAGUUUG
2652 26320 UUAUGAUCCUUUGCAACCUGAAUUAGACUC
2653 26334 UGUAUGGUACAAGUAACUUGUGGUACAACU
2654 26336 UCCUCACAGAAAACUUGUUACUUUAUAUUG
2655 26344 UAGUGACAUUGACAUCACUUUCUUAAAGAA Sequence in priority
SEQ ID NO document Sequence
2656 26359 UACAUGCACCAUAUGGAAUUACCAACUGGA
2657 26361 UUCUGUUUCUUCACCUGAUGCUGUUACAGC
2658 26366 UGCUGAUUAUUCUGUCCUAUAUAAUUCCGC
2659 26367 UGGUGCUGUCUGUAGACAUCAUGCUAAUGA
2660 26369 UGGGUGUUGGUGGCAAACCUUGUAUCAAAG 2661 26370 UGUAUGCCUAUUUUGGAAUUGCAAUGUCGA 2662 26373 UUCUGUUGCUUAUGAAAGUUUACGCCCUGA
2663 26378 UGGUGAUUAUUUUGUGCUGACAUCACAUAC
2664 26395 UGCUGCAGCUUAUUAUGUGGGUUAUCUUCA
2665 26398 UUCUGUUAGAGUGGUAACAACUUUUGAUUC
2666 26404 UGCUGCAUUACAAAUACCAUUUGCUAUGCA
2667 26407 UACAUGUCAGCAUUAAAUCACACUAAAAAG
2668 26418 UAGUCUUGUAGUGCGUUGUUCGUUCUAUGA
2669 26462 UGCUGCUAUUUUCUAUUUAAUAACACCUGU
2670 26478 UGCUGCUGGCCUUGAAGCCCCUUUUCUCUA
2671 26489 GUUAAAUCCAGAGAAGAAACUGGCCUACUC
2672 26499 UUUAGUGGUUAUUUAAAACUUACUGACAAU
2673 26513 UUAGAUAUAUGAAUUCACAGGGACUACUCC
2674 26514 UCUCACUUGAACUGCAAGAUCAUAAUGAAA
2675 26516 UGUAUACGUUGUCUUUGGAGCACAAAACCA
2676 26520 UUUGUACUUGCACUGUUAUCCGAUUUACAG
2677 26554 UACAUUUACUUGUGCUAGUGAGUACACUGG
2678 26557 UUAGAUGAUGAUAGUCAACAAACUGUUGGU
2679 26572 UGCUGGUUCUGAUAAAGGAGUUGCACCAGG
2680 26574 UACAUUUGGCUAGGUUUUAUAGCUGGCUUG 2681 26598 UGCUGUACCUACAGGUUAUGUUGAUACACC 2682 26602 UGCUGUAGACAUAAACAAGCUUUGUGAAGA
2683 26606 GUUGCAGGAGCCUUAAAUAAGGCUACUAAC
2684 26617 UGCUGUAGUUGUCUCAAGGGCUGUUGUUCU
2685 26618 UACUGAAGAUGAUUACCAAGGUAAACCUUU
2686 26624 GUUCUCUUAUGUUGGUUGCCAUAACAAGUG
2687 26627 UACAUUUUUCCCUGACUUAAAUGGUGAUGU
2688 26632 UUAGAUUCUUUAGACACCUAUCCUUCUUUA
2689 26642 GUUUUUCGGCUUUAGAACCAUUGGUAGAUU
2690 26648 UGCUGUCUGUAGACAUCAUGCUAAUGAGUA
2691 26660 UCAGGCAAUAACAGUUACACCGGAAGCCAA
2692 26661 UUCUGCCUUUCCAACAAUUUGGCAGAGACA
2693 26665 GUUCCACGUGCUAGCGCUAACAUAGGUUGU
2694 26675 UGUAGUCUUCUUGCAUGUGACUUAUGUCCC
2695 26679 GUUGCAGCCGAUCAUCAGCACAUCUAGGUU
2696 26693 U ACCAACCAU ACAG AG U AG U AG U ACU U UCU
2697 26713 UGCUGUUCUUUAUCAGGAUGUUAACUGCAC
2698 26721 UUCUGAUGUUCUU U ACCAACCACCAC AAAC
2699 26725 UUUGAUAACCCUGUCCUACCAUUUAAUGAU
2700 26739 UCAGGGUUUAAAUGGUUACACUGUAGAGGA Sequence in priority
SEQ ID NO document Sequence
2701 26744 UUCUGAUAAAGGAGUUGCACCAGGUACAGC
2702 26756 UACCAAUUUACCUUUACAGCUAGGUUUUUC 270B 26758 UUUAGUCCAGAGUACUCAAUGGUCUUUGUU
2704 26776 UACCACAGAAAUUCUACCAGUGUCUAUGAC
2705 26781 UACCACAUAUAUCACGUCAACGUCUUACUA
2706 26793 UG U AGG AG ACAU U AU ACU UAAACCAGCAAA
2707 26803 UCUAUGAUGCACAGCCUUGUAGUGACAAAG
2708 26806 UGUAGCUUGUCACACCGUUUCUAUAGAUUA
2709 26810 UGCUUACUCUAAUAACUCUAUUGCCAUACC
2710 26821 UCUAUGACUGACAUAGCCAAGAAACCAACU
2711 26827 GUUCCAUUUGUAGUUUCAACUGGAUACCAC
2712 26833 UCUAUGAAGACUUUUUAGAGUAUCAUGACG
2713 26837 UUUUGGCAUAUAUUCUUUUCACUAGGUUUU
2714 26855 GUUCCCACCUACAAGUUUUGGACCACUAGU
2715 26857 UCCUAUUCUGGACAAUCUACACAACUAGGU
2716 26858 U U U G U A AC AC A A AG G A A U U U U U AUG AACCA
2717 26864 UUAUGGAGAUUUUAGUCAUAGUCAGUUAGG
2718 26865 UGCUUAUGAAAGUUUACGCCCUGACACACG
2719 26872 GUGUGGACAUUGCUGCUAAUACUGUGAUCU
2720 26884 UAGAUGAUGAUAGUCAACAAACUGUUGGUC
2721 26901 UCUAUAUGCCUGCUAGUUGGGUGAUGCGUA
2722 26905 GUUGCAACUGAGGGAGCCUUGAAUACACCA
2723 26912 UGUAGAUUCUUAUUAUUCAUUGUUAAUGCC
2724 26921 UUUUCUAUGUACUUGGAUUGGCUGCAAUCA
2725 26928 UGUAGAUGCUGUAAAUUUACUUACUAAUAU
2726 26930 UGUAGAUGCAGAUAGUAAAAUUGUUCAACU
2727 26932 UUUUGUCGUGCCUGGUUUGCCUGGCACGAU
2728 26953 UUAGCUGCCACAGUACGUCUACAAGCUGGU
2729 26963 UUAGCUGCUGUUAAUAGUGUCCCUUGGGAU
2730 26967 GUUCCCUUGAACAUAAUACCUCUUACAACA
2731 26975 UCUAGUGGCUAGCAUAAAGAACUUUAAGUC
2732 26985 UGUAGACGGUUGUAAUUCAUCAACUUGUAU
2733 26990 UGCUUGCAUACGUAGACCAUUCUUAUGUUG
2734 27003 UACUGGUCAGGCAAUAACAGUUACACCGGA
2735 27004 UUUUCAAACACGUGCAGGCUGUUUAAUAGG
2736 27015 UGUAGAAGCUGUUAUGUACAUGGGCACACU
2737 27017 UUAGGAAGUCUAAUCUCAAACCUUUUGAGA
2738 27022 UUCUCACUUGAACUGCAAGAUCAUAAUGAA
2739 27030 UCAGUUGACUUCGCAGUGGCUAACUAACAU
2740 27035 UUCUCAAUCGAUUUACCACAACUCUUAAUG
2741 27036 UGCUUGUAUUGACUGUAGUGCGCGUCAUAU
2742 27045 UAGUACAUUUAUUAGUGAUGAAGUUGCGAG
2743 27068 UUUAAUGGUAUUGGAGUUACACAGAAUGUU
2744 27069 UAGUACAACUACUAACAUAGUUACACGGUG
2745 27086 UCCUAUUACGGAUGUUUUCUACAAAGAAAA Sequence in priority
SEQ ID NO document Sequence
2746 27092 UGCUUUACUU AC A A AG U CC U C AG A A U AC A A
2747 27100 UGUACUGACAUUAGAUAAUCAAGAUCUCAA
2748 27135 UCUACUUGCACCAUUAUUAUCAGCUGGUAU
2749 27144 UUUUUGGCAUAUAUUCUUUUCACUAGGUUU
2750 27158 GUUUUUAACAUUUGUCAAGCUGUCACGGCC
2751 27164 UGCUUUGGACAUAUCAGCAUCUAUAGUAGC
2752 27172 UGUACGCUGCUGUUAUAAAUGGAGACAGGU
2753 27186 UGUACGAUCAAUUUUCUCCCGCACUCUUGA
2754 27188 UUUAAUGUCUAAUUUAGGCAUGCCUUCUUA
2755 27214 UUCUAUCAUUAAUAACACUGUUUACACAAA
2756 27220 UACCCGUGAACUCAUGCGUGAGCUUAACGG
2757 27227 UUCUAUAGAUUAGCUAAUGAGUGUGCUCAA
2758 27234 UUAUGAUUACUUAGUUUCUACACAGGAGUU
2759 27243 UGGAAAAGAUGGCUGAUCAAGCUAUGACCC
2760 27246 UCCGUGGCUAUAAAGAUAACAGAACAUUCU
2761 27280 UACUGGUAAGAGUCAUUUUGCUAUUGGCCU
2762 27335 UAGGUUUGUACUUGCACUGUUAUCCGAUUU
2763 27341 UGGAACCUCAUCAGGAGAUGCCACAACUGC
2764 27343 UGGUACCAAUUUACCUUUACAGCUAGGUUU
2765 27355 UCAUCAAACGUUCGGAUGCUCGAACUGCAC
2766 27372 UGGUGCAUCGUGUUGUCUGUACUGCCGUUG
2767 27393 UCUAAUGUUUUUCAAACACGUGCAGGCUGU
2768 27395 UCAUCAGACAAGAGGAAGUUCAAGAACUUU
2769 27401 UUUUUCACUUACAUUUGUGGGUUUAUACAA
2770 27405 UGUAAUUCAUCAACUUGUAUGAUGUGUUAC
2771 27421 UUCUACACAGGAGUUUAGAUAUAUGAAUUC
2772 27422 UUUAAUUAUGCUUAUUAUCUUUUGGUUCUC
2773 27436 UUCUAAUGUUUUUCAAACACGUGCAGGCUG
2774 27437 UCAUCCGGAGUUGUUAAUCCAGUAAUGGAA
2775 27438 UGUAAUGGCCUACAUUACAGGUGGUGUUGU
2776 27443 GUUUUGUCGUGCCUGGUUUGCCUGGCACGA
2777 27459 UUAUGCUUGGAACAGGAAGAGAAUCAGCAA
2778 27470 UCAUCUAAGUGUGUGUGUUCUGUUAUUGAU
2779 27474 UUCUAAGGUUGUCAAAGUGACUAUUGACUA
2780 27479 UACUGACUUUAAUGCAAUUGCAACAUGUGA
2781 27485 UUUAGCUUGGUUGUACGCUGCUGUUAUAAA
2782 27487 UGGAAUUGCUAUCGCAAUGGCUUGUCUUGU
2783 27489 UCCAUGUGGUCAUUCAAU CC AG A A AC U A AC
2784 27501 UG U AAU AGG AAU UG UCAACAACACAG U U U A
2785 27505 UAGGUGGUUUACAUCUACUGAUUGGACUAG
2786 27530 UUCUAAAUCACCCAUUCAGUACAUCGAUAU
2787 27534 UGUAAUAACUAUAUGCUCACCUAUAACAAA
2788 27536 UGGACAAUUAUUAUAAGAAAGACAAUUCUU
2789 27543 UCUAAAUCACCCAUUCAGUACAUCGAUAUC
2790 27546 UUUAGCUGCUGUUAAUAGUGUCCCUUGGGA Sequence in priority
SEQ ID NO document Sequence
2791 27551 UUUAAUUGUUACUUUCCUUUACAAUCAUAU
2792 27561 UGGACAGCCUUUGUUACUAAUGUGAAUGCG
2793 27566 UGGACAGCUGGUGCUGCAGCUUAUUAUGUG
2794 27570 GUUGAUGUAGAAUUGUUUGAAAAUAAAACA
2795 27575 UAGGUGAUGUUAGAGAAACAAUGAGUUACU
2796 27580 UCUAAACGAACUAAAUAUUAUAUUAGUUUU
2797 27588 UUAUGAUUGAUGUUCAACAAUGGGGUUUUA
2798 27591 UAGAUUUGCCAAUAGGUAUUAACAUCACUA
2799 27609 UGGACCCUCAGAUUCAACUGGCAGUAACCA
2800 27623 UUCGUGUCUUUAGCUAUAGAUGCUUACCCA 2801 27626 UGGACCUUUGGUGCAGGUGCUGCAUUACAA 2802 27640 UGUAACCAUACAGGUGUUGUUGGAGAAGGU
2803 27656 GUUCCUUUUUGUUGCUGCUAUUUUCUAUUU
2804 27660 U G U A AC A AC A A AG A U AGCACUUAAGGGUGG
2805 27682 GUUUUGGCUGCUGAAUGUACAAUUUUUAAA
2806 27684 UCAUGCUGGCACAGACUUAGAAGGUAACUU
2807 27690 U U U AAU U U U UCACAAAU AU U ACCAG AUCCA
2808 27692 UGUAAAUGCUGUUACGACCAUGUCAUAUCA
2809 27693 UGGAGAAGGUUCCGAAGGUCUUAAUGACAA
2810 27696 UUCGUCCGUGUUGCAGCCGAUCAUCAGCAC 2811 27702 UCGUUCUAUGAAGACUUUUUAGAGUAUCAU 2812 27707 UUUUCUACAGGUGUUAACCUAGUUGCUGUA
2813 27718 UGUAAAUAAGGGACACUUUGAUGGACAACA
2814 27728 UAGGUACAUGUCAGCAUUAAAUCACACUAA
2815 27730 UGUAAAGAUGGCCAUGUAGAAACAUUUUAC
2816 27732 UCCUAUAAAGAUUGGUCCUAUUCUGGACAA
2817 27735 UUUACAAACAAUUUGAUACUUAUAACCUCU
2818 27741 UACCUUCUCUUGCCACUGUAGCUUAUUUUA
2819 27742 U G U A A AC A U U C A A A A AG A A A UUGACCGCCU
2820 27744 UACCUUCUUCAUCUACAAUAAAAUUGUUGA 2821 27752 UUAGUUCCCUUCCAUCAUAUGCAGCUUUUG 2822 27754 UACUGGCGAUAGUUGUAAUAACUAUAUGCU
2823 27756 UCGUGUUGUUUUAGAUUUCAUCUAAACGAA
2824 27779 UCAUGUCAUGUCUAAACAUACUGACUUUUC
2825 27780 UUUUUUCACUUACAUUUGUGGGUUUAUACA
2826 27781 UCGUGUCUUUAGCUAUAGAUGCUUACCCAC
2827 27790 UAGAUGGGUACUUAACAAUGAUUAUUACAG
2828 27803 UCAUGUGGUAGUGUUGGUUUUAACAUAGAU
2829 27806 GUGUUAUCACGCAUGAUGUUUCAUCUGCAA
2830 27809 UCAUGUGUGGCGGUUCACUAUAUGUUAAAC
2831 27818 UCAUGUUAUGGUUGAGCUGGUAGCAGAACU
2832 27820 U U U ACAACCAUCUG U AGG UCCCAAACAAGC
2833 27828 UAGAUUUCCUAAUAUUACAAACUUGUGCCC
2834 27837 UACGACCAUGUCAUAUCAACAUCACAUAAA
2835 27844 GUUUGUACUAAUUAUAUGCCUUAUUUCUUU Sequence in priority
SEQ ID NO document Sequence
2836 27848 UACGACUAUUGUAUACCUUACAAUAGUGUA
2837 27849 UUCGCGACGUGCUCGUACGUGGCUUUGGAG
2838 27856 UGGUUUUAAUUU U UCACAAAU AU UACCAGA
2839 27857 G U U U U ACAGG U AACCU ACAAAGCAACCAUG
2840 27862 UGGUUUUAACAUAGAUUAUGACUGUGUCUC
2841 27865 UGGAUAAUGAUGCACUCAACAACAUUAUCA
2842 27901 UGGAUAUGGUUGAUACUAGUUUGUCUGGUU
2843 27909 U U A U A AC AC UUUGCUUCACACU C A A A AG A A
2844 27916 UGGUUUCUCAAUCGAUUUACCACAACUCUU
2845 27933 UUUAGAUUUCAUCU A A ACG A AC A A AC U AAA
2846 27941 UUAUAAGAAACCUGCUUCAAGAGAGCUUAA
2847 27947 UCCAUGCUAUACAUGUCUCUGGGACCAAUG
2848 27948 UUUAGAUUCUUUAGACACCUAUCCUUCUUU
2849 27958 UUUGCAACAACUCAGAGUAGAAUCAUCAUC
2850 27970 UGGAUGGAAAGUGAGUUCAGAGUUUAUUCU
2851 27971 UGGUUUACAUCUACUGAUUGGACUAGCUAA
2852 27997 UCGUAGUGGUGAGACACUUGGUGUCCUUGU
2853 27999 UUCCUUUAGUACUUUUGAAGAAGCUGCGCU
2854 28008 UUCACUAUAUGUUAAACCAGGUGGAACCUC
2855 28013 UUUGCCUCAACUUGAACAGCCCUAUGUGUU
2856 28038 UACGCUGCUUGUCGAUUCAGAUCUUAAUGA
2857 28047 UGGUUGGCACAACAUGUUAAAAACUGUUUA
2858 28048 GUGUUGAGUAUUGCCCUAUUUUCUUCAUAA
2859 28051 GUUUGUUCUAUGACUGACAUAGCCAAGAAA
2860 28060 UCAUUUAUUGAAGAUCUACUUUUCAACAAA 2861 28062 UGGUUGCCAUAACAAGUGUGCCUAUUGGGU 2862 28063 U ACGG ACACAACU AU UACAG UUAAUGUUUU
2863 28074 UGGCAAACCUUGUAUCAAAGUAGCCACUGU
2864 28098 UACGGCGCCGAUCUAAAGUCAUUUGACUUA
2865 28103 U U UACACU UAAAAACACAGUCUGUACCGUC
2866 28127 UUUAGAUAUGUGUGCUUCAUUAAAAGAAUU
2867 28133 UUAUACAACAAAAGCUAGCUCUUGGAGGUU
2868 28137 UUUACAGAAGGCCGCUAUAACAAUACUAGA
2869 28141 UUCACUACUUUCUGUUUUGCUUUCCAUGCA
2870 28153 U G G C AC A AC A U G U U A A A A AC UGUUUAUAGU
2871 28156 G U U U U ACAG AAGGCCGCU AU AACAAU ACU A
2872 28161 UUCCUAUUCCUUACAUGGAUUUGUCUUCUA
2873 28175 UGGCACUACUGAAAUGCUAGCGAAAGCUUU
2874 28176 UUCCUAUAAAGAUUGGUCCUAUUCUGGACA
2875 28184 UCCUAAAGUGAAGUAUUUAUACUUUAUUAA
2876 28206 GUUUGUCUUAGUGGUUUAGAUUCUUUAGAC
2877 28214 UCGGAUGCUCGAACUGCACCUCAUGGUCAU
2878 28225 UGGUUAUACUGAAAAAUGGGAAUCUGGAGU
2879 28233 GUUUUACACUU A A A A AC AC AG UCUGUACCG
2880 28239 UUCCGUGGCUAUAAAGAUAACAGAACAUUC Sequence in priority
SEQ ID NO document Sequence
2881 28243 UCCAACUUAUUUGGAUGGAGCUGAUGUUAC
2882 28246 UUUACAGGUAACCUACAAAGCAACCAUGAU
2883 28257 UGGU U ACCAACCAU ACAG AG U AG U AG U ACU
2884 28258 UGGCAGUUUGUAUGUAAAUAAACAUGCAUU
2885 28261 UUUUCGGCUUUAGAACCAUUGGUAGAUUUG
2886 28263 UUAUACUGAAAAAUGGGAAUCUGGAGUAAA
2887 28272 UUUACAGGUUCGCGACGUGCUCGUACGUGG
2888 28280 UGGUAAUUAUAAUUACCUGUAUAGAUUGUU
2889 28283 UUCCGAAGGUCUUAAUGACAACCUUCUUGA
2890 28286 UGGCAUCAUUCUAUUGGAUUUGAUUACGUC
2891 28287 UACGUGCCAGAUCAGUUUCACCUAAACUGU
2892 28301 UAGCUUACUACAACACAACAAAGGGAGGUA
2893 28305 UCCAAUUAACACCAAUAGCAGUCCAGAUGA
2894 28321 UACUGCUGUU AUG UCU UUAAAAGAAGGUCA
2895 28335 UGGUAAAAUUGUUAAUAAUUGGUUGAAGCA
2896 28337 GUGUUCUGUUAUUGAUUUAUUACUUGAUGA
2897 28341 UGGUGUUGUUCAGUUGACUUCGCAGUGGCU
2898 28360 UUUACAUCUACUGAUUGGACUAGCUAAACG
2899 28372 UGGCCACACAGAUCUAAUGGCUGCUUAUGU
2900 28381 UCGCGCUACUGCAACGAUACCGAUACAAGC
2901 28384 UUUUCAGAGCGCUUCCAAAAUCAUAACCCU
2902 28389 UUUACAUUCAACUCAGGACUUGUUCUUACC
2903 28393 UCGCGACGUGCUCGUACGUGGCUUUGGAGA
2904 28400 UUCCAUUUGGAAUCUUGAUUACAUCAUAAA
2905 28401 UCGCCUGUGUUGUGGCAGAUGCUGUCAUAA
2906 28417 UCCACGUGCUAGCGCUAACAUAGGUUGUAA
2907 28418 GUUUGUGUAUCUACUAGUGGUAGAUGGGUA
2908 28426 UUCCAUGCUAUACAUGUCUCUGGGACCAAU
2909 28430 UUCCAUCCAUCUUUACUUUGAUAAAGCUGG
2910 28431 UGGUAAACCUAGACCACCACUUAACCGAAA
2911 28435 UUAUAGUGAUGUAGAAAACCCUCACCUUAU
2912 28442 U CGC AU U CAACCAG G AC AG AC U U U U U CAG U
2913 28452 GUUGAGUAUUGCCCUAUUUUCUUCAUAACU
2914 28466 UUAUAUAAAAAUACAUGUGUUGGUAGCGAU
2915 28472 UGGUGUCACUCGUGACAUAGCAUCUACAGA
2916 28474 GUUAACCUAGUUGCUGUACCUACAGGUUAU
2917 28477 UCCAGACAUGUUCCUCGGAACUUGUCGGCG
2918 28487 UCGCACUAUUGCCUUUGGAGGCUGUGUGUU
2919 28490 UGGUGUACUGACAUUAGAUAAUCAAGAUCU
2920 28492 UACUAAGAGGUUUGAUAACCCUGUCCUACC
2921 28505 UUCCACGUGCUAGCGCUAACAUAGGUUGUA
2922 28520 UUUUGUAUAUAAUUAAGUUAAUUUUCCUCU
2923 28531 UACUAAUCCUUAUGACAGCAAGAACUGUGU
2924 28556 UACUAAUGUGAAUGCGUCAUCAUCUGAAGC
2925 28568 UGGUGGUAAUUAUAAUUACCUGUAUAGAUU Sequence in priority
SEQ ID NO document Sequence
2926 28589 UUCCAACCCACUAAUGGUGUUGGUUACCAA
2927 28604 UACUACACAAACUGCUUGCACUGAUGACAA
2928 28610 UAGAAUGUACAUCUUCUUUGCAUCAUUUUA
2929 28616 GUUGAGGCUUUUGAGUACUACCACACAACU
2930 28620 UAGAAUUACUGGCUUAUACCCAACACUCAA
2931 28630 UUUGGAUUAUAAAGCAUUCAAACAAAUUGU
2932 28631 UAGAAUUCGAUCUGUCUAUCCAGUUGCGUC
2933 28638 UGGUGGCAAACCUUGUAUCAAAGUAGCCAC
2934 28640 G UUGACACU AAA U U C A A A AC U G A AG G U U U A
2935 28642 UUAUUCUACAGGUUCUAAUGUUUUUCAAAC
2936 28643 UUAUUCUAGUGCGAAUAAUUGCACUUUUGA
2937 28655 UUUUGGUUUAUAUAAAAAUACAUGUGUUGG
2938 28661 GUUGACAUACCUGGCAUACCUAAGGACAUG
2939 28662 GUUCUUUGCAAUUCACAGACUUCAUUAAGA
2940 28669 UUUGCUGCAUACAGUCGCUACAGGAUUGGC
2941 28673 GUUGAAAAGAAAAAGCUUGAUGGCUUUAUG
2942 28677 UAGACAAUGCUCAGGUGUUACUUUCCAAAG
2943 28702 UAGCGGGUACAAUCACUUCUGGUUGGACCU
2944 28708 UUAUUAUGGUAAUGCUUUAGAUCAAGCCAU
2945 28718 UUUGCCUGGCACGAUAUUACGCACAACUAA
2946 28723 UAGACAUGUAUUCUGUUAUGCUUACUAAUG
2947 28730 UUAUCACCCGCGAAGAAGCUAUAAGACAUG
2948 28752 UACUACUUUAGAUUCGAAGACCCAGUCCCU
2949 28759 UUAUUGGACAUUCUAUGCAAAAUUGUGUAC
2950 28763 UUCAUGUGGUAGUGUUGGUUUUAACAUAGA
2951 28782 UAGCGAUAAUGUUACUGACUUUAAUGCAAU
2952 28783 UACUAGAUCAGGCAUUAGUGUCUGAUGUUG
2953 28793 UUUACCUAAUGAUGACACUCUACGUGUUGA
2954 28797 UUUGCUUUCCAUGCAGGGUGCUGUAGACAU
2955 28816 UUAUUACCCUGACAAAGUUUUCAGAUCCUC
2956 28819 U U AU U ACCACAAAAACAACAAAAG U UGG AU
2957 28833 U AG ACU U AU AAU U AG AG AAAACAACAG AG U
2958 28834 UACUUUUGGUGAUGACACUGUGAUAGAAGU
2959 28835 UACUAGUGCUAUGCAGACAAUGCUUUUCAC
2960 28845 UUAUUGUUUCUUAGGCUAUUUUUGUACUUG
2961 28849 UUAUUUAAAACUUACUGACAAUGUAUACAU
2962 28855 UUCAUCUGCAAUUAACAGGCCACAAAUAGG
2963 28858 U AG AG AAACAAUG AG U U ACU UG U U UCAACA
2964 28865 UUCAUCUAAGUGUGUGUGUUCUGUUAUUGA
2965 28876 UACUAUAGCAGAGAUAUUACUAAUUAUUAU
2966 28879 UUUGGCUGCUGAAUGUACAAUUUUUAAAGA
2967 28880 UUCAUCCGGAGUUGUUAAUCCAGUAAUGGA
2968 28892 GUUGAACAUGUUACCUUCUUCAUCUACAAU
2969 28907 UUCAUCAAAAAUUAUUGAAAUCAAUAGCCG
2970 28910 UACUUUCCUUUACAAUCAUAUGGUUUCCAA Sequence in priority
SEQ ID NO document Sequence
2971 28912 U AC U U U CCA A AG U G C AG U G A A A AG A AC A A U
2972 28924 UACUUUAUAUUGACAUUAAUGGCAAUCUUC
2973 28927 U UAUCGUGUAACU A A A A AC AG U A A AG U ACA
2974 28948 UUAUGUUGAUACACCUAAUAAUACAGAUUU
2975 28972 UGUUUGUUCUAUGACUGACAUAGCCAAGAA
2976 28977 UUUUAAUUGUUACUUUCCUUUACAAUCAUA
2977 28979 UGUUUUAACUGCUGUGGUUAUACCUACUAA
2978 28988 UGUUUGUGUAUCUACUAGUGGUAGAUGGGU
2979 28990 UACUUGUUUCAACAUGCCAAUUUAGAUUCU
2980 28991 G U U AG AGG U ACAACAG U ACU U U UAAAAGAA
2981 28995 U U G U A AC AC A A AG G A A U U U U U AUG AACCAC
2982 28998 UUUUAAUUU U UCACAAAU AU UACCAGAUCC
2983 29001 UUGUAACAGUUUACUCACACCUUUUGCUCG
2984 29002 UGUUUUAAUGUCUAAUUUAGGCAUGCCUUC
2985 29004 UUGUAACCAUACAGGUGUUGUUGGAGAAGG
2986 29016 UGUUUGUACAGAAAUUGACCCUAAGUUGGA
2987 29017 UGUUUGUAACAGUUUACUCACACCUUUUGC
2988 29024 UGGUCGCACUAUUGCCUUUGGAGGCUGUGU
2989 29029 GUUGUGGCAGAUGCUGUCAUAAAAACUUUG
2990 29032 UG U U U U AG AU U UCAUCU AAACG AACAAACU
2991 29036 UUUCCUAUUCCUUACAUGGAUUUGUCUUCU
2992 29053 UUGUAAUUCAUCAACUUGUAUGAUGUGUUA
2993 29067 UAACCUAGUUGCUGUACCUACAGGUUAUGU
2994 29072 UAACCUACAAAGCAACCAUGAUCUGUAUUG
2995 29074 GUUGAAGAAGUU AC A AC A AC U C U G G A AG A A
2996 29077 UUGUACAGAAAUUGACCCUAAGUUGGACAA
2997 29089 U U U UACACU U AAAAACACAG UCUG U ACCG U
2998 29102 UAACCCUAAAGCUAUUAAGUGUGUACCUCA
2999 29106 UAUGCUUACUAAUGAUAACACUUCAAGGUA
3000 29115 UAACUGCACAGAAGUCCCUGUUGCUAUUCA
3001 29117 UUGUACGCUGCUGUUAUAAAUGGAGACAGG
3002 29122 UUGUACUAAUUAUAUGCCUUAUUUCUUUAC
3003 29130 U U U U ACAGG U A ACC U AC A A AG C A ACC A U G A
3004 29148 UAACUGGUAUGAUUUCGGUGAUUUCAUACA
3005 29151 U UG U ACU UGCACUGUUAUCCGAUUU ACAGG
3006 29155 UAACUGGUUAUAAGAAACCUGCUUCAAGAG
3007 29167 UAACUGUGAUGUUGUAAUAGGAAUUGUCAA
3008 29181 UAACUGUUUGGAUGACAGAUGCAUUCUGCA
3009 29188 UAACUUAGACAACCUGAGAGCUAAUAACAC
3010 29190 UUGUAGAUGCAGAUAGUAAAAUUGUUCAAC
3011 29202 UUGUAGAUUUGACACUAGAGUGCUAUCUAA
3012 29203 G U U ACU U U CCA A AG U G C AG U G A A A AG A AC A
3013 29218 UUAUGUUCACACCUUUAGUACCUUUCUGGA
3014 29222 UUGGUGGUAAUUAUAAUUACCUGUAUAGAU
3015 29235 UAACAUCUGUUACACACCAUCAAAACUUAU Sequence in priority
SEQ ID NO document Sequence
3016 29238 UGUUUCCUUUAGUACUUUUGAAGAAGCUGC
3017 29240 UUGGUGGACCCUCAGAUUCAACUGGCAGUA
3018 29244 U AUGGAGUGUCUCCU ACU AAAU UAAAUG AU
3019 29247 GUUAACUGUUUGGAUGACAGAUGCAUUCUG
3020 29258 UUUCCAUUGUGUGCUAAUGGACAAGUUUUU
3021 29271 UAUGCAAAAG UAU UCU ACACUCCAGGG ACC
3022 29278 UAUGAUUUUGUAGAAAACCCAGAUAUAUUA
3023 29280 UAACAGGACACAUGUUAGACAUGUAUUCUG
3024 29281 UAACUUUUAUGGACCUUUUGUUGACAGGCA
3025 29313 UGUUUAUUUUGCUUCCACUGAGAAGUCUAA
3026 29317 UCCAUCCAUCUUUACUUUGAUAAAGCUGGU
3027 29326 UAUGAUUUCGGUGAUUUCAUACAAACCACG
3028 29330 UUUUGCACAAGU C A A AC A A A U U U AC A A A AC
3029 29334 GUGUUUAU U ACCACAAAAACAACAAAAG U U
3030 29344 U AACACUCCAACAAAU AG AG U UG AAG U U U A
3031 29348 UGUUUAUUACCCUGACAAAGUUUUCAGAUC
3032 29350 UAUGGCCAGUAACUUUAGCUUGUUUUGUGC
3033 29351 UG U U U AU U ACCACAAAAACAACAAAAG U UG
3034 29364 UUGUAUGGUACAAGUAACUUGUGGUACAAC
3035 29367 UGGUAACAUCUGUUACACACCAUCAAAACU
3036 29370 UUGUAUGUAAAUAAACAUGCAUUCCACACA
3037 29374 UGUUUAUGAUUACUUAGUUUCUACACAGGA
3038 29376 UUGUAUGUGAUAAUAUCAAAUUUGCUGAUG
3039 29394 UAACAAUGCAACUAAUAAAGCCACGUAUAA
3040 29396 UUGGUCCAACUUAUUUGGAUGGAGCUGAUG
3041 29415 UACUAUUACCGUUGAAGAGCUUAAAAAGCU
3042 29417 UUAUUUUAAAAUAUAUUCUAAGCACACGCC
3043 29420 UAUGAUGUCAGCACCACCUGCUCAGUAUGA
3044 29423 UUGUCAAACAUAAGCAUGCAUUUCUCUGUU
3045 29429 UUGUCAAAGUGACUAUUGACUAUACAGAAA
3046 29434 UAACAACUUUUGAUUCUGAGUACUGUAGGC
3047 29441 U AACAACU AAACG AACAAUG U UUGUUUUUC
3048 29447 UUGGUAUGCAAAAGUAUUCUACACUCCAGG
3049 29462 U A AC A A AG GUGAAGACAUUCAACUUCUUAA
3050 29468 GUUUGCCUAGGUUCUUUAAUCUACUCAACC
3051 29472 U AG C A A A A AG UCACAACAUUGCUUUGAUAU
3052 29473 UUAACACCAGUUUACUCAUUCUUACCUGGU
3053 29482 UCGCACAAAUGUCUACUUAGCUGUCUUUGA
3054 29496 UUCUUUAAUCUACUCAACCGCUGCUUUAGG
3055 29499 U U AU ACCU UCCCAGG U AACAAACCAACCAA
3056 29509 UUACUCAUUCUUACCUGGUGUUUAUUCUGU
3057 29510 U U UAU ACCU UCCCAGG U AACAAACCAACCA
3058 29522 UUGCCUAGGUUCUUUAAUCUACUCAACCGC
3059 29544 UUGUGUAGAUACUGUUCGCACAAAUGUCUA
3060 29547 UAACAAACCAACCAACUUUCGAUCUCUUGU Sequence in priority
SEQ ID NO document Sequence
3061 29548 UCUUUAAUCUACUCAACCGCUGCUUUAGGU
3062 29566 GUGGCUGUCACUCGGCUGCAUGCUUAGUGC
3063 29579 GUAGAUACUGUUCGCACAAAUGUCUACUUA
3064 29594 CACUCGGCUGCAUGCUUAGUGCACUCACGC
3065 29602 ACUCUGUUUAACACCAGUUUACUCAUUCUU
3066 29608 ACACUGACUUUGCAACAUCAGCUUGUGUUU
3067 29612 AACAGGACUCUUUAAAGAUUGUAGUAAGGU
3068 29623 ACUCUUUAAAGAUUGUAGUAAGGUAAUCAC
3069 29635 CACAACAUUGCUUUGAUAUGGAACGUUAAA
3070 29670 AACAAACCAACCAACUUUCGAUCUCUUGUA
3071 29693 GGCUGUCACUCGGCUGCAUGCUUAGUGCAC
3072 29697 AGAUACUGUUCGCACAAAUGUCUACUUAGC
3073 29700 CUGCAUGCUUAGUGCACUCACGCAGUAUAA
3074 29701 GCACUCACGCAGUAUAAUUAAUAACUAAUU
3075 29724 AG C A A A A AG UCACAACAUUGCUUUGAUAUG
3076 29736 AUG UCCGCAAU U UACAACACAGACU U U AUG
3077 29762 CCGCAAUUUACAACACAGACUUUAUGAGUG
3078 29767 CUGUCACUCGGCUGCAUGCUUAGUGCACUC
3079 29799 AACACAAGCUUUCGGCAGACGUGGUCCAGA
3080 29815 U U ACCU U U UACAAU U AAU UGCCAGG AACCU
3081 29818 UUUAGCCAGCGUGGUGGUAGUUAUACUAAU
3082 29825 UUCCUGUUUACCUUUUACAAUUAAUUGCCA
3083 29834 UAAUUAUACAGUUUCCUGUUUACCUUUUAC
3084 29835 UUAGCCAGCGUGGUGGUAGUUAUACUAAUG
3085 29869 AAUUAUACAGUUUCCUGUUUACCUUUUACA
3086 29875 GUUUGCCUAGGUUCUUUAACCUACUCAACC
3087 29897 U AG C A A A A AG UCACAGCAUUGCUUUGAUAU
3088 29905 UUCUUU AACCU ACUCAACCGCUGCUUUAGG
3089 29909 UUGCCUAGGUUCUUU AACCU ACUCAACCGC
3090 29916 UUGUGUAGAUACUGUUCGCACGAAUGUCUA
3091 29921 UCUUU AACCU ACUCAACCGCUGCUUUAGGU
3092 29929 UCGCACGAAUGUCUACUUAGCUGUCUUUGA
3093 29957 CUGUCACUCGGCAGCAUGCCGAGUGCAGCC
3094 29975 GUAGAUACUGUUCGCACGAAUGUCUACUUA
3095 29977 AGCAAAAAGUCACAGCAUUGCUUUGAUAUG
3096 29982 AGAUACUGUUCGCACGAAUGUCUACUUAGC
3097 30005 GCAGCCACACAGUAUAAUUAAUAACUAAUU
3098 30015 GUGGCUGUCACUCGGCAGCAUGCCGAGUGC
3099 30027 ACACUGACAUUGCAACAUCAGCUUGUGUUU
3100 30037 GGCUGUCACUCGGCAGCAUGCCGAGUGCAG
3101 30041 CACUCGGCAGCAUGCCGAGUGCAGCCACAC
3102 30045 CACAGCAUUGCUUUGAUAUGGAACGUUAAA
3103 30048 CAGCAUGCCGAGUGCAGCCACACAGUAUAA

Claims

1. A protein-RNA complex where here the protein is CAS13 and where and the RNA is an RNA guide strand that comprises a sequence that is complimentary to one of the sequences: SEQ ID NO 3029, OR ONE OF SEQ ID NO 1- SEQ ID NO 3028 or ONE OF SEQ ID NO 3030 - SEQ ID NO 3103.
2. The protein-RNA complex of claim 1 where the sequence is SEQ ID NO 3029.
3. A protein-RNA complex according to claim 1 or 2 for use in therapy.
4. A protein-RNA complex according to any one of claims 1 to 3 for use in the treatment of a corona virus infection.
5. A plasmid encoding the protein is CAS13 and an RNA guide strand that comprises a se quence that is complimentary to one of the sequences SEQ ID NO 1 to SEQ ID NO 3103, preferably SEQ ID no 3029, where the plasmid is adapted for expression of the protein and the transcription of the RNA guide strand in a mammalian cell.
6. A pharmaceutical composition comprising a. a protein -RNA complex according to any one of claims 1 to 4 or b. a plasmid according to claim 5; or c. two separate plasmids of which one encodes the protein is CAS13 and the other encodes an RNA guide strand that comprises a sequence that is complimentary to one of the sequences SEQ ID NO 1 to SEQ ID NO 3103, preferably SEQ ID no 3029, where the plasmids are adapted for expression of the protein and transcription of the RNA guide strand in a mammalian cell, or d. an RNA guide strand for Casl3 comprising a sequence that is complimentary to one of SEQ ID NO 1 to SEQ ID NO 3103, preferably SEQ ID no 3029, and a plasmid that encodes the protein Casl3 where the plasmid is adapted for expression of the protein in a mammalian cell.
7. A method of treatment of a virus infection comprising administering a protein-RNA com plex according to claim 1 to 4 or a plasmid according to claim 5 or pharmaceutical accord ing to claim 6 to a patient in need thereof.
8. A method for RNA knock-down of virus RNA in a virus-infected cell comprising using a pro- tein-RNA complex comprising a Cas 13 protein and an RNA guide strand that comprises a sequence that is complimentary to one of sequences SEQ ID NO 1 to SEQ ID NO 3103, pref erably SEQ ID no 3029, and where the method comprises introducing the protein-RNA complex, or means for expression of these, in a cell.
PCT/EP2021/052336 2020-01-30 2021-02-01 Virus therapy WO2021152181A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE2050090 2020-01-30
SE2050090-6 2020-01-30

Publications (1)

Publication Number Publication Date
WO2021152181A1 true WO2021152181A1 (en) 2021-08-05

Family

ID=74553802

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2021/052336 WO2021152181A1 (en) 2020-01-30 2021-02-01 Virus therapy

Country Status (1)

Country Link
WO (1) WO2021152181A1 (en)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3882364A4 (en) * 2020-02-06 2022-01-05 Daan Gene Co., Ltd. Dual detection kit for 2019 novel corona virus
US20220042117A1 (en) * 2020-08-06 2022-02-10 Roche Molecular Systems, Inc. COMPOSITIONS AND METHODS FOR THE SIMULTANEOUS DETECTION OF INFLUENZA A, INFLUENZA B, AND SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS 2 (SARS-CoV-2)
WO2022194756A3 (en) * 2021-03-15 2022-12-01 F. Hoffmann-La Roche Ag Compositions and methods for detecting severe acute respiratory syndrome coronavirus 2 (sars-cov-2) variants having spike protein mutations
WO2023145884A1 (en) * 2022-01-28 2023-08-03 国立大学法人京都大学 SARS-CoV-2-DERIVED POLYNUCLEOTIDE AND USE THEREOF

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5846946A (en) 1996-06-14 1998-12-08 Pasteur Merieux Serums Et Vaccins Compositions and methods for administering Borrelia DNA
US8404658B2 (en) 2007-12-31 2013-03-26 Nanocor Therapeutics, Inc. RNA interference for the treatment of heart failure
US8454972B2 (en) 2004-07-16 2013-06-04 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Method for inducing a multiclade immune response against HIV utilizing a multigene and multiclade immunogen
WO2019010422A1 (en) * 2017-07-07 2019-01-10 The Broad Institute, Inc. Crispr system based antiviral therapy

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5846946A (en) 1996-06-14 1998-12-08 Pasteur Merieux Serums Et Vaccins Compositions and methods for administering Borrelia DNA
US8454972B2 (en) 2004-07-16 2013-06-04 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Method for inducing a multiclade immune response against HIV utilizing a multigene and multiclade immunogen
US8404658B2 (en) 2007-12-31 2013-03-26 Nanocor Therapeutics, Inc. RNA interference for the treatment of heart failure
WO2019010422A1 (en) * 2017-07-07 2019-01-10 The Broad Institute, Inc. Crispr system based antiviral therapy

Non-Patent Citations (18)

* Cited by examiner, † Cited by third party
Title
ABUDAYYEH ET AL., NATURE, vol. 550, 2017, pages 280 - 284
BAWAGE SWAPNIL S. ET AL: "Synthetic mRNA expressed Cas13a mitigates RNA virus infections", BIORXIV, 23 July 2018 (2018-07-23), XP055796108, Retrieved from the Internet <URL:https://www.biorxiv.org/content/10.1101/370460v1.full.pdf> [retrieved on 20210416], DOI: 10.1101/370460 *
COXGOOTENBERGABUDAYYEH ET AL., SCIENCE, 2017
FREIJE ET AL., MOLECULAR CELL, vol. 76, 2019, pages 826 - 837
GLASSLEELIXU, TRENDS IN BIOTECHNOLOGY, 2017
LEE ET AL., NATURE BIOMEDICAL ENGINEERING, vol. 1, 2017, pages 889 - 901
LI ET AL., BIOMATERIALS, vol. 178, 2018, pages 652 - 662
LIUZHANGLIUCHENG, JOURNAL OF CONTROLLED DISEASE, vol. 266, 2017, pages 17 - 26
LOTFI MELIKA ET AL: "CRISPR/Cas13: A potential therapeutic option of COVID-19", BIOMEDICINE AND PHARMACOTHERAPY, ELSEVIER, FR, vol. 131, 17 September 2020 (2020-09-17), XP086322133, ISSN: 0753-3322, [retrieved on 20200917], DOI: 10.1016/J.BIOPHA.2020.110738 *
MALI ET AL., SCIENCE, vol. 339, 2013, pages 823 - 826
MOUT ET AL., ACS NANO, vol. 11, 2017, pages 2452 - 2458
PARASKEVIS D ET AL: "Full-genome evolutionary analysis of the novel corona virus (2019-nCoV) rejects the hypothesis of emergence as a result of a recent recombination event", INFECTION, GENETICS AND EVOLUTION, ELSEVIER, AMSTERDAM, NL, vol. 79, 29 January 2020 (2020-01-29), XP086053411, ISSN: 1567-1348, [retrieved on 20200129], DOI: 10.1016/J.MEEGID.2020.104212 *
PARK ET AL., NATURE COMMUNICATIONS, vol. 9, 2018, pages 3313
PHAN TUNG ED - MOKROUSOV IGOR ET AL: "Novel coronavirus: From discovery to clinical diagnostics", INFECTION, GENETICS AND EVOLUTION, ELSEVIER, AMSTERDAM, NL, vol. 79, 30 January 2020 (2020-01-30), XP086053410, ISSN: 1567-1348, [retrieved on 20200130], DOI: 10.1016/J.MEEGID.2020.104211 *
SMARGONCOXPYZOCHA ET AL., MOLECULAR CELL, 2017
UEDA, MICROBIOLOGY AND IMMUNOLOGY, vol. 60, July 2016 (2016-07-01), pages 483 - 496
WANG ET AL., PNAS, vol. 113, no. 11, 15 March 2016 (2016-03-15), pages 2868 - 2873
ZETSCHE ET AL., CELL, vol. 163, 2015, pages 759 - 771

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3882364A4 (en) * 2020-02-06 2022-01-05 Daan Gene Co., Ltd. Dual detection kit for 2019 novel corona virus
US11649511B2 (en) 2020-02-06 2023-05-16 Daan Gene Co., Ltd. Multiplex PCR method for the detection of SARS-CoV-2
US20220042117A1 (en) * 2020-08-06 2022-02-10 Roche Molecular Systems, Inc. COMPOSITIONS AND METHODS FOR THE SIMULTANEOUS DETECTION OF INFLUENZA A, INFLUENZA B, AND SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS 2 (SARS-CoV-2)
WO2022194756A3 (en) * 2021-03-15 2022-12-01 F. Hoffmann-La Roche Ag Compositions and methods for detecting severe acute respiratory syndrome coronavirus 2 (sars-cov-2) variants having spike protein mutations
WO2023145884A1 (en) * 2022-01-28 2023-08-03 国立大学法人京都大学 SARS-CoV-2-DERIVED POLYNUCLEOTIDE AND USE THEREOF

Similar Documents

Publication Publication Date Title
WO2021152181A1 (en) Virus therapy
Li et al. CRISPR/Cas9 therapeutics: progress and prospects
Han et al. Mitigating off-target effects in CRISPR/Cas9-mediated in vivo gene editing
US20180179526A1 (en) Method and Medicament For Inhibiting The Expression of A Given Gene
CN105899658B (en) Delivery, use and therapeutic applications of CRISPR-CAS systems and compositions for HBV and viral diseases and disorders
US20170349894A1 (en) Escorted and functionalized guides for crispr-cas systems
US20210222164A1 (en) Crispr-cas systems having destabilization domain
KR20230169449A (en) Rna-guided nucleic acid modifying enzymes and methods of use thereof
KR20230170126A (en) Rna-guided nucleic acid modifying enzymes and methods of use thereof
EP3237615A1 (en) Crispr having or associated with destabilization domains
CA2764158A1 (en) Polynucleotides for multivalent rna interference, compositions and methods of use thereof
KR20220123398A (en) Synthetic guide RNA, composition, method and use thereof
WO2022165262A1 (en) Compositions and methods for delivering cargo to a target cell
Pushpendra et al. Nucleic acids as therapeutics
WO2023098485A1 (en) C2c9 nuclease-based novel genome editing system and application thereof
JP7133856B2 (en) A method for converting a nucleic acid sequence of a cell, which specifically converts a targeted DNA nucleobase using a DNA-modifying enzyme endogenous to the cell, and a molecular complex used therefor
KR20240017367A (en) Class II, type V CRISPR systems
US20220119787A1 (en) Virus therapy
US20210317429A1 (en) Methods and compositions for optochemical control of crispr-cas9
JP2024510800A (en) Compositions and methods for treating hypercholesterolemia
CN117925585A (en) Adenosine deaminase, base editor fusion protein, base editor system and use

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 21703400

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 21703400

Country of ref document: EP

Kind code of ref document: A1